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Abstract 
 This thesis investigates the effect of Sox9 knockdown on anti-regenerative scar gene 
expression, neuroplasticity, and hind limb functional recovery following mouse spinal cord 
injury. We hypothesized that Sox9 knockdown would reduce expression of anti-regenerative 
chondroitin sulfate proteoglycans both at the lesion site and at sites distant to the injury, thus 
providing an avenue for increased neuroplasticity and locomotor recovery after spinal cord 
injury. The first chapter provides a general introduction to the biological problem of spinal cord 
injury. The development of the glial scar and expression of the anti-regenerative chondroitin 
sulfate proteoglycan (CSPG) extracellular matrix is introduced, and Sox9 is identified as a 
transcription factor that may control expression of these anti-regenerative genes. The second 
chapter is a manuscript that describes the molecular changes and improved locomotor function 
seen when Sox9 knockdown is carried out just prior to spinal cord injury. The third chapter is 
more clinically relevant as it is a manuscript detailing the effects of Sox9 knockdown after spinal 
cord injury on the recovery of hind limb motor function. The fourth chapter is a manuscript 
investigating the neuro-anatomical mechanism of the improved functional recovery seen in Sox9 
knockdown mice after spinal cord injury. The fifth chapter reflects on the findings presented 
herein, and suggests possible future plans of study. This dissertation demonstrates that inhibition 
of Sox9 leads to reduced CSPG expression, improved hind limb function, and increased total 
locomotion. It further provides compelling evidence that increased neuroplasticity as evidenced 
by increased reactive sprouting and increased expression of the presynaptic markers 
synaptophysin and VGLUT1 caudal to the injury site underlies the improved neurological 
recovery observed in spinal cord injured Sox9 conditional knockdown mice. 
Key words: spinal cord injury, Sox9, chondroitin sulfate proteoglycans, neuroplasticity, reactive 
sprouting 
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Chapter 1: Introduction 
 
1.0 Spinal cord injury 
 
The spinal cord serves as the communication relay between the brain and the periphery. It 
conveys messages from the brain to control movement, breathing, and other bodily functions, 
and messages from sensory organs to the brain to allow us to interpret and act on those 
sensations. These messages are transmitted by long extensions of neurons called axons. The 
spinal cord is surrounded by vertebrae that protect it. If these bones are damaged, the spinal cord 
and the axons therein may be injured and vital information that needs to be transmitted to, or 
from, the brain does not reach its destination. 
Spinal cord injury (SCI) is a devastating event resulting in immediate life-altering 
consequences for not only the affected individual but their family and friends. SCI can result in 
motor, sensory, and autonomic dysfunctions [1]. Depending on the severity of injury, SCI may 
leave patients with lifetime disability [1]. Although paralysis is the symptom most people 
associate with SCI, those who suffer a SCI may also develop numerous other debilitating 
symptoms including chronic pain [2], muscle spasticity [3], poor control of bladder and bowel 
function [4], and decreased sexual function [5, 6]. SCI resulting in permanent paralysis or 
significant neurological deficit occurs with an annual incidence between 25 and 93 cases per 
million North Americans [7]; in Canada this translates to over 1,000 new cases a year. SCI often 
has a profound socio-economic impact on people as they may be forced to leave their jobs, 
require ongoing medical care for the duration of their lives, and incur massive patient health care 
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costs [8]. This socio-economic burden is exacerbated by the fact that these injures are most 
common in young adults [7].  
SCI occurs in a two-stage process. The initial stage is known as the primary SCI which 
occurs at the time of injury due to physical trauma to the spinal cord [9]. Examples of primary 
injury include hyperextension of the cord, destruction due to sheering or twisting of the cord, 
vertebral fracture and contact with the side of the cord, and laceration due to a direct cut of the 
cord by sharp object, or projectile [10]. Most often these injuries also result in reduction of blood 
flow to the spinal cord resulting in ischemia [11] that contributes significantly to the destruction 
of the grey matter which requires considerable oxygen supply [10]. Damage to the spinal cord is 
not limited to this initial physical injury. A secondary phase of SCI begins in the hours following 
the initial trauma to the cord. This secondary SCI is characterized by the body’s activation of  
inter-related processes that lead to an expansion of the lesion and contribute to neuronal loss and 
increased functional defect [12]. Such secondary processes contributing to SCI include ischemia-
reperfusion [13], edema [14], excitotoxicity [15], oxidative damage [16], inflammation [17], and 
glial scarring [18].  
The debilitating neurological damage that results as a consequence of SCI has long been 
considered to be irreversible. Currently, there are no effective pharmacological treatments for 
SCI [19]. Thus, improved therapeutic strategies for the treatment of SCI need to be developed. A 
beneficial treatment for SCI will need to limit neuronal damage and subsequent functional 
degeneration, or promote axonal regeneration culminating in significant functional recovery. The 
project described herein focuses on the promotion of axonal regeneration post-SCI. 
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1.1 Nervous system plasticity 
 
Embryonic central nervous system (CNS) neurons display significant plasticity, however 
in the adult CNS this intrinsic ability to grow becomes suppressed to maintain proper synaptic 
organization [20]. Unlike embryonic CNS neurons, mature CNS neurons display minimal neurite 
outgrowth, do not respond readily to neurotrophic stimuli, are significantly inhibited by myelin-
associated inhibitors, and form few growth cones [21, 22]. Much like CNS neurons, peripheral 
neurons undergo similar reduction in their growth properties over time, but their intrinsic growth 
capabilities can be reactivated by peripheral nerve injury that may result in increased expression 
of pro-regeneration transcription factors and growth associated proteins thus allowing for 
considerable peripheral nerve regeneration [20, 23, 24]. This type of reactivation of pro-
regenerative transcription factors is not seen in response to CNS injuries, and thus CNS neurons 
do not regenerate to the same extent as peripheral nervous system (PNS) neurons post-injury. 
However, this is not the sole reason why CNS neurons do not regenerate to the same extent as 
PNS neurons. The PNS contains Schwann cells, and axons from both PNS and CNS neurons 
grow well in a Schwann cell rich environment [25-27]. The CNS, however, contains astrocytes 
and oligodendrocytes rather than Schwann cells, and culture experiments have shown that both 
PNS and CNS axons grow poorly across astrocyte and oligodendrocyte rich environments [28-
30]. Following CNS damage, axonal and glial debris remains for a significant period of time, 
often months, and has been suggested to act as a source of axonal growth inhibition. In 
comparison, post-injury debris is cleared much faster in the PNS [31, 32]. Perhaps the most 
significant impediment to axonal growth in the CNS is the response of cells located at the local 
site of injury. Unlike in the periphery [33], the adult CNS experiences the activation of 
astrocytes, and development of a subsequent astroglial scar. CNS trauma often results in a 
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disruption of the blood–brain barrier, which allows neutrophils and macrophage to extravasate 
from the blood to assist endogenous microglia with antigen recognition and phagocytic 
functions. Fibroblasts from the meninges converge with the inflammatory cells to the injury site 
and release various cytokines and chemokines [34, 35]. These small molecules activate reactive 
astrocytes to induce further gliosis and glial scar formation. This glial scar consists of a number 
of growth inhibiting molecules that contribute to the failure of axon regeneration [18, 36-42]. 
Many of the molecules (semaphorins, ephrins, netrins and slit) that are expressed after injury in 
the glial scar induce axonal growth cone collapse. Studies investigating the inhibition of these 
molecules have demonstrated some promise for the functional recovery after CNS injuries 
including SCI [43, 44]. There are also many myelin-derived inhibitors such as Nogo, myelin-
associated glycoprotein, repulsive guidance molecule, and oligodendrocyte myelin glycoprotein 
each of which inhibit neurite outgrowth in vitro [45]. However, their contribution in vivo is still 
under investigation as Nogo, myelin-associated glycoprotein, and oligodendrocyte myelin 
glycoprotein triple knockout mice do not display improved recovery post-SCI [46, 47]. In 1990 
Silver et al. found that a major component of the glial scar, chondroitin sulfate proteoglycans 
(CSPGs) that are up-regulated post-neurotrauma [48], prevent axonal growth as cultured axons 
from the E9 chick dorsal ganglia would not grow across a strip of CSPGs coated on 
nitrocellulose [49]. CSPG digestion abolished this inhibition and allowed the chick axons to 
grow across the plate. Thus, CSPGs became a focus for the investigation of axonal growth 
inhibitory molecules. 
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1.2 Chondroitin Sulfate Proteoglycans (CSPGs) 
 
CSPGs are a class of extracellular matrix macromolecules that share a common structure 
consisting of a central core protein with a number of chondroitin sulfate side chains attached 
[50]. More than 10 enzymes participate in the complex synthesis of a completed CSPG. First, the 
CSPG core protein is produced. Next a tetrasaccharide linker is synthesized. The rate limiting 
step in CSPG synthesis is the attachment of this tetrasaccharide linker to the CSPG core protein 
by way of a serine-xyline interaction catalyzed by the enzyme xylosyltransferase (XT) isoforms I 
and II (XT-I, XT-II) [51]. Chondroitin sulfate N-acetylgalactosaminyltransferase adds N-
acetylgalactosamine (GalNAc) to the tetrasaccharide linker [52], and chondroitin sulfate 
synthase, as well as chondroitin polymerizing factor, add glucuronic acid (GlcA) to the available 
N-acetylgalactosamine [53, 54]. This polymerization process repeats with the addition of 
subsequent (GalNAc-GlcA) disaccharides one after another to form a long carbohydrate chain. 
Finally, these side chains are sulfated by chondroitin 4-sulfotransferase (C4ST) [55] to make a 
complete CSPG.  
There are many different types of CSPGs, each defined by their core protein. There are 
large aggregating proteoglycans including aggrecan [56] and versican [57] localized in most 
smooth muscle tissues and in fibrous and elastic cartilage as well as the CNS, and CNS-specific 
proteoglycans neurocan [58], brevican[59], NG2 [60], and phosphacan [61]. These CSPGs exist 
abundantly within the CNS and interact with a variety of other ECM components including 
laminin, fibronectin, tenascin, hyaluronic acid and several collagens by way of interaction 
through their core protein, or sugar side chain [57, 62-65]. 
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CSPG expression is tightly controlled in the embryonic brain, with expression restricted 
during development to highly specialized and organized regions such as neural crest pathways 
and the spinal cord where they act as axon guidance molecules [66, 67]. The removal of these 
CSPGs results in abnormally formed axonal pathways [68]. In the adult CNS, the normal 
expression patterns of CSPGs become more diffuse. Neurocan (produced by astrocytes and 
oligodendrocyte precursor cells) is generally found in the white matter of the adult CNS [69]. 
NG2 is distributed throughout the adult brain existing on oligodendrocyte precursor cells [70], on 
blood vessels and meningeal cells [50]; and is often cleaved and secreted into the ECM [71]. 
Phosphacan is present throughout the CNS and at particularly high levels in the cerebellum [72]. 
Versican is produced by oligodendrocyte precursor cells and is found in high concentration in the 
white matter, [73]. Brevican is distributed throughout the CNS [74] and is produced 
predominantly by astrocytes [75]. CSPGs also amass in extracellular matrix structures  which 
surround synapses on the neuronal surface known as perineuronal networks (PNNs) [76].  This 
CSPG recruitment into PNN structures coincides with the end of the critical period of plasticity 
which occurs in the transition to adulthood [76]. These CSPGs exist normally within the adult 
CNS [77], but following SCI, their expression levels markedly increase [37, 78]. CSPGs become 
up-regulated to play a beneficial role post-injury as they surround the lesion site and disrupted 
blood-brain barrier to seal off the damaged tissue, limit the secondary inflammatory response, 
and prevent increased cavitation [79]. However, as previously mentioned, CSPGs both in the 
lesion site and in PNNs also pose a significant impediment to regeneration post neurotrauma.   
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1.3 Regenerative failure post-SCI – CSPGs in the glial scar 
 
Following SCI, axonal regeneration in the adult CNS is poor. However, axons do have an 
intrinsic ability to grow in both the CNS tissue and degenerating white matter. Davies et al. [42] 
demonstrated that adult dorsal root ganglion (DRG) sensory neurons transplanted into the white 
matter tracts of adult rats could grow in the CNS. If the transplantation procedure caused 
minimal damage to the local transplantation site, considerable numbers of regenerating adult 
axons rapidly extended through the white matter and eventually invaded the grey matter. If the 
surgical procedure caused considerable damage to the local area, failure in long range 
regeneration was noted. Increased CSPG expression was seen within the extracellular matrix at 
the transplant interface in those animals that displayed abortive regeneration, and minimal CSPG 
expression was noted in animals which displayed successfully regenerating transplants [42]. In a 
follow up study Davies et al. [36] transplanted DRG sensory neurons into degenerating white 
matter of the adult rat spinal cord several millimeters rostral to a severe lesion of the dorsal 
columns. DRG axonal growth away from the transplantation site, in both the rostral and caudal 
directions, was noted. Upon reaching the lesion site the rapidly extending axons stopped their 
growth, experienced growth cone collapse, and became dystrophic. High concentrations of 
CSPGs were found at the site of cessation of growth in the reactive glial matrix. These results 
suggested that the major impediment to axonal regeneration in the adult CNS was the molecular 
barrier found in the glial scar that forms at the lesion site, and that inhibition of axon growth 
correlates directly with elevated CSPG expression. 
In vitro studies have shown that explanted glial tissue expressing CSPGs do not permit 
neurite extension [37]. In cultures of primary astrocytes, neurites avoid patches of cells 
8 
 
 
 
expressing CSPGs [80]. Specific CSPGs have also been shown to inhibit neurite outgrowth 
including: aggrecan [81], neurocan [82], phosphocan [83], brevican [75], versican [84], and NG2 
[85]. Neurocan in particular has been identified as a major impediment to recovery post-SCI 
[86]. Importantly, following mid-thoracic SCI neurocan expression is increased throughout the 
lesion site both in the cervical dorsal columns and in the lumbar ventral horn much longer than 
other CSPGs [86]. The long lasting increase of neurocan in gray matter regions at distal levels of 
the spinal cord may contribute to the restriction of plasticity in the chronic phase after SCI.  
The mechanism behind CSPG inhibition of axonal growth is believed to be due to both 
the physical and molecular barrier that CSPGs impose at the glial scar. The negatively charged 
sulfates present on the sugar side chains are repellent to axon fibers [87] and CSPGs sterically 
inhibit access to substrate adhesion molecules [88]. Recently, the transmembrane receptor 
protein tyrosine phosphatase sigma (RPTPσ) has been identified as an axonal high affinity 
receptor for CNS CSPGs [89]. Following interaction with CSPGs, RPTPσ signals growth cone 
collapse and cessation of axonal growth [90-92]. In vitro work demonstrated that cerebellar 
granule neurons from RPTPσ knockdown mice display reduced sensitivity to CSPG growth 
inhibition [93]. In vivo, corticospinal tract axons were found to regenerate through the injury site 
and extend for long distances after a dorsal hemisection or contusion injury of the thoracic spinal 
cord in RPTPσ deficient mice [93]. Transmembrane leukocyte common antigen-related 
phosphatase receptor (LAR), another member of the RPTP family, has also been identified as a 
receptor for CSPGs [94]. Functional blockade of LAR reversed neurite growth inhibition 
induced by CSPGs and induced significant descending axonal growth and locomotor functional 
recovery in mice with thoracic SCI [94].  
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CSPG up-regulation in the glial scar at the local injury site is certainly an obstacle to 
regeneration post-SCI; however, CSPG inhibition of axonal regeneration does not only occur at 
the glial scar. CSPGs also act as natural endogenous regulators of synaptic plasticity and 
experience-dependent neural plasticity as the principle component of the perineuronal network at 
sites distant to injury, and can thus restrict axonal plasticity throughout the CNS [95-97]. 
 
1.4 The perineuronal network 
 
PNNs are composed of a highly condensed extracellular matrix that exists around the end 
feet of astrocytes surrounding the cell bodies and dendrites of CNS neurons [98]. PNNs were 
originally reported by Camillo Golgi in 1898 [99], and have since been confirmed to be produced 
by both neurons [100] and glia [101, 102]. PNNs are believed to play a number of functions in 
the adult brain; they maintain cellular positioning [103]; they modulate the chemotactic gradient 
of growth factors around neurons [98]; and they generate a polyanionic ion-buffering 
microenvironment to promote cell survival [104]. PNNs contain CSPGs, and tenascin-R [105], 
both non-permissive strata for axonal growth or attachment [106, 107]. This suggests that PNNs 
impede the formation of new synaptic contacts, and restrict axonal plasticity. In fact, PNNs play 
a crucial role in regulation of what is referred to as the critical period of synaptic plasticity in the 
brain.  
As the juvenile brain develops, particular systems display critical periods of plasticity 
where the neuronal circuitry controlling these systems shows significantly increased sensitivity 
to experience [108-110]. Experience during these critical periods is believed to have a significant 
effect on how these neuronal systems interconnect; thus contributing to learning specific skills 
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and behaviors including interpretation of one’s senses and emotional processing [110, 111]. This 
critical period comes to an end with a dramatic up-regulation of PNNs around neuronal cell 
bodies and dendritic synapses bringing to a close this period of increased plasticity [98], 
finalizing the adaptations to the neuronal network acquired during the critical period [112-114]. 
The PNNs contain CSPGs that stabilize those synapses formed by critical period experience, 
preventing the formation of inappropriate synapses in the future by stunting axonal sprouting 
onto incorrect targets after appropriate connections have been made [97, 101, 115-117]. This 
mechanism appears to function as a method to retain proper understanding of sensation and 
optimized motor behaviors without need for continual maintenance, as constantly plastic 
synapses might leave individuals unable to use that circuitry optimally, and thus would be unable 
to interact optimally with their environment. Multiple studies have shown that reducing CSPG 
levels at the lesion site and/or in PNNs results in increased structural neuroplasticity [118-122]. 
Thus, therapies targeting a reduction in CSPGs both near and far from the lesion epicenter may 
present an interesting strategy for improved recovery post-SCI. 
 
1.5 Anti-CSPG strategies show promise for the treatment of SCI 
 
 Thus far, three strategies have been devised to have broad effects on CSPGs and have 
been shown to improve axonal regeneration after SCI. The first strategy makes use of enzymatic 
digestion of the chondroitin sulfate side chains found on all CSPGs using the enzyme 
chondroitinase ABC. Chondroitinase treatment renders glia permissive to neurite outgrowth in 
vitro [118], and intrathecal chondroitinase treatment in the rat resulted in minor improvements in 
recovery and regeneration of ascending axonal tracts post-SCI [119], Axonal regeneration 
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following chondroitinase treatment of the injured spinal cord was modest.  The lack of extensive 
improvement was attributed to the carbohydrate stubs left on the CSPG core proteins after 
chondroitinase treatment [123]. Another strategy was devised to block glycosylation of 
proteoglycan core proteins using an anti-XT-I ribozyme administered after SCI, and resulted in 
improved axonal regeneration [124]. A third approach investigated mice carrying a gene 
knockdown for Chondroitin sulfate N-acetylgalactosaminyltransferase-1, a key enzyme in CSPG 
biosynthesis. N-acetylgalactosaminyltransferase-1 knockdown mice displayed reduced CSPG 
expression, and recovered more completely from SCI than both wild-type mice or chondroitinase 
treated mice [125]. Thus, strategies targeting CSPG expression are particularly interesting as 
potential therapeutics for the treatment of SCI.  
   
1.6 Existing therapies for SCI 
Currently, there are remarkably few treatments for SCI. Spinal cord decompression is 
widely practiced as a surgical intervention designed to relieve the physical pressure applied to a 
compressed spine and to reduce secondary damage. Spinal decompression leads to improved 
neurological function, reduced hospital stay, fewer secondary complications, earlier 
mobilization, and quicker transfer to rehabilitation centers [126-130]. However, the 
decompression surgery needs to occur immediately after SCI as studies have demonstrated that 
no significant neurologic benefit was seen when spinal cord decompression was performed just 
over 24 hours post-injury (mean 1.8 days) or during a more chronic time point (mean, 16.8 days) 
[131].  
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A pharmacological treatment for SCI also exists; methylprednisolone (MP) has been used 
as an approved anti-inflammatory clinical treatment for SCI due to its promising  
immunosuppressive effects [132] and profound anti-oxidant properties [133] in pre-clinical 
models. However, MP treatment is not without its detractors. In 1979 a multicenter, randomized, 
double-blinded clinical trial referred to as National Acute Spinal Cord Injury Study (NASCIS) 
analyzed 330 patients treated with MP or placebo and found no beneficial effect of MP treatment 
on neurological recovery, motor function, or sensory function, at 6 weeks or 6 months after 
injury [134]. However, animal studies suggested that the MP dose used in NASCIS I was not 
sufficient to confer neuroprotection [135, 136]. Thus, a second multicenter trial (NASCIS II) was 
initiated in 1985 using a higher MP dose, and 487 participants. The administration of a higher 
dose of MP within 8 hours after injury was associated with a statistically significant 
improvement in motor and sensory function at the 6-month follow up compared with patients 
receiving placebo or MP at later time-points [137]. However, there were no functional outcome 
measures designed to assess whether the statistical improvements noted with MP treatment were 
indeed clinically relevant. As a whole, this trial was criticized for methodological, scientific, and 
statistical design issues [138-141]. These criticisms resulted in the development of a third 
NASCIS trial. The study began in 1991 and followed 499 patients, this time also assessing self-
care, mobility, locomotion, sphincter control, communication and social cognition in acute SCI 
patients. Any benefit of MP treatment was only observed at the 6 week and 6 month follow-ups 
and no positive effect was noted beyond 1 year [142, 143]. Importantly, all NASCIS trials 
reported a statistically significant increase in adverse side effects, including: infections, 
gastrointestinal hemorrhages, sepsis, pulmonary embolism, severe pneumonia, and death [140, 
141].  
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In 2002, the American Association of Neurological Surgeons/Congress of Neurological 
Surgeons (AANS/CNS) released a statement indicating that the harmful side effects of MP 
treatment outweighed the potential for clinical benefit [144]. In Canada, administration of MP 
was common practice following NASCISII (administered in 76% of acute SCI cases) and, 
following the AANS/CNS recommendations, Canadian clinicians dramatically reduced MP 
usage for treatment of SCI (administered in only 24% of acute SCI) [145]. As MP is losing favor 
among clinicians treating SCI, and spinal decompression intervention must occur in the very 
acute stages after injury, there is clearly a need to develop new efficacious treatments for SCI.  
 
1.7 Sox9 was identified as a potential regulator of CSPG biosynthesis 
 
Given that CSPGs are such a potent obstacle to regeneration post-SCI the regulation of 
XT-I, XT-II and C4ST, the enzymes that synthesize the chondroitin sulfate side chains on 
CSPGs, was investigated. Following SCI, XT-I, XT-II and C4ST all show similar temporal 
patterns of up-regulated gene expression [146], and are followed by the detection of increased 
CSPG levels [146]. As the formation of the glial scar is a process that does not occur in the 
undamaged adult spinal cord, it seemed reasonable to presume that a genetic program for the 
elaboration of the glial scar would be activated post-SCI to up-regulate the expression of CSPGs 
and other relevant genes. Thus, researchers in the Brown laboratory conducted an in silico 
phylogenetic footprinting analyses [147] to identify transcription factors that could potentially 
activate XT-I, XT-II, and C4ST expression. Genomatix software identified five transcription 
factors which have putative binding sites within the promoters of human, rat, and mouse, XT-I, 
XT-II and C4ST. Of the five, Sox9 was particularly interesting as it plays a key role in astrocyte 
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development [148, 149] and positively regulates the expression of proteoglycans during 
chondrogenesis in the periphery [150-152]. 
 
1.8 Transcription factor Sox9 
 
SOX (SRY-type HMG box) transcription factors are part of a DNA-binding protein 
subfamily with a high-mobility-group (HMG) domain [153]. Individual members of the SOX 
family show greater than 50% identity in their HMG domain to SRY, the testes-determining 
factor, and thus it is not surprising that SOX transcription factors play roles in sex determination 
[153, 154]. However, SOX transcription factors are involved in a wide range of developmental 
processes beyond sex determination, including neurogenesis, hematopoiesis, lens development, 
and skeleton formation [153, 155-161]. 
Sox9 has two essential functions: it regulates the activity of genes required for testes 
development, and it regulates essential genes required for cartilage and bone development. 
Mutations to SOX9 have significant consequences for those afflicted. Disrupting Sox9 results in 
sex reversal, in which a genetically male (XY) individual will appear phenotypically female as 
Sox9 is unable to carry out its normal role in testes development [162, 163]. Mutations to Sox9 
also result in a genetically dominant skeletal condition known as campomelic dysplasia that 
presents alongside sex reversal [162, 163]. It is characterized by bone and cartilage abnormalities 
causing short arms and legs, short digits, bowing of the legs, dislocated hips, feet that are 
abnormally rotated, and small chest size. The condition is life threatening during the newborn 
period, with death often resulting from breathing problems as a result of underdeveloped chest or 
lungs [164]. A few individuals have survived with campomelic dysplasia past infancy. As they 
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age they develop further orthopedic problems and hearing loss [165, 166]. Mutations to the 
regions near the SOX9 locus may disrupt enhancer elements that normally regulate the activity 
of Sox9. If this leads to reduced Sox9 activity an inability to properly control the development of 
facial structures known as isolated Pierre Robin sequence may result [167]. These skeletal 
abnormalities result from the individual’s inability to form proper cartilaginous structures due to 
Sox9 mutation. Sox9’s role in cartilage development is particularly important to this study as 
proteoglycans are required for proper cartilage formation. 
 
1.9 The role of Sox9 in cartilage formation 
 
Cartilage formation is an essential process during development. Cartilages do not only 
constitute permanent skeletal structures in the respiratory tract, articular joints, and other organs, 
but are also essential templates for the formation of endochondral bones. Cartilage is created by 
chondrocytes secreting specific extracellular matrix components such as various collagens and 
proteoglycans. Sox9 is expressed in all chondroprogenitors and differentiated active 
chondrocytes [168]. In vitro studies have shown that Sox9 binds and activates chondrocyte-
specific enhancer elements for the Col2a1, Col11a2, Aggrecan, and CD-RAP genes in vitro, 
demonstrating that these genes are targets of Sox9 [169-172]. Sox9 can also directly activate type 
2 collagen expression when ectopically expressed in some non-cartilaginous sites in transgenic 
mice [173]. 
Studies using mouse embryo chimeras derived from Sox9 knockdown embryonic stem 
(ES) cells demonstrated that Sox9 null mutant cells were excluded from chondrogenic 
mesenchymal condensations and did not express chondrocyte-specific markers for collagen 
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expression or aggrecan proteoglycan expression [174]. To elucidate further the role of Sox9 in 
chondrogenesis and chondrocytic differentiation, Akiyama et al. [175] developed a Sox9 
conditional knockdown line using the Cre recombinase system. Embryos, in which Sox9 was 
deleted after mesenchymal condensations, exhibited a severe generalized chondrodysplasia.  
Most cells were arrested as condensed mesenchymal cells and did not undergo overt 
differentiation into chondrocytes. Furthermore, chondrocyte proliferation was severely inhibited 
and joint formation was defective. Embryos missing Sox9 from undifferentiated mesenchymal 
cells of limb buds displayed the complete absence of both cartilage and bone, and developed 
chondrodysplasia. This was associated with dramatically reduced expression of Runx2, a 
transcription factor needed for osteoblast differentiation, as well as an absence of Sox5/Sox6 
expression [175]. Sox5 and Sox6 work alongside Sox9 to play a crucial role in chondrocytic 
differentiation [176]. Sox5 and Sox6 are co-expressed with Sox9 in all chondroprogenitors and 
all differentiated chondrocytes, and cooperate with Sox9 to activate the Col2a1 enhancer and the 
Col2a1 gene [177]. Sox9’s involvement in the control of so many genes that contribute to 
expression of the extracellular matrix, including collagen and proteoglycan genes, suggested that 
Sox9 may be a master regulator of many genes required for scar formation. Thus, Sox9 was 
chosen as the first transcription factor to be investigated in search of a putative CSPG modulator 
in glial scarring post-SCI.  
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1.10 Sox9 modulates enzymes essential for CSPG production 
 
Researchers in the Brown laboratory have carried out chromatin immunoprecipitation 
(ChIP) assays to determine whether Sox9 directly binds XT-I, XT-II and C4ST. Mouse genomic 
DNA from developing testes that express Sox9 was immunoprecipitated with an anti-SOX9 
antibody.  The Sox9-immunoprecipitated DNA was purified and subsequently amplified by PCR 
using primers that flank the Genomatix predicted Sox9 binding sites in the XT-I, XT-II, and 
C4ST promoters. The ChIP experiments demonstrate in vivo binding of Sox9 to the XT-I and 
C4ST promoters. Experiments are ongoing to identify Sox9 binding sites in the XT-II promoter 
region.  
To investigate the effects of Sox9 on astrocyte-produced XT-I, XT-II, and C4ST, a 
primary rat astrocyte tissue culture model was used. Over-expression of Sox9 was accomplished 
by transient transfection of a Sox9 expression cassette and demonstrated increased astrocyte XT-
I, XT-II, and C4ST expression. Sox9 knockdown in primary rat astrocyte cultures, accomplished 
by treatment with anti-Sox9 siRNA, demonstrated decreased astrocyte XT-I, XT-II, and C4ST 
expression along with increased laminin and fibronectin expression [146]. These findings 
suggested that Sox9 plays a role in up-regulating anti-regenerative CSPG production as well as 
down-regulating pro-regenerative laminin and fibronectin expression [146].  
A second, seemingly unrelated, experimental strategy to promote recovery post-SCI, is 
the intravenous administration of anti-CD11d monoclonal antibody.  This anti-inflammatory 
treatment that blocks leukocytes from infiltrating into the damaged spinal cord  has been shown 
to decrease lesion size, improve neurological recovery after rodent SCI, and indirectly result in 
reduced levels of Sox9 at the lesion epicenter [178]. The observed reduction in Sox9 was 
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accompanied by a reduction in XT-I, XT-II, and C4ST expression as well as an increase in 
laminin and fibronectin expression [179]. Consistent with these mRNA changes, CSPGs were 
reduced by approximately one half in the lesions of anti-CD11d-treated rats, and laminin was 
increased. These results are in keeping with our previous observation that pro-inflammatory 
cytokines (IL-6, TGF-β2 and PDGF) up-regulate the expression of SOX9 [146].  We conjectured 
that these changes in Sox9, CSPG, and laminin/fibronectin expression in the scars of anti-CD11d 
mAb-treated rats greatly contributed to the increase in axonal growth and sprouting as well as 
functional recovery observed [178]. We were thus interested in investigating CSPG expression, 
recovery of hind limb motor function, and neuroplasticity in Sox9 knockdown mice. 
 
1.11 The dorsal contusion spinal cord injury model used in these studies  
 
The SCI model used in this dissertation is a thoracic spinal cord dorsal contusion. Mice 
are anesthetized, restrained in a mechanical device which stabilizes their spinal cord, and a 
laminectomy is performed to expose the 9th thoracic spinal segment. A computer controlled 
injury is induced by the Infinite Horizons Impactor mechanically delivering a blunt contusion to 
the exposed spinal cord (without disruption of the dura) [180]. The device records precise force 
delivered and displacement of spinal tissue, thus allowing for consistent and reproducible 
injuries. This contusion model of SCI produces primary mechanical trauma to the cord as well as 
significant secondary damage [181]. The resulting injury generates motor and behavioral deficits 
similar in morphology and pathology to common human SCI [182, 183]. Following SCI, motor 
function is evaluated using the Basso Mouse Scale (BMS) for scoring hind limb function [184] 
as well as locomotor activity box for assessment of total locomotion over a given period of time.  
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1.12 Conditional Sox9 knockdown mouse breeding strategy 
 
Conventional Sox9 knockdown embryos have been generated but are unsuitable for 
studies of SCI as Sox9 knockdown embryos do not survive to birth [174, 185]. Thus, to study the 
effect of Sox9 knockdown in adult mice which develop with normal Sox9 activity, we bred two 
existing mouse strains together. The first mouse strain used was Sox9flox/flox, a transgenic strain 
carrying floxed Sox9 alleles (exons 2 and 3 of Sox9 surrounded by loxP sites) which has been 
used successfully for the conditional knockdown of Sox9 in various cell types [148, 175]. The 
second mouse strain used was CAGGCre-ER, a transgenic line that ubiquitously expresses Cre 
recombinase fused to the mutated ligand binding domain of the mouse estrogen receptor under 
the control of the chicken beta actin promoter/enhancer coupled to the Cytomegalovirus (CMV) 
immediate early enhancer [186]. The mutated estrogen receptor ligand binding domain does not 
bind endogenous estradiol but rather binds to exogenously administered tamoxifen. Cre 
recombinase expressed in these animals is trapped outside the nucleus by the mutated estrogen 
receptor until tamoxifen administration releases Cre allowing for its transport to the nucleus 
where it excises floxed regions of DNA. By breeding the Sox9flox/flox mice to the CAGGCre-ER 
mice we generate Sox9flox/flox;CAGGCre-ER offspring (Sox9flox/flox;Cre). The F1 pups of 
Sox9flox/flox;Cre genotype were backcrossed with the Sox9flox/flox mice for more than 5 generations 
to attain the Sox9flox/flox;Cre and their Sox9flox/flox littermates described herein. In these 
Sox9flox/flox;Cre mice, tamoxifen administration allows us to examine the molecular, cellular, and 
neurological responses to SCI in the presence of greatly reduced expression levels of Sox9. In all 
of our studies Sox9flox/flox littermates that do not carry the CAGGCre-ER allele serve as controls 
as they express normal levels of Sox9 (even after tamoxifen administration). These Sox9 
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conditional knockdown (Sox9flox/flox;Cre) and control mice expressing normal levels of Sox9 
(Sox9flox/flox) were used to evaluate the following specific goals for this thesis. 
 
1.13 Specific goals 
 
This thesis had three major goals: 1) to determine if the transcription factor Sox9 controls 
chondroitin sulfate proteoglycan gene expression, 2) to determine if Sox9 conditional knockdown 
mice display improved hind limb functional recovery post-SCI, and 3) to determine if Sox9 
conditional knockdown mice display increased neuroplasticity post-SCI.   
 I set out the following seven objectives to investigate these goals: 
1) To breed Sox9 conditional knockdown mice for use in studying the effect of Sox9 
knockdown on recovery post-SCI in the mouse. 
2) To determine if Sox9 conditional knockdown mice display decreased CSPG expression in 
vitro. 
3) To determine if Sox9 conditional knockdown mice display decreased CSPG expression in 
vivo. 
4) To determine if Sox9 conditional knockdown mice display increased hind limb function 
post-SCI. 
5) To determine if Sox9 conditional knockdown mice display increased locomotion post-
SCI. 
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6) To determine if Sox9 conditional knockdown mice display increased axonal regeneration 
post-SCI. 
7) To determine if Sox9 conditional knockdown mice display increased synapse plasticity 
post-SCI. 
The first objective was accomplished by breeding Sox9flox/flox mice to CAGGCre-ER mice 
to generate Sox9flox/flox;Cre and their Sox9flox/flox littermates. On tamoxifen administration the 
Sox9flox/flox;Cre mice lose expression of Sox9 while the Sox9flox/flox littermates will still express 
wild type levels of Sox9flox/flox. By comparing Sox9flox/flox;Cre and Sox9flox/flox littermates we can 
ascertain the effect of Sox9 knockdown on mouse physiology post-SCI. The second objective 
was accomplished by using real time PCR to monitor mRNA changes in Sox9 knockdown and 
control primary astrocyte cultures. The third objective was accomplished by using western blot 
and immunohistochemistry to monitor protein changes in Sox9 knockdown and control mice. 
The fourth objective evaluated hind limb functional recovery in both a proof of principle model, 
as well as a more clinically relevant delayed knockdown model. Hind limb functional recovery 
from a T9 dorsal contusion SCI was evaluated in both models by way of Basso mouse scale hind 
limb function scoring. The fifth objective was accomplished by use of rodent activity box 
locomotion testing performed on Sox9 knockdown and control mice in both a proof of principle 
model, as well as a more clinically relevant delayed knockdown model. The sixth objective was 
accomplished by neuronal labeling techniques including retrograde labeling to assess for sparing 
and long range regeneration of axons through the injury site, and anterograde labeling to assess 
for axonal sprouting caudal to the injury site. The seventh and final objective was investigated 
using synapse markers to assess synaptic plasticity. 
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1.14 Summary 
 
The failure of CNS axons to undergo significant regeneration following injury is 
considered to be the main reason why most animals do not display significant functional 
recovery post-neurotrauma. One of the most detrimental causes of this failure of CNS axons to 
undergo significant regeneration is the expression of CSPG extracellular matrix post-injury. We 
have previously identified Sox9 as a transcription factor which may up-regulate expression of 
this anti-regenerative CSPG extracellular matrix. This thesis will attempt to determine if Sox9 
ablation will inhibit CSPG extracellular matrix production both in vitro and in vivo, result in 
increased neuroplasticity and axonal regeneration, and lead to improved hind limb motor 
function post-SCI. Chapter 2 of this thesis contains our proof of principle study in which we 
show that, following SCI, Sox9 knockdown mice display reduced CSPG expression and 
improved hind limb functional recovery. Chapter 3 of this thesis details a more clinically 
relevant injury model in which Sox9 is knocked down approximately 2 weeks post-injury, and 
still results in reduced CSPG expression and improved hind limb functional recovery. Chapter 4 
of this thesis investigates the neuronal mechanism behind this improved hind limb functional 
recovery and finds evidence for increased neuroplasticity, revealed as reactive sprouting and 
increased synaptic plasticity, in Sox9 knockdown mice post-SCI.  
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2.0 Abstract 
 
Chondroitin sulfate proteoglycans (CSPGs) found in perineuronal nets and in the glial 
scar after spinal cord injury have been shown to inhibit axonal growth and plasticity.  Since we 
have previously identified SOX9 as a transcription factor that up-regulates the expression of a 
battery of genes associated with glial scar formation in primary astrocyte cultures, we predicted 
that conditional Sox9 ablation would result in reduced CSPG expression after spinal cord injury 
and that this would lead to increased neuroplasticity and improved locomotor recovery.  Control 
and Sox9 conditional knockdown mice were subject to a 70 kdyne contusion spinal cord injury at 
thoracic level 9.  One week after injury, Sox9 conditional knockdown mice expressed reduced 
levels of CSPG biosynthetic enzymes (XT-1 and C4st), CSPG core proteins (brevican, neurocan 
and aggrecan), collagens 2a1 and 4a1, and GFAP, a marker of astrocyte activation, in the injured 
spinal cord compared to controls. These changes in gene expression were accompanied by 
improved hind limb function and locomotor recovery as evaluated by the Basso Mouse Scale 
(BMS) and rodent activity boxes.  Histological assessments confirmed reduced CSPG deposition 
and collagenous scarring at the lesion of Sox9 conditional knockdown mice, and demonstrated 
increased neurofilament-positive fibers in the lesion penumbra and increased serotonin 
immunoreactivity caudal to the site of injury.  These results suggest that SOX9 inhibition is a 
potential strategy for the treatment of SCI.  
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2.1 Introduction 
 
Damaged axons have a limited capacity for regeneration following adult mammalian 
spinal cord injury (SCI) [1]. This limited capacity for repair has been attributed, in part, to the 
nonpermissive environment of the glial scar that forms in the penumbra surrounding the lesion 
site [2-6]. This glial scar is predominantly formed from extracellular matrix (ECM) molecules 
expressed by reactive astrocytes although macrophages, microglia, oligodendrocytes, invading 
Schwann cells and meningeal fibroblasts all contribute to production of the scar matrix [6]. Chief 
of the many ECM molecules that serve to inhibit axonal regeneration are the chondroitin sulfate 
proteoglycans (CSPGs) [7, 8] that have greatly increased expression following SCI [4, 9]. 
CSPGs are a class of ECM macromolecules that share a common structure composed of a central 
core protein and a number of chondroitin sulfate side chains [10]. Both in vitro and in vivo 
studies have shown that axons do not extend into CSPG-rich ECM [4, 5, 11-13], and specific 
CSPGs which inhibit neurite outgrowth have been identified including: aggrecan [14], neurocan 
[15], phosphocan [16], brevican [17], versican [18], and NG2 [19].  
Strategies designed to target CSPGs at the spinal lesion have resulted in improved axonal 
regeneration after SCI. Enzymatic digestion of the chondroitin sulfate side chains, found on all 
CSPGs, by intrathecal chondroitinase treatment resulted in increased regeneration of ascending 
and descending tracts after SCI [20]. The combination of chondroitinase ABC with peripheral 
nerve grafts [21, 22], rehabilitation [23, 24], or neural precursor cell transplantation [25] have all 
led to improved axonal regeneration and recovery.   
We have previously argued that genes with related function are regulated together as 
classes or batteries after SCI [26] and that, in astrocytes, genes that promote axon regeneration 
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and genes that inhibit axon regeneration would be regulated as gene classes.  We predicted that 
the transcription of genes involved in CSPG production, the genes encoding CSPG core proteins, 
and genes encoding the enzymes responsible for generating the chondroitin sulfate side chains 
such as xylosyltransferase-I (XT-I), XT-II and chondroitin-4-sulfotransferase-1 (C4st-1), would 
be coordinately regulated after SCI.  Using bioinformatics we identified putative binding sites for 
the transcription factor SOX9 (sex-determining region Y-box 9) in the promoter sequences of 
XT-I, XT-II and C4st-1 in rats, mice and humans. We subsequently used gain of function and 
loss of function experiments to demonstrate that SOX9 positively regulates the expression of 
XT-I, XT-II, and C4st-1 in primary astrocyte cultures [27]. Thus we hypothesized that 
conditional ablation of Sox9 in mice would result in reduced expression of CSPGs and improved 
recovery after SCI.  We herein report improved hindlimb locomotor recovery after SCI in a line 
of conditional Sox9 knockdown mice that correlates with reduced expression of CSPGs and 
related ECM proteins in the lesion penumbra and at sites more distant to the lesion epicenter.  
 
2.2 Materials and Methods 
 
Mouse breeding and Sox9 conditional knockdown 
Conventional Sox9 knockdown mice have been generated but are unsuitable for studies of 
SCI as both Sox9 knockdown (Sox9-/-) and heterozygote (Sox9+/-) embryos do not survive to birth 
[28]. To evaluate SOX9 loss-of-function after SCI, in a nervous system that developed with 
normal levels of SOX9 activity, a tamoxifen-inducible conditional Sox9 knockdown strategy was 
used. We bred a mouse strain that carries floxed Sox9 (exons 2 and 3 of Sox9 surrounded by loxP 
sites) alleles [29] (Sox9flox/flox) with a transgenic mouse line that expresses Cre recombinase fused 
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to the mutated ligand binding domain of the human estrogen receptor (ER) under the control of a 
chimeric cytomegalovirus immediate-early enhancer/chicken β–actin promoter (B6.Cg-Tg(CAG-
Cre/Esr1)5Amc/J)[30] (Jackson Laboratories, Bar Harbor, Maine). The mutated ER ligand 
binding domain of the fusion protein does not bind endogenous estradiol but is highly sensitive 
to nanomolar concentrations of tamoxifen [31]. The Cre-ER fusion protein remains trapped in 
the cytoplasm of all cells until tamoxifen administration allows its transport to the nucleus where 
it excises loxP-flanked Sox9 DNA [30]. The resulting Sox9flox/flox;CAGGCreER (Sox9flox/flox;Cre) 
offspring served as tamoxifen inducible Sox9 knockdown animals, and Sox9flox/flox offspring 
served as control animals expressing normal levels of SOX9. Animals were genotyped by PCR 
analysis using the following primers:  
Sox9flox allele:  5’-ACACAGCATAGGCTACCTG-3’ and  
5’-TGGTAATGAGTCATACACAGTAC-3’. 
Sox9wildtype allele: 5’-GGGGCTTGTCTCCTTCAGAG-3’ and  
5’- TGGTAATGAGTCATACACAGTAC-3’. 
Sox9knockdown allele: 5’-GTCAAGCGACCCATG-3’ and  
5’-TGGTAATGAGTCATACACAGTAC-3’. 
Cre+ allele: 5’-CAATTTACTGACCGTACAC-3’ and 5’-AGCTGGCCCAAATGTTGCTG-3’. 
Tamoxifen (Sigma Aldrich, St. Louis, Missouri) was administered at 3 mg/20 g mouse by 
oral gavage to all Sox9flox/flox;Cre and Sox9flox/flox littermates once per day for 7 days. Following 
the final day of tamoxifen oral gavage, the animals were housed for 7 days without treatment to 
allow time for Cre-mediated recombination and tamoxifen clearance prior to subsequent SCI.  
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Primary astrocyte culture 
Primary astrocyte cultures were prepared from newborn Sox9flox/flox;Cre or Sox9flox/flox 
control mice at postnatal day 1. The upper portion of the skull was removed and the meninges 
carefully dissected away to avoid contamination of the culture with fibroblasts. The neocortices 
were removed, individually placed into serum-free Eagle Minimum Essential Medium (EMEM) 
(Lonza, Walkersville, Maryland), homogenized by trituration, and gravity-filtered through a 40-
μm cell strainer (Becton Dickinson and Company, Toronto, Ontario). The cells were plated in 
EMEM + 20% FBS (Invitrogen, Carlsbad, California), penicillin/streptomycin (Invitrogen, 
Carlsbad, California); each animal’s cells were divided into two wells each of a 6-well dish 
(Becton Dickinson and Company, Toronto, Ontario).  After 2 days, media was changed to 
EMEM + 10% FBS, penicillin/streptomycin, and was changed three times per week thereafter. 
After 2 weeks in culture 1 μM 4-hydroxytamoxifen (Sigma Aldrich, St. Louis, Missouri) was 
administered in three changes of media over 1 week. Following 4-hydroxytamoxifen 
administration the cells were cultured in normal media for 1 more week.  The percentage of 
GFAP-expressing cells in these cultures was found to be >95%.  
 
Real time PCR 
RNA was extracted from Sox9 conditional knockdown and Sox9 positive control primary 
astrocyte cultures 1 week post tamoxifen administration, and from the lesion epicentre of Sox9 
conditional knockdown and Sox9 positive control mice 1 week post-SCI, using the RNA-Easy kit 
according to the manufacturer's instructions (Qiagen, Valencia, California). First strand cDNA 
was synthesized from 1 μg RNA per sample using the High Capacity cDNA Archive Kit 
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according to the manufacturer instructions (Applied Biosystems, Carlsbad, California). The 
primer probe sets, optical adhesive covers, and PCR plates were purchased from Applied 
Biosystems (Carlsbad, California). All primer probes were labeled with 5'FAM and with 
3'TAMRA as quencher with the exception of the 18s ribosomal probe, which was labeled with 5' 
VIC. TaqMan assays were conducted using the Applied Biosystems gene expression assay 
primer probe sets listed in Table 1. 
 
Table 1. List of TaqMan Real-Time PCR Primer Probe Sets 
Primer Probe    Catalog number   PCR Ct range 
18s     4308329    14.72–16.07 
Sox9     Mm00448840_m1   21.88–23.64 
XT-I     Mm00558690_m1   27.34–29.57 
XT-II     Mm00461181_m1   24.72–25.87 
C4st-1     Mm00517563_m1   21.72–23.01 
Aggrecan    Mm00545807_m1   24.53–27.07 
Brevican    Mm00476090_m1   18.35–21.70 
Neurocan    Mm00484007_m1   17.31–20.73 
Collagen 2A1    Mm01309562_g1   23.40–27.33 
Collagen 4A1    Mm00802377_m1   20.73–21.39 
GFAP     Mm01253033_m1   19.96–22.16 
Cartilage link protein   Mm00488952_m1   28.35–29.94 
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TaqMan (Applied Biosystems, Carlsbad, California) gene expression assays were 
conducted on a 7900HT fast real time PCR apparatus (Applied Biosystems, Carlsbad, California) 
using thermal cycler conditions set as follows; 10 min at 95°C followed by 40 cycles of 30 s at 
95°C followed by 30 s at 60°C. Cycle thresholds (Ct) for all target genes were kept below 30 as 
indicated in Table 1. A standard curve of cycle thresholds using cDNA serial dilutions was 
established and used to calculate mRNA expression. Target gene mRNA expression was 
normalized to the amount of 18S mRNA present in each sample. The ratio of knockdown to 
control sample normalized target gene mRNA was analyzed by Student's T-test.  
 
Western blotting 
Protein was isolated from the lesion site (0.45 cm) in tamoxifen-treated Sox9 conditional 
knockdown and Sox9 positive control mice 2 weeks post-SCI. The spinal cord tissue was lysed in 
modified RIPA buffer (1% nonidet P-40, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris, 1 mM EDTA, pH 7.5, plus 1 complete Mini protease inhibitor tablet/7mL RIPA 
buffer (Roche Molecular Biochemicals, Indianapolis, Indiana) on ice using a ground glass 
homogenizer. The protein mixture was centrifuged at 13,000 x g for 5 min and the supernatant 
collected, and diluted in reducing PAGE loading buffer. Protein samples were loaded on 
reducing SDS-PAGE gels at 10 μg/well. The membrane was blocked in 10% nonfat powdered 
milk and then incubated with primary antibodies; anti-SOX9 (AB 5535, Millipore, Billerica, 
Massachusetts used at 1:1000), anti-GFAP (MAB360, Millipore, Billerica, Massachusetts, used 
at 1:1000), and anti-β-actin (A1978, Sigma, St. Louis, Missouri, used at 1:10,000) for protein 
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expression assessed by western blot. HRP conjugated anti-mouse IgG (715-035-151, Jackson 
ImmunoResearch Laboratories, West Grove, Pennsylvania) and HRP conjugated anti-rabbit IgG 
(711-035-152, Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) secondary 
antibodies were used at 1:20,000 dilution to detect SOX9, GFAP, and β-actin protein expression. 
SOX9 and GFAP protein expression was normalized to β-actin protein expression by 
densitometry using the EpiChemi3 Darkroom (UVP Bioimaging Systems, Upland, California) 
and LabWorks software (Media Cybernetics Inc, Bethesda, Maryland). Protein samples were 
also loaded in parallel at 3 μg/well into a Bio-Rad Slot-blot apparatus (BioRad, Mississauga, 
Ontario) and vacuum transferred onto a nitrocellulose membrane (BioRad, Mississauga, 
Ontario). The membrane was blocked in 10% nonfat powdered milk and then incubated with 
primary antibody at 1:200 dilution overnight for anti-CS-56 (C8035, Sigma, St. Louis, Missouri) 
or 1:10,000 dilution for anti-β-actin (A1978, Sigma, St. Louis, Missouri). HRP conjugated anti-
mouse IgM (62-6820, Invitrogen, Carlsbad, California) and anti-mouse IgG (715-035-151, 
Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) secondary antibodies were 
used at 1:20,000 dilutions to detect CS56 and β-actin protein expression. CS56 protein 
expression was normalized to β-actin protein expression by densitometry using the EpiChemi3 
Darkroom (UVP Bioimaging Systems, Upland, California) and LabWorks software (Media 
Cybernetics Inc, Bethesda, Maryland). 
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Spinal cord injury 
All protocols for these experiments were approved by the University of Western Ontario 
Animal Care Committee in accordance with the policies established in the Guide to Care and 
Use of Experimental Animals prepared by the Canadian Council on Animal Care. One week 
after the last tamoxifen oral gavage, 13 female Sox9flox/flox;Cre and 16 female Sox9flox/flox mice 
were anesthetized with 100 mg/kg ketamine: 5 mg/kg xylazine. The T9 spinal cord segment was 
exposed by a dorsal laminectomy. The spinal cord was stabilized at T7 and T9 with forceps. The 
T9 spinal segment was injured by a 70 kdyne contusion delivered with a 1s dwell time by 
computer controlled Infinite Horizons Impactor (displacement range: 500-900 μM) (Precision 
Systems and Instrumentation, Fairfax, Virginia). Following SCI the mice were housed 
individually. Baytril (25?mg/kg, Bayer, Toronto, Ontario, Canada) and buprenorphine (0.01 
mg/kg, Schering-Plough, Hertfordshire, UK) were injected subcutaneously for 3 days post-SCI. 
Bladders were manually emptied twice daily for the duration of the experiment.  
 
Behavioral testing 
Locomotor recovery of the animals was assessed by two blinded observers using the 
Basso Mouse Scale (BMS) open field locomotor score [32]. The day following SCI, all mice 
were evaluated for any signs of locomotor recovery in their hindlimbs and mice that had BMS 
scores > 0.5 were excluded from further analyses (4 Sox9 conditional knockdowns and 5 
controls).   Animals were evaluated once per week for 14 weeks after SCI. Left and right hind 
limb scores were averaged to generate a composite score. In addition, locomotion was evaluated 
at 14 weeks post-SCI by rodent activity box (Accuscan Instruments Inc, Columbus, Ohio). The 
43 
 
 
 
activity box records distance traveled by detecting breaks in a series of infrared light beams. The 
total distance the mice traveled was measured over a 2 hour period at night (during their normal 
awake circadian cycle).  
 
Spinal cord sectioning 
Protein expression levels of SOX9 target genes were assessed at 14 weeks post-SCI.  
Animals were deeply anesthetized with 100 mg/kg ketamine: 5 mg/kg xylazine, and cardiac 
perfusion was carried out with 20 ml of saline at pH 7.4 followed by 20 ml 4% 
paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH 7.4). Spinal cords were dissected 
and post-fixed for 2 h in 4% PFA followed by cryoprotection in 20% sucrose in 0.1 M phosphate 
buffer at pH 7.4 at 4 ˚C overnight. Spinal cords were embedded in Tissue-Tek O.C.T. Compound 
(Sakura Finetek U.S.A. Inc, Torrance, California), frozen over dry ice, and stored at -80 ˚C 
overnight. Frozen cords were then cross-sectioned at 16 µm using a cryostat, and serially thaw-
mounted on SuperfrostTM glass slides (Fisher Scientific Company, Ottawa, Canada).  
 
Immunohistochemistry and trichrome staining 
Immunohistochemistry was conducted using the primary antibodies listed in Table 2. 
Cryosectioned slides were rinsed in PBS and treated with 5% normal goat serum and 0.1% 
triton-X-100 in PBS at room temperature for 1 h. Slides were incubated with the appropriate 
dilutions of primary antibodies in a humidified chamber at 4˚C overnight. Sections were stained 
for CSPG expression using the monoclonal antibody CS56 that recognizes the terminal portions 
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of chondroitin sulfate-4 or -6 side chains and thus detects a variety of CSPGs [33] and a 
biotinylated goat anti-mouse IgM (Vector laboratories, Burlingame, California) secondary 
antibody (1:200). Sections were then incubated for 45 min with avidin-peroxidase conjugate 
(Elite Kit, Vector laboratories, Burlingame, California) at room temperature, and the signal 
visualized by peroxidase diaminobenzine (DAB, Invitrogen, Carlsbad, California). Sections to be 
stained for perineuronal nets (PNNs) were washed in PBS 3 x 10 min, and incubated with 
biotinylated Wisteria Floribunda Lectin (WFA, Sigma Aldrich, St. Louis, Missouri) (1:1000) for 
1 h at room temperature. Sections were then incubated for 45 min with avidin-peroxidase 
conjugate (Elite Kit, Vector laboratories, Burlingame, California) at room temperature, and the 
signal visualized by peroxidase diaminobenzine (DAB, Invitrogen, Carlsbad, California). All 
DAB staining was conducted with a 2 min DAB reagent incubation time for all Sox9 conditional 
knockdown and control cord sections, and were completed at the same time. Immunofluorescent 
labeling of the remaining proteins was performed using the following secondary antibodies; 
Alexa-Fluor 488-conjugated goat anti-mouse IgG (1:500, Invitrogen, Carlsbad, California), 
Alexa-Fluor 488-conjugated goat anti-rabbit IgG (1:500, Invitrogen, Carlsbad, California), or 
Alexa-Fluor 594-conjugated goat anti-rabbit IgG (1:500, Invitrogen, Carlsbad, California), for 1 
h at room temperature. Slides were then washed in PBS and coverslips were attached with 
ProLong Gold Anti-Fade mounting medium (Invitrogen, Carlsbad, California).  Gomori’s 
Trichrome staining was used to stain for collagen according to the manufacturer’s instructions 
(HT10316, Sigma Aldrich, St. Louis, Missouri).  
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Table 2. List of primary antibodies and stains used for spinal cord staining 
Antibody Dilution Isotype Source 
Anti-GFAP 1:500  Mouse IgG Millipore, Billerica, Massachusetts 
Anti-CS56 1:300  Mouse IgM Sigma Aldrich, St. Louis, Missouri  
Anti-NF200 1:1000  Rabbit IgG Sigma Aldrich, St. Louis, Missouri  
Anti-5HT 1:500  Rabbit IgG ImmunoStar, Hudson, Wisconsin 
WFA  1:1000    Sigma Aldrich, St. Louis, Missouri  
 
Quantification of GFAP, CS56, trichrome, NF-200, 5-HT, and WFA staining 
GFAP, CS56, trichrome, and NF-200 staining were analyzed as follows. Cross-sections 
16 μm thick and 160 μm apart between 1.6 mm rostral through 1.6 mm caudal to the epicentre of 
injury were analyzed for positive staining using Image Pro Plus software (Media Cybernetics 
Inc, Bethesda, Maryland). A threshold was set for each stain that identified positive signal 
(staining above background levels). The area of positive staining was normalized to total cord 
area. Staining results were grouped into 5 bins based on position relative to the lesion epicentre 
that was arbitrarily set as zero. The bin set as the epicenter encompassed 0.65 mm rostral and 
0.65 mm caudal to the epicenter.  The 1.3 mm included in the “epicenter” bin that approximates 
the size of the head of the impactor.  The rostral bins encompassed two directly adjacent  
segments of spinal cord rostral to the lesion (0.8 mm each) and the two caudal bins encompassed 
two directly adjacent segments of spinal cord rostral to the lesion (0.8 mm each).  
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The area of 5-HT immunoreactivity (area per area of interest) was quantified in the 
intermediolateral cell column (IML) and in the ventral horns in 16 μm thick cross-sections 160 
μm apart obtained 0.8-1.6 mm caudal to the injury site using Image Pro Plus Software (Media 
Cybernetics Inc, Bethesda, Maryland). A single pre-set area was used to define all IML or 
ventral horn regions in all cords across both Sox9 conditional knockdown and control animal 
sections. The area of positive 5-HT immunoreactivity was quantified within this set area defined 
as the IML or ventral horn.  The area of WFA immunoreactivity to identify PNNs was analyzed 
using 16 μm thick cross-sections 160 μm apart sampled at T10. Positive staining was quantified 
using Image Pro Plus Software (Media Cybernetics Inc, Bethesda, Maryland) using a threshold 
which identified positive signal (staining above background levels). 
    
Statistical analysis 
Mean values are expressed ± SE. Both in vitro and in vivo mRNA analyses were 
subjected to statistical analysis using Student’s T-test. 5-HT and WFA quantification was 
subjected to statistical analysis using Student’s T-test. CS56, trichrome, GFAP, and NF-200 
immunohistochemical quantification was subjected to statistical analysis using two-way 
ANOVA with Neuman-Keuls post-hoc test at each binned region of the cord, rostral, epicenter, 
and caudal to the site of injury. BMS results were subjected to statistical analysis using two-way 
repeated measures ANOVA with Neuman-Keuls post-hoc test. Activity Box locomotion was 
subjected to statistical analysis using one-way ANOVA with Neuman-Keuls post hoc test. 
Analyses were conducted with GraphPad Prism software (GraphPad Software Inc, La Jolla, 
California), except for two-way ANOVAs which were conducted with SigmaStat software 
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(Systat Software Inc, San Jose, California), and significance was accepted at p<0.05. A two-way 
ANOVA summary table is provided as Supplementary Table 1. 
 
2.3 Results 
 
Changes in gene expression in primary astrocytes isolated from Sox9 conditional 
knockdowns 
Astrocyte cultures were isolated from Sox9 conditional knockdown and from control 
mice to evaluate the effects of Sox9-ablation on gene expression in primary astrocytes.  All 
cultures were treated with 4-hydroxytamoxifen for 1 week and then cultured free of tamoxifen 
for an additional week before harvesting for RNA isolation.  Using quantitative-PCR (Q-PCR) 
we measured the mRNA levels of Sox9, XT-I, XT-II, C4st-1, Col2a1, Col4a1, cartilage link 
protein (Crtl), and aggrecan (Agc) (Fig. 1).  The mRNA levels of glial fibrillary acidic protein 
(GFAP), a marker of astrocyte activation, and brevican and neurocan (two CSPG core proteins) 
were also measured as we predicted that SOX9 would regulate genes broadly associated with 
astrocyte activation and scar production. Quantitative PCR demonstrated that administration of 
4-hydroxytamoxifen resulted in a 72% ± 4% reduction in Sox9 mRNA expression compared to 
control mouse astrocyte cultures.  Reduced Sox9 expression was associated with a statistically 
significant reduction in the expression of XT-I, Agc, brevican, neurocan, Col2a1, and GFAP, in 
comparison to control astrocyte cultures (Fig. 1). 
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Figure 1.  Astrocytes from Sox9 conditional knockdown mice demonstrate reduced glial 
scar gene expression compared to control mice. Treating Sox9flox/flox;Cre  astrocyte cultures 
with 1 μM 4-hydroxytamoxifen for one week results in a 72% ± 4% reduction in Sox9 mRNA 
levels and is accompanied by a statistically significant reduction in XT-1, aggrecan (Agc), 
brevican (B-can), neurocan (N-can), Col2A1, and GFAP  mRNA levels compared to Sox9flox/flox 
astrocytes treated with 1 μM 4-hydroxytamoxifen, (p<0.05, Student’s T-test;  n=4 per group).  
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Figure 1.  Astrocytes from Sox9 conditional knockdown mice demonstrate reduced glial scar 
gene expression compared to control mice. 
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Changes in gene expression in the injured spinal cord in Sox9 conditional knockdowns 
To determine if the reductions in gene expression observed in the Sox9flox/flox;Cre  primary 
astrocyte cultures  would also be observed after SCI we evaluated mRNA expression levels at 
the lesion in Sox9 conditional knockdown and control mouse spinal cords one week after a 70 
kdyne SCI. Q-PCR demonstrated a 62% ± 11% reduction in Sox9 mRNA levels in the Sox9 
conditional knockdown mice compared to controls (Fig. 2). This reduction in Sox9 mRNA levels 
was associated with a statistically significant reduction in XT-I, C4st-1, Agc, brevican, neurocan, 
Col2a1, Col4a1, and GFAP mRNA expression as compared to control mice (Fig. 2).  To 
determine if these changes in mRNA levels result in parallel changes in protein levels we 
evaluated protein expression by western and slot blot analysis. Sox9 conditional knockdown 
mice displayed significantly reduced SOX9, GFAP and CSPG protein expression 2 weeks post-
SCI (Fig. 3).   
 
Sox9 conditional knockdown mice demonstrate improved locomotor recovery after SCI 
As the glial scar in general and CSPGs in particular have been identified as inhibitors of 
axonal regeneration after SCI we predicted that the reduction in CSPG and collagen expression 
at the spinal lesion observed at 1-2 weeks post-injury would lead to improved locomotor 
recovery in Sox9 conditional knockdown mice.  Sox9flox/flox;Cre and control mice were 
administered tamoxifen for one week and allowed a week for tamoxifen washout before 
undergoing a 70 kdyne SCI using the Infinite Horizon impactor.  Hind limb function was 
evaluated weekly for 14 weeks post-SCI.  On day one following SCI all mice displayed 
paralyzed hind limbs, scoring a zero on the Basso Mouse Scale (BMS).   In both Sox9  
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Figure 2.  Sox9 conditional knockdown mice demonstrate reduced glial scar gene 
expression compared to control mice. Spinal cord-injured, tamoxifen-treated Sox9flox/flox;Cre  
mice demonstrate a 62% ± 11% reduction in Sox9 mRNA expression compared to spinal cord-
injured, tamoxifen-treated Sox9flox/flox mice one week post-SCI. This reduction in Sox9 expression 
is associated with a statistically significant reduction in XT-1, C4st-1, Agc, brevican (B-can), 
neurocan (N-can), Col2A1 and 4A1, and GFAP mRNA levels (p<0.05, Student’s T-test; n=5 per 
group).  
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Figure 2.  Sox9 conditional knockdown mice demonstrate reduced glial scar gene 
expression compared to control mice. 
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Figure 3. Sox9 conditional knockdown mice demonstrate reduced SOX9, GFAP, and CSPG 
protein 2 weeks post-SCI. A) Western blot analysis and subsequent densitometry (B, C) 
demonstrate reduced SOX9 and GFAP levels in Sox9 conditional knockdown mice in 
comparison to control mice (normalized to β-actin levels) (p=<0.05, Student’s T-test;  n=3).  D) 
Slot blot and subsequent densitometry (E) demonstrates reduced CSPG expression in Sox9 
conditional knockdown mice compared to controls (normalized to β-actin levels) (p=<0.05, 
Student’s T-test; n=3). 
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Figure 3. Sox9 conditional knockdown mice demonstrate reduced SOX9, GFAP, and CSPG 
protein 2 weeks post-SCI. 
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conditional knockdown and control mice hind limb locomotion gradually improved over time. 
Locomotor BMS scoring in control mice reached a plateau of 0.63 ± 0.21 at 4 weeks post-SCI, 
(Fig. 4a). The median BMS score in this group of 0.5 indicates slight (less than 90˚) movement 
in one ankle.  In contrast, the BMS scores of the Sox9 conditional knockdown mice continued to 
improve past 4 weeks and did not reach a plateau until 11 weeks post-SCI, achieving an average 
BMS score of 1.81 ± 0.19. The median BMS score for Sox9 conditional knockdown mice of 2 
indicates extensive (greater than 90˚) movement in both ankles. The significantly higher scores 
of the Sox9 conditional knockdown mice were accompanied by a statistically significant increase 
in ability to achieve plantar placement of their hind limbs (Chi squared test p=0.005); six of nine 
Sox9 conditional knockdown mice displayed at least one limb capable of plantar placement 
compared to one of eleven control mice which were capable of plantar placement.  Finally, Sox9 
conditional knockdown mice and controls were placed in a computer-monitored rodent activity 
box to record total distance traversed over a 2 h period. Fourteen weeks after SCI, control mice 
covered a total distance of 1414 ± 269 cm in 2 h, whereas Sox9 conditional knockdown mice 
covered a total distance of 3481 ± 814 cm in 2 h.  The distance traversed by the Sox9 conditional 
knockdown mice was significantly greater than that in the injured control animals and was not 
significantly different from uninjured Sox9flox/flox mice (3330 ± 402 cm in 2 h) or uninjured 
control mice (3452 ± 526.5 cm in 2 h) (p=0.027 by 1-way ANOVA with Neuman-Keuls post hoc 
test) (Fig. 4b) . 
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Figure 4.  Sox9 conditional knockdown mice demonstrate improved locomotor recovery 
after SCI. A) Sox9 conditional knockdown mice display increased hind limb functional recovery 
in comparison to control mice. Both Sox9 conditional knockdown and control mice display hind 
limb paralysis immediately following SCI on day 1 post-SCI. Sox9 conditional knockdown mice 
score higher (increased hind limb function) on the Basso Mouse Scale (BMS) in comparison to 
control mice every week between 1 and 14 weeks after SCI (p<0.05, 2 way repeated measures 
ANOVA, Newman-Keuls post-hoc tests (p<0.05); n=9 SOX9 KO, n= 11 control). B) Sox9 
conditional knockdown mice demonstrate increased distance traveled in comparison to control 
injured mice measured over a 2 h period in a rodent activity box (p<0.05, 1-way ANOVA; n=9 
SOX9 KO, n= 11 controls). 
 
 
 
 
 
57 
 
 
 
 
 
Figure 4.  Sox9 conditional knockdown mice demonstrate improved locomotor recovery 
after SCI. 
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Sox9 conditional knockdown mice display reduced CSPG, collagen and GFAP expression at the 
lesion site 14 weeks following SCI 
Since the Sox9 conditional knockdown animals had reduced levels of XT-I, C4st-1, Agc, 
brevican, neurocan, Col2a1, Col4a1, and GFAP mRNA at 1 week post-SCI and concomitant 
reductions in CSPG and GFAP protein levels at the lesion 2 weeks post-SCI, we anticipated that 
these animals would display reduced evidence of a glial scar at 14 weeks post-SCI. Spinal cord 
sections from Sox9 conditional knockdown mice at 14 weeks after SCI demonstrated a 
significant reduction in CSPG immunoreactivity (area immunoreactivity per cord area) rostral to, 
caudal to and at the lesion epicenter compared to controls  (Fig. 5). Decreased CSPG staining 
correlated with increased BMS scores by linear regression analysis (r2 = 0.69). Quantifying the 
area of positive trichrome staining for collagen (blue stain in Fig. 6) demonstrated reduced 
amounts of collagen (area immunoreactivity per cord area) in the lesion epicenter in Sox9 
conditional knockdown mice compared to controls. Finally, in agreement with the Q-PCR data at 
1 week post-SCI and the protein quantitation at 2 weeks post-SCI, immunohistochemistry 
demonstrated reduced expression of GFAP (area immunoreactivity per cord area) in Sox9 
conditional knockdown mice rostral to, caudal to and at the lesion epicenter 14 weeks post-injury 
(Fig. 7).  Together these data indicate that at 14 weeks post-injury, the lesion of spinal cord 
injured Sox9 conditional knockdown animals contains fewer reactive astrocytes and less glial and 
collagenous scarring than that of the control animals.  
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Figure 5. Sox9 conditional knockdown mice display reduced CSPG expression 14 weeks 
post-SCI. Representative photomicrographs of anti-CSPG DAB immunohistochemical staining 
approximately 1 mm rostral to the lesion epicenters (A) at the epicenters (B) and 1 mm caudal to 
the lesion epicenters (C) from Sox9 conditional knockdowns and controls as indicated. D) 
Quantification of area of CSPG immunoreactivity in Sox9 conditional knockdown and control 
sections. The area of immunostaining per cross-sectional area of spinal cord was quantified using 
ImageProPlus software on sections spaced 160 μm apart.  The area per area measurements were 
then grouped into bins centered on the positions indicated.  The bin representing epicenter in 
each animal extended 0.65 mm rostral and caudal to the center of the lesion.  The bins rostral and 
caudal to the epicenter were centered on the positions shown relative to the epicenter and 
included sections 0.4 mm rostral and caudal.  * indicates statistically significantly different from 
controls (p<0.05, 2 way ANOVA, Newman-Keuls post-hoc test (p<0.05); n = 9 Sox9 KO, n =11 
controls). Bars = 100 µm. 
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Figure 5. Sox9 conditional knockdown mice display reduced CSPG expression 14 
weeks post-SCI. 
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Figure 6. Sox9 conditional knockdown mice demonstrate reduced collagen at the lesion 
epicenter 14 weeks post-SCI. A) Representative photomicrographs of Trichrome-stained spinal 
cord sections from the lesion epicenters of Sox9 conditional knockdown and control mice.   B) 
High power magnifications of boxed areas in A). C) Quantification of area of collagen (blue) 
staining in Sox9 conditional knockdown and control sections.  Areas of collagen staining were 
quantified as explained in legend to Figure 5. * indicates statistically significantly different from 
controls (p<0.05, 2 way ANOVA, Newman-Keuls post-hoc test (p<0.05); n=9 Sox9 KO, n = 11 
control). Bars = 100 µm. 
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Figure 6. Sox9 conditional knockdown mice demonstrate reduced collagen at the 
lesion epicenter 14 weeks post-SCI. 
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Figure 7. Sox9 conditional knockdown mice demonstrate reduced GFAP expression 14 
weeks post-SCI. A) Representative photomicrographs of anti-GFAP immuno-staining from 
spinal cord sections approximately 1 mm rostral to the lesion epicenters (A) at the epicenters (B) 
and 1 mm caudal to the lesion epicenters C) from Sox9 conditional knockdowns and controls as 
indicated.  D) Quantification of area of GFAP immunoreactivity (area per area) in Sox9 
conditional knockdown and control sections. Areas of GFAP immuno-staining were quantified 
as explained in legend to Figure 5. * indicates statistically significantly different from controls 
(p<0.05, 2 way ANOVA, Newman-Keuls post-hoc test (p<0.05); n=9 Sox9 KO, n = 11 controls). 
Bars = 100 µm. 
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Figure 7. Sox9 conditional knockdown mice demonstrate reduced GFAP expression 14 
weeks post-SCI. 
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Sox9 conditional knockdown mice have increased neurofilament-positive fibers in the 
penumbra of the lesion site following SCI 
As the reduced CSPG and collagen levels in the Sox9 conditional knockdown lesions 
would be predicted to correlate with an environment more permissive to axonal growth and 
sprouting, we expected to observe an increased number of neurofilament-positive fibers in the 
spinal lesions of the Sox9 conditional knockdown mice compared to controls.  Immuno-stained 
spinal cord sections from Sox9 conditional knockdowns and controls demonstrated significant 
reductions in neurofilament at the lesion epicenter (Fig. 8).  Whereas the area of neurofilament 
immunoreactivity (area immunoreactivity per cord area) in the Sox9 conditional knockdown 
mice was not significantly different from controls at the lesion epicenter, neurofilament 
immunoreactivity was increased in the bins 0.8 mm rostral and caudal to the lesion epicenter in 
Sox9 conditional knockdowns compared to controls (Fig. 8).   
 
Sox9 knockdown mice display increased 5-HT immunoreactivity caudal to the lesion site 
following SCI 
Descending serotonergic (5-HT positive) projections from the raphe nuclei control a 
variety of normal body functions. Serotonergic projections synapsing in the dorsal horn modulate 
pain sensation [34, 35], serotonergic projections targeting sympathetic preganglionic neurons in 
the intermediolateral cell column (IML) contribute to autonomic regulation [36], and 
serotonergic projections synapsing in the ventral horn provide excitatory input to motor neurons, 
the loss of which correlates with locomotor dysfunction [37]. To evaluate whether the improved 
recovery achieved by the Sox9 conditional knockdown mice could be attributed to increased  
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Figure 8. Sox9 conditional knockdown mice demonstrate increased neurofilament 
immunoreactivity rostral and caudal to their lesion epicenters 14 weeks post-SCI. A) 
Representative photomicrographs of anti-neurofilament immuno-staining from spinal cord 
sections approximately 0.5 mm rostral to the lesion epicenters (A) at the epicenters (B) and 0.5 
mm caudal to the lesion epicenters C) from Sox9 conditional knockdowns and controls as 
indicated. D) Quantification of area of neurofilament immunoreactivity (area per area) in Sox9 
conditional knockdown and control sections. Areas of neurofilament immuno-staining were 
quantified as explained in legend to Figure 5. * indicates statistically significantly different from 
controls (p<0.05, 2 way ANOVA, Newman-Keuls post-hoc test (p<0.05); n=9 Sox9 KO, n = 11 
control). Bars = 100 µm. 
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Figure 8. Sox9 conditional knockdown mice demonstrate increased neurofilament 
immunoreactivity rostral and caudal to their lesion epicenters 14 weeks post-SCI. 
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Figure 9. Sox9 conditional knockdown mice display increased 5-HT immunoreactivity 
caudal to the lesion. Immunohistochemistry was used to detect serotonin in the spinal cord 14 
weeks post-SCI. A) Representative photomicrographs of sections stained for 5-HT 
immunoreactivity ~1.2 mm caudal to the lesion epicenter from Sox9 conditional knockdown and 
control mice.  Almost no 5-HT immunoreactivity was observed caudal to the lesion in control 
mice, however 5-HT immunoreactivity was observed caudal to the lesion in SOX9 conditional 
knockdown mice.  B) High power magnifications of boxed areas in A). C) Quantification of 5-
HT immunoreactivity. 5-HT-immunoreactivity was significantly increased in intermediolateral 
cell column and the ventral horn of Sox9 conditional knockdown mice in comparison to control 
mice. * indicates statistically significantly different from controls (Student’s T-test, p=<0.05; 
n=9 Sox9 KO, n = 11 controls). Bars = 100 µm. 
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Figure 9. Sox9 conditional knockdown mice display increased 5-HT immunoreactivity 
caudal to the lesion. 
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5-HT inputs onto targets caudal to the injury we performed immunostaining for 5-HT on cross-
sections from Sox9 conditional knockdowns and controls 14 weeks after SCI. Between 0.8 mm - 
1.6 mm caudal to the lesion epicenter Sox9 conditional knockdown mice displayed a statistically 
significant increase in 5-HT immunoreactivity in the IML and ventral horn, compared to control 
mice (Fig. 9).  
 
Sox9 conditional knockdown mice display decreased WFA caudal to the lesion site 
following SCI 
In addition to their contribution to the glial scar matrix CSPGs are also a major 
component of the PNN ECM that stabilize synapses during development [38] and limit plasticity 
in the adult nervous system. Since Sox9 conditional knockdowns demonstrated reduced levels of 
CSPGs and other ECM components at the glial scar we evaluated whether they may also 
demonstrate reductions in the ECM in their PNNs. Cross-sections from Sox9 conditional 
knockdowns and controls were stained with biotinylated Wisteria floribunda agglutinin (WFA).  
WFA binds N-acetylgalactosamine side chains in proteoglycans including CSPGs [39, 40].  
Cross-sections 1.6 – 3.2 mm caudal of the lesion epicenter were selected for WFA-staining to 
determine whether conditional Sox9 ablation might lead to a reduction in PNN ECM distal to the 
lesion. WFA staining revealed a reduction in PNNs in the Sox9 knockdown mice caudal to the 
lesion compared to control mice 14 weeks post-SCI (Fig. 10).  This suggests that ablation of 
Sox9 creates a more growth-permissive environment in the mouse spinal cord, possibly 
contributing to improved motor function after spinal cord injury.  
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Figure 10. Perineuronal net matrix is reduced in Sox9 conditional knockdown mice caudal 
to lesion 14 weeks post-SCI. WFA staining was used to detect PNN matrix caudal to lesion 
epicenter in control and Sox9 conditional knockdown mice. A) Representative photomicrographs 
of sections stained for WFA caudal to the lesion epicenter from Sox9 conditional knockdown and 
control mice.  B) High power magnifications of boxed areas in A. C) Quantification of area of 
WFA staining in Sox9 conditional knockdown and control sections. The area of WFA stained 
tissue per cross-sectional area of spinal cord was quantified using ImageProPlus software on 
sections spaced 160 μm apart from 1.6 to 3.2 mm caudal to the epicenters.  * indicates 
statistically significantly different from controls (Student’s T-test, p=<0.05; n=9 Sox9 KO, n = 
11 controls). Bars = 100 µm. 
 
 
 
 
 
72 
 
 
 
 
 
Figure 10. Perineuronal net matrix is reduced in Sox9 conditional knockdown mice 
caudal to lesion 14 weeks post-SCI. 
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2.4 Discussion 
 
Although the glial scar plays a key role in the acute response to SCI by sealing the lesion 
site, restoring homeostasis, and modulating immunity, it also presents an obstacle to recovery 
[41].  In the adult mammalian CNS, glial scarring is a major constraint to successful axonal 
regeneration.  The scar impedes axonal growth through the lesion and leads to either misrouting 
or growth arrest, both ultimately resulting in chronic denervation [42-45].  These anti- 
regenerative properties of the glial scar are predominantly caused by the build-up of various 
proteoglycans and collagens after injury [46-48]. Having previously demonstrated that siRNA 
knock-down of the transcription factor SOX9 down-regulates the expression of CSPG-synthetic 
enzymes in astrocyte cultures [27], we investigated the effect of in vivo Sox9 conditional 
knockdown on gene expression, glial scarring and functional recovery after SCI. 
In addition to our siRNA work demonstrating SOX9 regulation of xylosyltransferase-I 
and II and C4st-1[27] , others have shown that SOX9 also regulates the expression of Col2a1 
[49, 50], Col4a1 [51],  the CSPG core protein Agc [52], and Crtl [53].  4-hydroxytamoxifen-
induced knock-down of SOX9 expression in astrocyte cultures was accompanied by reduced 
mRNA expression of most of the predicted SOX9 target genes.  In the injured spinal cord of 
tamoxifen-treated Sox9flox/flox;Cre  mice the mRNA expression of these same genes with the 
addition of C4st-1, Col4a1 were also significantly reduced compared to controls;  this was 
paralleled by reductions in SOX9, GFAP and CSPG protein levels.  These results largely confirm 
the anti-Sox9 siRNA results in rat primary astrocytes previously reported [27] and demonstrate 
that the SOX9 target genes identified in astrocyte cell culture experiments are also regulated by 
SOX9 in vivo in the injured spinal cord.   
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Some predicted SOX9 target genes did not show reduced expression in Sox9 knockdown 
astrocyte cultures or spinal cord-injured mice.  XT-II expression was not reduced in either the 
Sox9flox/flox;Cre  astrocyte cultures or spinal cord injured mice, suggesting that SOX9 activity is 
not necessary for the expression of this isoform of xylosyltransferase.  The reduction of XT-II 
expression that we previously described in rat primary astrocyte cultures may simply reflect a 
minor species difference in SOX9 activities between rats and mice.  Whereas C4st-1expression 
was not reduced in Sox9flox/flox;Cre  astrocyte cultures it was reduced in the injured spinal cords of 
Sox9flox/flox;Cre  mice.  This may reflect in vitro versus in vivo differences in the regulation of 
C4st-1 gene expression.  The greater dependence C4st-1 expression on SOX9 activity in the 
injured spinal cord may be due to the large increase in SOX9 expression that occurs within the 
first 12 hours of SCI that may mask the effects of other regulators that are important to C4st-1 
expression in vitro.  Expression of Col4a1, like C4st-1, was not reduced in the Sox9 conditional 
knockdown astrocyte cultures but was reduced in the spinal lesions of Sox9 conditional 
knockdown mice after SCI.  Others have shown that collagen 4 is expressed in the lesion 
epicenter in a directly adjacent but non-overlapping pattern with the GFAP-positive astrocytes in 
the surrounding penumbra [54]. Together this suggests that SOX9 is required for the expression 
of Col4a1 in the cells (likely meningeal fibroblasts) that produce collagen 4 in the lesion 
epicenters.  Finally Crtl expression was not reduced in the Sox9 conditional knockdown cultures 
or in the Sox9 conditional knockdown mice after SCI suggesting that SOX9 activity is not 
necessary for Crtl expression.   This result was surprising as others have demonstrated that anti-
Sox9 siRNA transfection into a human chondrosarcoma cell line, OUMS-27, resulted in reduced 
levels of Crtl expression [53].  However this same group also demonstrated the presence of a 
SOX9-independent enhancer element in the 5’-UTR of the Crtl gene.  Thus we suggest that this 
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SOX9 independent enhancer element may be regulating expression of Crtl in astrocyte cultures 
and in the injured spinal cord.  
The Sox9 conditional knockdown mice achieved significantly higher BMS scores than 
controls, improved rates of plantar placement and traversed 2-3 times the distance traversed by 
controls 14 weeks post-SCI. The strong correlation (r2 = 0.61) between BMS scores at 14 weeks 
post-SCI and decreased area of CSPG staining at the lesion site suggests that the improved 
locomoter function in the Sox9 conditional knockdowns is due to the decreased CSPG expression 
in these mice following SCI. The reduced expression of XT-I, C4st-1, Agc, brevican, neurocan, 
Col2a1and  Col4a1would be expected to produce a less fibrous scar with less CSPG content.  
Gomori’s trichrome staining 14 weeks post-injury confirmed that the Sox9 conditional 
knockdown lesions had less collagen than controls.  Immunohistochemistry further demonstrated 
that there was less CSPG content in the Sox9 conditional knockdown lesions than controls.  
Neurofilament immuno-staining showed that the area of neurofilament immunoreactivity at the 
lesion epicenter did not differ significantly between Sox9 conditional knockdowns and controls.  
This suggests that the improved locomotor recovery in Sox9 conditional knockdowns is not due 
to a greater degree of axonal sparing in these mice nor is it likely due to greater numbers of 
axons traversing the lesion site to connect caudal to the lesion.  However neurofilament immuno-
staining rostral and caudal to the lesion epicenters was increased in the Sox9 conditional 
knockdown mice, consistent with the suggestion that the reduced CSPG content in the penumbra 
of the Sox9 conditional knockdowns permits greater amounts of axonal sprouting.  Axonal 
sprouting rostral and caudal to the lesion may allow the formation of connections with spared 
propriospinal neurons and underlie the improved locomotor behavior in the Sox9 conditional 
knockdowns.   
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CSPG immunoreactivity and WFA-staining demonstrate reduced CSPG expression and 
PNN matrix rostral and caudal to the penumbra 14 weeks post-SCI in the Sox9 conditional 
knockdowns.  Evidence suggests that CSPGs are up-regulated within PNNs both near and far 
from a CNS lesion [55]. PNNs are produced by both neurons and astrocytes and surround 
synapses throughout the nervous system [39].  CSPG expression in PNNs is low during the 
initial stages of synaptogenesis, and dramatically increases toward the end of developmental 
plasticity [56, 57]. Enzymatic digestion of PNNs by chondroitinase ABC leads to reactivation of 
plasticity in adult animals [57, 58] , and enhances spared fiber collateral sprouting and synapse 
formation in injured animals [59]. Thus reduced SOX9 expression may open a window for 
increased plasticity following SCI at denervated sites within and remote to the lesion. In the Sox9 
conditional knockdowns, reduced PNNs and CSPG content in the PNNs may have permitted 
spared propriospinal or descending supraspinal axons to synapse on deafferented targets caudal 
to the lesion. Evidence in support of this comes from the 5-HT immuno-staining which clearly 
showed increased 5-HT immunoreactivity caudal to the lesion around the IML and ventral horn 
in Sox9 conditional knockdowns.  
The postulate that reduced CSPGs in the PNNs distal to the lesion may account for the 
improved locomotor recovery observed in the Sox9 conditional knockdowns might explain other 
facets of the recovery in these mice.  For example the Sox9 conditional knockdowns have higher 
BMS scores than controls starting at one week post-SCI.  This improvement in locomotor 
activity seems to occur too quickly to be explained by long-range regeneration of inputs rostral 
to the lesion.  Furthermore the absence of increased neurofilament immunoreactivity at the lesion 
epicenter also argues against any significant amount of regeneration across the lesion epicenter.  
However short-range sprouting of spared axons onto deafferented targets promoted by reduced 
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CSPGs in PNNs would be expected to occur rapidly.  This type of repair may also be less prone 
to mis-wiring of circuits as the most likely axons to form new synapses on a target will be those 
that are already innervating adjacent neurons in the same field.  This type of repair may be far 
less demanding on axonal growth and targeting than long range regeneration. 
A second possible explanation for improved locomotor recovery of the Sox9 conditional 
knockdowns may be the reduced GFAP expression in these mice after SCI.  Unlike the other 
SOX9 target genes that are involved in ECM production, GFAP is a cytoskeletal protein and 
used most often as a marker of astrocyte activation [60].  Its identification as part of a battery of 
genes up-regulated by SOX9 after SCI suggests that SOX9 not only up-regulates the expression 
of ECM-related genes but also regulates the overall state of astrocyte activation and response to 
injury.   In addition to being a major producer of the glial scar, astrocytes also play an important 
role in inflammation.  In response to TGF-β1 astrocytes up-regulate expression of the pro-
inflammatory genes nitric oxide synthase-2 (NOS-2) and cyclooxygenase-2 (COX-2) [61].  IL-
1β and TNF-α also increase astrocyte production of nitric oxide [61, 62].  In the Sox9 
conditional knockdown mice, reduced GFAP expression might indicate less astrocyte activation 
and perhaps less production of pro-inflammatory mediators. Thus a muted inflammatory 
response may account for some of the improved recovery observed in the Sox9 conditional 
knockdowns.  
A third possible explanation for improved locomotor recovery of the Sox9 conditional 
knockdowns rests on evidence that SOX9 may play a role in neural stem differentiation. 
Expression studies have shown that SOX9 is expressed by neuroepithelial cells in the ventricular 
zone of the developing spinal cord, by oligodendrocytes and by astrocytes but not by neurons 
[63].  Knocking out Sox9 in the developing mouse spinal cord results in perinatal lethality, 
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decreased numbers of oligodendrocyte progenitors and astrocytes and an increased number of 
motor neurons [63] and neuroblasts [64].  MicroRNA studies also suggest that SOX9 is 
gliogenic, promoting neural stem cells to adopt an astrocyte or oligodendrocyte fate [65].   
Following injury, neural stem cells proliferate and differentiate almost exclusively into astrocytes 
[66, 67] that generate scar, but not into neurons [66].  These results are consistent with the 
hypothesis that, in neural stem cells, SOX9 expression promotes a glial rather than a neuronal 
cell fate and that, in Sox9 conditional knockdowns, neural stem cells activated by the injury may 
adopt a neuronal as opposed to a glial fate.  If astrocytes newly-born after injury contribute to 
CSPG production, or if newly-born neuroblasts are able to generate new neurons or produce 
growth factors that support neuronal survival [68-70], then the effect of Sox9 ablation on neural 
stem cell behavior (decreasing the number of newborn astrocytes and increasing the number of 
neuroblasts or neurons) may explain the improved recovery of Sox9 conditional knockdown mice 
after SCI. This possibility is being evaluated by fate mapping studies in the Sox9 conditional 
knockdowns after SCI. 
In summary, Sox9 conditional knockdown improved hind limb motor function in mice 
following T9 SCI. The improved recovery in the Sox9 conditional knockdowns correlated with 
reduced GFAP, collagen, and CSPG expression at the lesion and at sites distant from the lesion.  
We suggest that the reduced CSPG expression at the glial scar and in PNNs distant to the injury 
opened up a window of opportunity for increased local plasticity possibly allowing for the 
formation of new propriospinal connections or sprouting from spared axons onto deafferented 
targets below the lesion.  This explanation is consistent with the neurofilament immunoreactivity 
showing increased fiber sprouting in the lesion penumbra but no increase in fibers that traverse 
the lesion epicenter.  It is also consistent with the demonstrated reduction in PNNs caudal to the 
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lesion and increased 5-HT immunoreactivity demonstrating more serotonergic inputs onto IML 
and ventral horn targets caudal to the lesion. These results suggest that inhibition of SOX9 
activity may be a novel therapeutic strategy for the treatment of SCI.  
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2.7 Supplementary Table 1. Two Way ANOVA Summary Table 
 
Experiment Source DF SS MS F P 
BMS Genotype 1 53.355 53.355 25.151 <0.001 
  Time 15 55.027 3.668 28.615 <0.001 
  Interaction 15 10.116 0.674 5.26 <0.001 
CS56 Position 4 0.0483 0.0121 12.426 <0.001 
  Genotype 1 0.133 0.133 136.651 <0.001 
  Interaction 4 0.0231 0.00577 5.941 <0.001 
Trichrome Position 4 0.0135 0.00338 15.497 <0.001 
  Genotype 1 0.00629 0.00629 28.886 <0.001 
  Interaction 4 0.00267 0.000666 3.06 0.029 
GFAP Position 4 0.041 0.0102 4.027 0.007 
  Genotype 1 0.145 0.145 57.079 <0.001 
  Interaction 4 0.00184 0.00046 0.181 0.947 
NF-200 Position 4 0.0121 0.00304 4.007 0.007 
  Genotype 1 0.0157 0.0157 20.669 <0.001 
  Interaction 4 0.00597 0.00149 1.969 0.115 
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3.0 Abstract  
 
Chondroitin sulfate proteoglycans (CSPGs) limit neuroplasticity during development and 
following spinal cord injury (SCI). We have previously identified SOX9 as a transcription factor 
that up-regulates the expression of CSPGs and have demonstrated that Sox9 ablation prior to SCI 
leads to reduced CSPG expression and improved locomotor recovery.  The present study sought 
to determine whether Sox9 ablation would reduce CSPG levels in the injured cord and improve 
locomotor recovery if initiated a week after injury. Sox9flox/flox (control) and Sox9flox/flox;Cre (Sox9 
knockdown) mice were subjected to a 70 kdyne contusion SCI at thoracic spinal cord level 9.  
One week after injury, tamoxifen was administered to ablate Sox9. Quantitative-PCR 
demonstrated that this experimental protocol caused Sox9 mRNA levels to decline at 13 days 
post-SCI. Six weeks post-SCI mice with delayed Sox9 knockdown expressed reduced levels of 
CSPG core proteins (neurocan and aggrecan), and glial fibrillary acidic protein (a marker of 
astrocyte activation) in the injured spinal cord compared to controls. These changes in gene 
expression were accompanied by improved hind limb function and locomotor recovery as 
evaluated by the Basso Mouse Scale (BMS) and rodent activity boxes. Histological assessments 
confirmed reduced CSPG deposition at the lesion site and in perineuronal nets of mice with 
delayed Sox9 knockdown, and demonstrated increased serotonin immunoreactivity caudal to the 
injury site. Improved recovery following Sox9 knockdown delayed for 1 week after SCI 
highlights the clinical potential of an anti-SOX9 treatment for SCI.  
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3.1 Introduction 
 
The limited spontaneous recovery from spinal cord injury (SCI) observed in humans [1, 
2] and adult animals [3, 4] has been attributed, in part, to injury-induced neuroplasticity. Axon 
growth that underlies structural neuroplasticity has been shown to be limited by chondroitin 
sulfate proteoglycans (CSPGs) in vitro [5-7] and in vivo [8-13].  CSPGs are a family of proteins 
composed of a core protein with chondroitin sulfate side chains [14].  In the injured spinal cord 
CSPGs are a major component of the glial scar that is mostly produced by reactive astrocytes 
[15, 16], with contributions from macrophages, microglia, oligodendrocytes, invading Schwann 
cells and meningeal fibroblasts [17]. Enzymatic removal of chondroitin sulfate side chains from 
CSPGs at the lesion site using chondroitinase ABC has been demonstrated to increase axon 
sprouting and neurological recovery [8, 9]. CSPGs are also found in extracellular matrix 
structures called perineuronal nets (PNNs) that surround the cell bodies and dendrites of some 
classes of neurons [18]. CSPGs in PNNs have been suggested to stabilize synapses by preventing 
axonal sprouting onto inappropriate targets after appropriate connections have been made during 
development [11]. Enzymatic digestion of PNNs by chondroitinase leads to reactivation of 
plasticity in adult animals [19, 20].  
For several years our laboratory has been studying the molecular mechanisms that control 
CSPG production by reactive astrocytes with the goal of developing a strategy to reduce CSPG 
expression after SCI. This work led us to the identification of SOX9 as a transcription factor that 
up-regulates the expression of CSPGs in primary astrocytes [21]. Using a line of tamoxifen-
inducible conditional Sox9 knockdown mice, we subsequently demonstrated that SOX9 regulates 
the expression of a battery of genes involved in astrocyte activation and CSPG production and 
that SOX9 ablation reduces CSPG levels at the lesion site and in PNNs distant to the SCI  [22].   
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We also demonstrated that conditional SOX9 ablation leads to improved locomotor outcomes 
after SCI. One of the difficulties in this previous study was that we elected to ablate Sox9 before 
carrying out the SCI. Tamoxifen was administered once per day for one week, two weeks prior 
to SCI in order to allow one week for the Cre-mediated recombination to occur and one week for 
tamoxifen wash-out.  This experimental design allowed us to maximize the effects of SOX9 
ablation on scar formation but did not answer the more clinically relevant question - whether 
SOX9 ablation after scar formation has already begun could appreciably reduce CSPG levels in 
the injured cord and improve neurological outcomes.  In the present study we report that ablating 
Sox9 during the second week after SCI results in reduced levels of CSPGs at the lesion site and 
in PNNs in the lumbar enlargement.  These reductions in CSPGs are accompanied by improved 
locomotor recovery in the spinal cord-injured Sox9 conditional knockdown mice.  
 
3.2 Materials and Methods 
 
Sox9 conditional knockdown mice 
Mice carrying floxed Sox9 (exons 2 and 3 of Sox9 surrounded by loxP sites) alleles [23] 
(Sox9flox/flox) were crossed with a transgenic mouse line that expresses Cre recombinase fused to 
the mutated ligand binding domain of the human estrogen receptor (ER) under the control of a 
chimeric cytomegalovirus immediate-early enhancer/chicken β–actin promoter (B6.Cg-Tg(CAG-
Cre/Esr1)5Amc/J)[24] (Jackson Laboratories, Bar Harbor, Maine). The mutated ER ligand 
binding domain of the fusion protein binds tamoxifen [25]. The Cre-ER fusion protein remains 
trapped in the cytoplasm of all cells due to interactions with Hsp90.  Tamoxifen binds to the 
mutated ER portion of the fusion protein releasing it from Hsp90 allowing its transport to the 
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nucleus where it excises loxP-flanked Sox9 DNA [24]. Tamoxifen-treated 
Sox9flox/flox;CAGGCreER (Sox9flox/flox;Cre) mice served as inducible Sox9 knockdown animals and 
their tamoxifen-treated Sox9flox/flox littermates (not carrying the Cre transgene) served as control 
animals (expressing normal levels of SOX9).  Tamoxifen (Sigma Aldrich, St. Louis, Missouri) 
was administered at 3 mg/20 g mouse by oral gavage to all Sox9flox/flox;Cre and Sox9flox/flox 
littermates starting 7 days post-SCI, once per day, for 7 days.   
Animals were genotyped by polymerase chain reaction (PCR) analysis using the 
following primers:  
Sox9flox allele:  5’-ACACAGCATAGGCTACCTG-3’ and  
5’-TGGTAATGAGTCATACACAGTAC-3’. 
Sox9wildtype allele: 5’-GGGGCTTGTCTCCTTCAGAG-3’ and  
5’- TGGTAATGAGTCATACACAGTAC-3’. 
Sox9knockdown allele: 5’-GTCAAGCGACCCATG-3’ and  
5’-TGGTAATGAGTCATACACAGTAC-3’. 
Cre+ allele: 5’-CAATTTACTGACCGTACAC-3’ and 5’-AGCTGGCCCAAATGTTGCTG-3’. 
 
Spinal cord injury 
All protocols for these experiments were approved by the University of Western Ontario 
Animal Care Committee in accordance with the policies established in the Guide to Care and 
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Use of Experimental Animals prepared by the Canadian Council on Animal Care.  
Sox9flox/flox;Cre and Sox9flox/flox mice were anesthetized with 100 mg/kg ketamine: 5 mg/kg 
xylazine. The spinal cord was stabilized at vertebra T7 and T9 with forceps, and a T8 dorsal 
laminectomy was performed to expose spinal segment T9. The Infinite Horizons Impactor was 
used to deliver a 70 kdyne contusion injury with a 1 s dwell time (displacement range: 500-900 
μM) to spinal segment T9 (Precision Systems and Instrumentation, Fairfax, Virginia). Following 
SCI the mice were housed individually. Baytril (25 mg/kg, Bayer, Toronto, Ontario, Canada) and 
buprenorphine (0.01 mg/kg, Schering-Plough, Hertfordshire, UK) were injected subcutaneously 
twice daily for 3 days post-SCI. Bladders were emptied manually twice daily for the duration of 
the experiment. The experimental timeline is shown in Figure 1. 
 
Quantitative-PCR 
RNA was extracted from a 5 mm segment of spinal cord centered on the lesion of 
delayed Sox9 knockdown and control mice 6 weeks post-SCI, using the RNA-Easy kit according 
to the manufacturer's instructions (Qiagen, Valencia, California). First strand cDNA was 
synthesized from 1 μg RNA per sample using the High Capacity cDNA Archive Kit according to 
the manufacturer instructions (Applied Biosystems, Carlsbad, California). The primer probe sets, 
optical adhesive covers, and quantitative-PCR (q-PCR) plates were purchased from Applied 
Biosystems. All primer probes were labeled with 5'FAM and with 3'TAMRA as quencher. 
TaqMan assays were conducted using the Applied Biosystems gene expression assay primer 
probe sets listed in Table 1. 
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Figure 1.  Experimental timeline.  Sox9flox/flox;Cre and Sox9flox/flox control mice were subjected 
to a SCI at T9 using the infinite Horizons Impactor.  Beginning at 7 days post-SCI all mice 
received daily administrations of tamoxifen for one week.  Changes in Sox9 mRNA levels at the 
lesion were monitored by Q-PCR in a subset of animals on days 2, 4 and 6 after initiating 
tamoxifen administration (corresponding to days 9, 11 and 13 after SCI).  Changes in SOX9 
target gene protein and mRNA expression levels at the lesion by Western blot analyses and Q-
PCR was carried out 6 weeks post-SCI.  Hind limb function was assessed using the BMS on the 
day following SCI and then at weekly intervals until 14 weeks post-SCI.  Locomotor activity was 
assessed using rodent activity boxes at 1 week, 6 weeks and 14 weeks post-SCI.  After 
sacrificing the mice at 14 weeks post-SCI their spinal cords were removed for 
immunohistochemical analyses. 
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Figure 1.  Experimental timeline.   
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Table 1. List of TaqMan Real-Time PCR Primer Probe Sets 
Primer Probe    Catalog Number   PCR Ct Range 
GAPDH     Mm99999915_g1   17.04-18.65 
Sox9     Mm00448840_m1   22.10-25.97 
Aggrecan    Mm00545807_m1   23.47-25.97 
Neurocan    Mm00484007_m1   23.48-29.98 
GFAP     Mm01253033_m1   17.04-18.97 
 
TaqMan (Applied Biosystems) gene expression assays were conducted on a 7900HT fast 
q-PCR apparatus (Applied Biosystems) using thermal cycler conditions set as follows; 10 min at 
95°C followed by 40 cycles of 30 s at 95°C followed by 30 s at 60°C. Cycle thresholds (Ct) for 
all target genes were kept below 30 as indicated in Table 1. Target gene mRNA expression was 
normalized to the amount of GAPDH mRNA present in each sample and analyzed using the 
comparative Ct method [26]. The ratio of knockdown to control sample normalized target gene 
mRNA was analyzed by Student's T-test.  
 
Time course of Sox9 expression after tamoxifen administration 
Sox9flox/flox;Cre and Sox9flox/flox control mice underwent SCI as described above. 
Tamoxifen administration began 1 week after SCI. Mice were sacrificed at 2, 4, and 6 days after 
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the start of tamoxifen administration and Q-PCR was carried out to characterize the time course 
with which Sox9 mRNA levels decline following tamoxifen administration in Sox9flox/flox;Cre 
mice.  
 
Western blotting 
Protein was isolated from a 5 mm segment of spinal cord tissue centered on the lesion site 
in delayed Sox9 knockdown and control mice 6 weeks post-SCI. The spinal cord tissue was lysed 
in modified RIPA buffer (1% nonidet P-40, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, 1 mM EDTA, pH 7.5, plus 1 complete Mini Protease Inhibitor tablet/7mL 
RIPA buffer (Roche Molecular Biochemicals, Indianapolis, Indiana) on ice using a ground glass 
homogenizer. The protein mixture was centrifuged at 13,000 x g for 5 min and the supernatant 
collected. For the neurocan and aggrecan analyses the protein aliquots (at a concentration of 2–
3 mg/ml) were treated with 0.3 U/ml chondroitinase ABC (Sigma-Aldrich) for 8 h at 37 °C. The 
protein samples were diluted in reducing PAGE loading buffer, and loaded on reducing SDS-
PAGE gels at 10 μg/well. The membrane was blocked in 10% nonfat powdered milk and then 
incubated with primary antibodies; anti-SOX9 (AB 5535, Millipore, Billerica, Massachusetts 
used at 1:1000), anti-glial fibrillary acidic protein (GFAP; MAB360, Millipore, Billerica, 
Massachusetts used at 1:1000), anti-neurocan (MAB5212, Millipore, Billerica, Massachusetts 
used at 1:1000), anti-aggrecan (WH0000176M1, Sigma, St. Louis, Missouri, used at 1:1000), 
and anti-β-actin (A1978, Sigma, St. Louis, Missouri, used at 1:10,000) for protein expression 
assessed by western blot. Horse radish peroxidase (HRP)-conjugated anti-mouse IgG (715-035-
151, Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) and HRP conjugated 
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anti-rabbit IgG (711-035-152, Jackson ImmunoResearch Laboratories, West Grove, 
Pennsylvania) secondary antibodies were used at 1:20,000 dilution to detect protein expression. 
SOX9, GFAP, neurocan, and aggrecan protein expression was normalized to β-actin protein 
expression by densitometry using the EpiChemi3 Darkroom (UVP Bioimaging Systems, Upland, 
California) and LabWorks software (Media Cybernetics Inc, Bethesda, Maryland). 
 
Behavioral testing 
All aspects of the behavioral testing and data analyses completed in this study were done 
using a blinded experimental design. Locomotor recovery of the mice was assessed by two 
observers, blinded to animal genotypes, using the Basso Mouse Scale (BMS) open field 
locomotor score [27]. The day following SCI, all mice were evaluated for any signs of locomotor 
recovery in their hindlimbs, and mice that had BMS scores > 0.5 were excluded from further 
analyses (3 delayed Sox9 knockdowns and 2 controls).   Animals were evaluated once per week 
for 14 weeks after SCI. Left and right hind limb scores were averaged to generate a composite 
score. In addition, locomotion was evaluated using rodent activity boxes (Accuscan Instruments 
Inc, Columbus, Ohio). The activity boxes use infrared sensors to track the animal’s movements.  
The total distance the mice traveled was measured over a 2 h period at night (during their normal 
awake circadian cycle) at 1, 6, and 14 weeks post-SCI.   
 
 
 
96 
 
 
 
Spinal cord sectioning 
Fourteen weeks post-SCI the animals were deeply anesthetized with 50 mg/kg ketamine: 
5 mg/kg xylazine, and cardiac perfusion was carried out with 20 ml of saline at pH 7.4 followed 
by 20 ml 4% paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH 7.4). Spinal cords 
were dissected and post-fixed for 2 h in 4% PFA followed by cryoprotection in 20% sucrose in 
0.1 M phosphate buffer at pH 7.4 at 4 ˚C overnight. Spinal cords were embedded in Tissue-Tek 
O.C.T. Compound (Sakura Finetek U.S.A. Inc, Torrance, California), frozen over dry ice, and 
stored at -80 ˚C overnight. Frozen cords were then sectioned at 16 µm using a cryostat, and 
serially thaw-mounted on SuperfrostTM glass slides (Fisher Scientific Company, Ottawa, 
Canada).  
 
Immunohistochemistry  
Immunohistochemistry was conducted using the primary antibodies listed in Table 2. 
Slides were rinsed in PBS and treated with 5% normal goat serum and 0.1% triton-X-100 in 
phosphate buffered saline (PBS) at room temperature for 1 h and then incubated with the primary 
antibodies in a humidified chamber at 4 ˚C overnight. Sections were immunostained for CSPG 
expression using the monoclonal antibody CS56 that recognizes the terminal portions of 
chondroitin sulfate-4 or -6 side chains and thus detects a variety of CSPGs [28]. CS56 was 
detected with a biotinylated goat anti-mouse IgM (Vector laboratories, Burlingame, California) 
secondary antibody (1:200). Sections were then incubated for 45 min with avidin-peroxidase 
conjugate (Elite Kit, Vector laboratories, Burlingame, California) at room temperature, and the 
signal visualized by peroxidase diaminobenzine (DAB, Invitrogen, Carlsbad, California). All 
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DAB staining was conducted with a 2-min DAB reagent incubation time for spinal cord sections 
from all delayed Sox9 knockdown and control mice, and were processed at the same time. 
Sections to be stained for perineuronal nets were washed in PBS 3 x 10 min, and incubated with 
biotinylated Wisteria Floribunda agglutinin (WFA, Sigma Aldrich, St. Louis, Missouri) (1:1000) 
for 1 h at room temperature. Sections were then incubated for 45 min with streptavidin 
conjugated Alexa-Fluor 594 (1:500 Invitrogen, Carlsbad, California) at room temperature, and 
counter-stained with a fluorescent Nissl stain, N-21479 (Invitrogen) (1:100) for 1 h at room 
temperature. Sections were stained for serotonin with an antibody against 5-hydroxytryptamine 
(5-HT) and for GFAP. Anti-5-HT and anti-GFAP antibodies were detected by Alexa-Fluor 488-
conjugated goat anti-rabbit IgG (1:500, Invitrogen, Carlsbad, California), or Alexa-Fluor 488-
conjugated goat anti-mouse IgG (1:500, Invitrogen, Carlsbad, California), for 1 h at room 
temperature. Slides were then washed in PBS and coverslips applied with ProLong Gold Anti-
Fade mounting medium (Invitrogen, Carlsbad, California).   
 
Table 2. List of primary antibodies and stains used for spinal cord staining 
Antibody Dilution Isotype Source 
Anti-GFAP 1:500  Mouse IgG Millipore, Billerica, Massachusetts 
Anti-CS56 1:300  Mouse IgM Sigma Aldrich, St. Louis, Missouri  
Anti-5HT 1:500  Rabbit IgG ImmunoStar, Hudson, Wisconsin 
WFA  1:1000    Sigma Aldrich, St. Louis, Missouri  
Nissl  1:100    Invitrogen, Carlsbad, California 
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Quantification of GFAP, CS56, 5-HT, and WFA staining 
For GFAP and CS56 immunostaining, six 16 μm thick longitudinal sections, 160 μm 
apart were analyzed using ImagePro Plus software (Media Cybernetics Inc, Bethesda, 
Maryland). A threshold was set for each immunostain that identified positive signal (staining 
above background levels). For GFAP and CS56 immunoreactivity the area of positive staining 
was quantified within an area of interest that was centered on, and spanned 3.5 mm rostral and 
caudal to the lesion epicenter. This area of interest was kept constant for all sections. The area of 
5-HT immunoreactivity (area per area of interest) was quantified in the ventral horns in 16 μm 
thick cross-sections 160 μm apart obtained 0.8-1.6 mm caudal to the injury site. A single pre-set 
area of interest was used to define all ventral horn regions in all cords in both the Sox9 
knockdown and control animal sections. The area of 5-HT staining was quantified using 
ImagePro Plus Software (Media Cybernetics Inc, Bethesda, Maryland) using a threshold which 
identified positive signal (staining above background levels).  The area of WFA 
immunoreactivity in the lumbar enlargement was analyzed using 16 μm thick cross-sections 160 
μm apart sampled at the L2 spinal level. A single pre-set area of interest was used to define all 
ventral horn regions in all cords across sections from both Sox9 knockdown and control animals. 
Positive WFA staining was quantified using ImagePro Plus Software (Media Cybernetics Inc, 
Bethesda, Maryland) using a threshold which identified positive signal (staining above 
background levels).  
  
 
  
99 
 
 
 
Statistical analysis 
Mean values are expressed ± SE.  mRNA levels were subjected to statistical analyses 
using Student’s T-test. GFAP, CS56, 5-HT and WFA levels were compared between delayed 
knockdown mice and controls using a Student’s T-test. BMS and activity box results were 
subjected to statistical analysis using a two-way repeated measures ANOVA followed by a 
Neuman-Keuls post-hoc test when a significant interaction term was achieved. Analyses were 
conducted with GraphPad Prism software (GraphPad Software Inc, La Jolla, California), except 
for two-way ANOVAs which were conducted with SigmaStat software (Systat Software Inc, San 
Jose, California). Statistical significance was accepted at p<0.05. A two way ANOVA summary 
table is provided as Supplementary Table 1. 
 
3.3 Results 
 
Tamoxifen administration requires 6 days to knock down Sox9 mRNA levels  
In this study we initiated delayed Sox9 ablation by administering tamoxifen for a period 
of 7 days starting 1 week after SCI. A time course study was carried out to determine how 
rapidly Sox9 mRNA levels might decline following tamoxifen administration. Sox9 knockdown 
and control mice were sacrificed at 2, 4 and 6 days after the first tamoxifen administration 
(corresponding to days 9, 11 and 13 after SCI, respectively) and RNA from a 5 mm segment of 
their spinal cords centered on the lesion epicenter was isolated and evaluated for SOX9 mRNA 
levels by Q-PCR. Sox9 knockdown and control mice displayed similar Sox9 mRNA levels until 
the 6th day after the first tamoxifen administration (13 days after SCI) when Sox9 mRNA 
expression was significantly reduced in Sox9 knockdown mice compared to controls (Fig. 2). 
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Figure 2.  Tamoxifen administration 1 week post-SCI requires 6 days to achieve significant 
Sox9 knockdown. Spinal cord-injured Sox9flox/flox and  Sox9flox/flox;Cre mice were administered 
tamoxifen daily for one week beginning at 7 days post-injury.  Sox9flox/flox and  Sox9flox/flox;Cre 
mice were sacrificed at 2, 4 and 6 days after initiating the tamoxifen administration and RNA 
from a 5 mm segment of spinal cord centered on the lesion was analyzed for Sox9 mRNA levels 
by Q-PCR. A decrease in Sox9 mRNA levels is not observed until 6 days after the first tamoxifen 
dose (13 days after SCI).  Values are means +/- S.E. * significantly different from control at the 
same time point (p <0.05, two-tailed Student t-test, n=3/group). 
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Figure 2.  Tamoxifen administration 1 week post-SCI requires 6 days to achieve significant 
Sox9 knockdown. 
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Delayed Sox9 ablation results in reduced scar gene expression 
We previously demonstrated that Sox9 ablation prior to SCI causes a decrease in the 
mRNA and protein levels for a variety of genes involved in CSPG biosynthesis and astrocyte 
activation when measured 1 week after injury [22].  To evaluate whether Sox9 ablation in the 
second week after SCI would yield similar reductions in SOX9 target gene expression, a subset 
of spinal cord-injured control and Sox9 knockdown mice were sacrificed at 6 weeks post-SCI. 
From these mice, 5 mm spinal cord segments centered on the lesions were harvested for mRNA 
and protein expression analyses. Six weeks after SCI (5 weeks after the  first dose of tamoxifen) 
Sox9 knockdown mice displayed a 72% reduction in Sox9 mRNA,  a 25% reduction in GFAP 
mRNA, a 36% reduction in neurocan mRNA and a 33% reduction in aggrecan mRNA levels 
(Fig. 3). To determine if the observed reductions in mRNA expression were accompanied by 
parallel reductions in protein levels, we investigated SOX9, GFAP, neurocan, and aggrecan 
protein levels by western blot analysis 6 weeks post-SCI. The spinal lesions of Sox9 knockdown 
mice displayed a 72% reduction in Sox9 protein, a 33% reduction in GFAP protein, a 51% 
reduction in neurocan protein and an 83% reduction in aggrecan protein (Fig. 3). 
 
Delayed Sox9 knockdown mice show improved hind limb function 
We have previously shown that knocking out Sox9 in an adult mouse prior to SCI results 
in improved hind limb recovery [22]. To investigate whether SOX9 ablation beginning 1 week 
after SCI also leads to improved hind limb locomotor function after SCI, we evaluated the 
delayed Sox9 knockdown and control mice weekly in an open field test using the Basso mouse 
scale (BMS) scoring  [29] for locomotor activity for 14 weeks after SCI.  Immediately after 
injury, all mice showed complete or near complete paralysis of the hind limbs, represented by a  
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Figure 3.  Sox9, GFAP, neurocan and aggrecan mRNA and protein expression levels are 
reduced 6 weeks post-SCI following Sox9 ablation initiated at 1 week after injury. Spinal 
cord-injured Sox9flox/flox and  Sox9flox/flox;Cre mice were administered tamoxifen daily for one 
week beginning at 7 days post-injury. Sox9flox/flox and Sox9flox/flox;Cre mice were sacrificed at 6 
weeks post-SCI and either protein (n=4/group) or RNA (n=5 per group) was isolated from a 5 
mm segment of spinal cord centered on the lesion epicenter. A) SOX9 protein levels (as 
measured by Western blot analyses) and mRNA levels (as measured by Q-PCR) are reduced in 
the Sox9 knockdown mice (p<0.05, Student's t-test).  The Sox9 knockdown mice demonstrate 
similar reduction in the protein and mRNA levels of GFAP (B), neurocan (C) and aggrecan (D).  
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score of 0, and on day one following SCI all mice displayed a score of < 0.5.  Whereas hind limb 
function in both delayed Sox9 knockdown mice and controls gradually improved over time the 
delayed Sox9 knockdowns demonstrated a statistically significant improvement over their control 
littermates. Locomotor BMS scoring in control mice reached a plateau of 0.63 ± 0.15 at 4 weeks 
post-SCI, (Fig. 4A). The median BMS score in this group of 0.5 indicates slight (less than 90˚) 
movement in only one of the two hindlimb ankles.  In contrast, the BMS scores of the delayed 
Sox9 knockdown mice continued to improve past 4 weeks and did not reach a plateau until 10 
weeks post-SCI, achieving an average BMS score of 1.48 ± 0.21. The median BMS score for 
delayed Sox9 knockdown mice of 1.5 indicates an extensive (greater than 90˚) movement in one 
ankle, and a slight (less than 90˚) movement in the other ankle.  
 
Sox9 knockdown mice display improved locomotor activity 
As a second measure of locomotor recovery we evaluated the delayed Sox9 knockdown 
and control mice for their overall level of mobility by tracking their locomotion over a 2-h time 
period using rodent activity boxes. The total distance traversed in a 2-h period was recorded for 
each mouse during their normal wake period (at night) on 2 consecutive nights and averaged. 
One week after SCI, and before tamoxifen administration, the Sox9flox/flox control mice  (Cre-
negative) traversed an average distance of 1412 ± 191 cm in 2 h (Fig. 4B), which was not 
significantly different from the distance traversed by the  Sox9flox/flox;Cre  mice (1456 ± 252 cm 
in 2 h). At 6 weeks post-SCI (5 weeks after the first tamoxifen administration) no significant 
differences in total distance traversed between control mice that traversed an average distance of 
1393 ± 235 cm in 2 h, and delayed Sox9 knockdown mice that averaged 1906 ± 451 cm in 2 h.  
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Figure 4.  Sox9 knockdown mice demonstrate improved locomotor recovery compared to 
control mice. A) Both delayed Sox9 knockdown and control mice display hind limb paralysis 
immediately following SCI, and on day 1 post-SCI (first time point before week 1). Sox9 
knockdown mice score higher (increased hind limb function) on the Basso Mouse Scale (BMS) 
beginning on the sixth week post-SCI (one week after first tamoxifen administration) in 
comparison to control mice as determined by a 2-way repeated measures ANOVA followed by a 
Neuman-Keuls post-hoc test (p<0.05; n=12 Sox9 knockdown mice and n=11 controls). B)  Sox9 
conditional knockdown mice demonstrate increased locomotion in comparison to control mice. 
Over a 2 h period in a rodent activity box Sox9 knockdown mice demonstrate increased 
locomotion in comparison to littermate controls at 14 weeks post-SCI as determined by a  2-way 
repeated measures ANOVA followed by a Neuman-Keuls post-hoc test (p<0.05; n=12 Sox9 
knockdown mice and n=11 controls).  
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Figure 4.  Sox9 knockdown mice demonstrate improved locomotor recovery 
compared to control mice. 
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At 14 weeks after SCI, control mice traversed an average distance of 1731 ± 300 cm in 2 h, 
whereas the delayed Sox9 knockdown mice traversed an average distance of 3537 ± 301 cm in 2 
h.  The distance traversed by the injured delayed Sox9 knockdown mice was significantly greater 
than that traversed by the  injured control animals and was not significantly different from 
tamoxifen-treated uninjured Sox9flox/flox;Cre mice (3446 ± 543 cm in 2 h, n=4) or uninjured 
control mice (3287 ± 396 cm in 2 h, n=4).  
 
Delayed Sox9 knockdown mice demonstrate decreased CSPG, GFAP and PNN protein 
expression 14 weeks following SCI 
To investigate CSPG and GFAP expression at the lesion, immunohistochemistry was 
carried out on spinal cords harvested from Sox9 knockdown and control mice at the end of 
behavioral testing, 14 weeks post-SCI.  Spinal cord sections from delayed Sox9 knockdown mice 
at 14 weeks after SCI had significant reductions in CSPG (Fig. 5) and GFAP (Fig. 6) 
immunoreactivity (area immunoreactivity per area of interest). In addition to their contribution to 
the glial scar matrix, CSPGs are also a major component of the PNN that stabilizes synapses 
during development [11] and limits plasticity in the adult nervous system. Since delayed Sox9 
knockdowns had reduced levels of CSPGs at the lesion site we evaluated whether they may also 
have reductions in their PNNs distant to the lesion. Cross-sections from the lumbar enlargement 
of delayed Sox9 knockdowns and controls were stained with biotinylated Wisteria floribunda 
agglutinin (WFA) that binds N-acetylgalactosamine side chains in proteoglycans including 
CSPGs [18, 30]. WFA staining revealed a reduction in PNN proteoglycans in the delayed Sox9 
knockdown mice caudal to the lesion compared to control mice 14 weeks post-SCI, with the  
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Figure 5.  Reduced CSPG expression levels in Sox9 knockdown mice 14 weeks post-SCI. 
(A,B) Representative photomicrographs of CS56 immunostaining of longitudinal spinal cord 
sections centered at the T9 spinal lesion. (A) CSPG expression in control mice shown at low (left 
panel) and high magnification (right panel). (B) CSPG expression in Sox9 knockdown mice 
shown at low (left panel) and high magnification (right panel).  (C) Quantification of area of 
CS56 immunoreactivity (area per area) in Sox9 conditional knockdown and control spinal cords. 
* indicates statistically significantly different from controls (p<0.05, Student's t-test; n=6 for 
Sox9 knockdown mice and n=5 for controls). Scale Bars = 100 µm. 
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Figure 5.  Reduced CSPG expression levels in Sox9 knockdown mice 14 weeks post-SCI. 
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Figure 6.  Reduced GFAP expression levels in Sox9 knockdown mice 14 weeks post-SCI.  
(A-D) Representative photomicrographs of anti-GFAP immunostaining of longitudinal spinal 
cord sections centered at the T9 spinal lesion. (A) Control mice have abundant GFAP 
immunoreactivity at the lesion. (B) High magnification photomicrograph of boxed area in panel 
A.  (C) Sox9 knockdown mice have low levels of GFAP immunoreactivity at the lesion.  (D) 
High magnification photomicrograph of boxed area in panel C.  (E) Quantification of area of 
GFAP immunoreactivity (area per area) in Sox9 conditional knockdown and control spinal cords. 
* indicates statistically significantly different from controls (p<0.05, Student's t-test; n=6 for 
Sox9 knockdown mice and n=5 for controls). Scale Bars = 100 µm. 
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Figure 6.  Reduced GFAP expression levels in Sox9 knockdown mice 14 weeks post-SCI.   
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most notable reduction occurring in the layer VIII interneuron pool of the lumbar enlargement 
(Fig. 7).   
 
Delayed Sox9 knockdown mice display increased 5-HT immunoreactivity caudal to the 
lesion site following SCI 
Serotonergic projections from the Raphe Nuclei synapse in the ventral horn to modulate 
motor activity [31], and the loss of these serotonergic inputs to the ventral horn leads to 
decreased motor function [31]. To evaluate whether the improvements in hind limb function seen 
in the delayed Sox9 knockdown mice could be attributed to increased ventral horn serotonergic 
input in comparison to control mice, we performed 5-HT immunostaining on spinal cord cross-
sections sections taken from 0.8 mm - 1.6 mm caudal to the lesion epicenter in the delayed Sox9 
knockdowns and controls 14 weeks after SCI. The delayed Sox9 knockdown mice demonstrated 
a statistically significant increase in 5-HT immunoreactivity in the ventral horn, compared to 
control mice (Fig. 8).  
 
 
 
 
 
 
 
 
 
114 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Reduced WFA staining in Sox9 knockdown mice 14 weeks post-SCI.  WFA 
staining (red) is reduced in the lumbar enlargement ventral horn of Sox9 knockdown mice (B) 
compared to controls (A) 14 weeks after SCI. Sections have been counterstained a fluorescent 
Nissl stain, N-21479 (green). C) Quantification of area of WFA staining (area per area of 
interest) in Sox9 conditional knockdown and control spinal cords. * indicates statistically 
significant difference from controls (p<0.05, Student's t-test; n=6 for Sox9 knockdown mice and 
n=5 for controls). Scale Bars = 100 µm. 
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Figure 7.  Reduced WFA staining in Sox9 knockdown mice 14 weeks post-SCI. 
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Figure 8.  Increased 5-HT immunoreactivity caudal to the lesion in Sox9 knockdown mice 
14 weeks post-SCI. Immunohistochemistry was used to detect serotonin in the spinal cord 14 
weeks post-SCI. (A, B) Representative photomicrographs of sections stained for 5-HT 
immunoreactivity  1.2 mm caudal to the lesion epicenter from Sox9 conditional knockdown and 
control mice. (A) Almost no 5-HT immunoreactivity was observed caudal to the lesion in control 
mice.  (B) 5-HT immunoreactivity was readily observed caudal to the lesion in the ventral horn 
and intermediolateral cell column of Sox9 knockdown mice. Insets are high power 
magnifications of the boxed areas in A and B.  (C) Quantification of area of 5-HT 
immunoreactivity (area per area) in Sox9 conditional knockdown and control spinal cords. * 
indicates statistically significantly different from controls (p<0.05, Student's t-test; n=3). Scale 
Bars = 100 µm. 
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Figure 8.  Increased 5-HT immunoreactivity caudal to the lesion in Sox9 knockdown mice 
14 weeks post-SCI. 
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3.4 Discussion 
 
CSPGs are present in the adult CNS [32], and following injury their  expression levels 
increase greatly [5, 33]. In the uninjured adult CNS, CSPGs are key components of PNNs [18] 
whereas, in the injured CNS, CSPGs are also key components of the glial scar [14, 34] . A 
demonstration that PNN CSPGs limit plasticity comes from studies in the development of ocular 
dominance columns.   Depriving rats of visual input from one eye by lid suturing until adulthood 
skews ocular dominance toward the non-deprived eye.  Reverse lid suturing when coupled with 
chondroitinase treatment of the visual cortices of these rats allows normalization of ocular 
dominance columns and visual function [35]. The inhibitory effect of glial scar CSPGs on 
recovery has been provided by numerous studies that demonstrate that chondroitinase treatment 
at the scar increases structural plasticity in the lesion and improves neurological outcomes in  
rodent models of SCI  [8, 9, 13, 36]. The inhibitory effect of PNN CSPGs distant to the lesion has 
been demonstrated by the application of chondroitinase at the level of the cuneate nucleus in the 
brain stem following an ipsilateral dorsal column transection at C6-C7.  This chondroitinase 
treatment resulted in reduced PNN CSPGs and enhanced collateral sprouting of spared afferents 
[37]. Thus, CSPGs in the uninjured and injured nervous system limit plasticity. 
Using a tamoxifen-inducible line of Sox9 knockdown mice we previously demonstrated 
that Sox9 ablation prior to SCI leads to significant reduction in CSPG levels at the lesion 
epicenter and in PNN matrix distant to the lesion  [22].  These changes in CSPG levels correlated 
with improved locomotor recovery in the delayed Sox9 knockdown mice. In this previous study 
we administered tamoxifen daily by gavage for one week and then allowed one week for 
tamoxifen to clear the system.  This experimental protocol avoided any confounding effects of 
tamoxifen on recovery from SCI, and maximized the possible effects of reduced SOX9 
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expression by employing a pre-injury ablation strategy.  However the disadvantage of this 
protocol was that it did not test the potential clinical value of an anti-SOX9 strategy as that 
requires an experimental protocol that ablates or inhibits Sox9 expression after SCI. 
In the present study we administered tamoxifen daily for 1 week beginning at 7 days after 
SCI.  Our time course evaluation of Sox9 mRNA levels in the injured spinal cords of tamoxifen-
treated control and knockdown mice indicates that significant decreases in Sox9 mRNA levels 
were not achieved until 6 days after the first tamoxifen administration.  This probably reflects the 
time taken for Cre activation by tamoxifen, and the half-life of Sox9 mRNA. We note that Sox9 
mRNA levels continued to decline relative to controls from 13 days after SCI to 6 weeks after 
SCI indicating that maximal Sox9 ablation was reached sometime after 13 days post-injury.  As 
SOX9 protein levels would not be expected to decline before Sox9 mRNA levels, SOX9 activity 
probably began to decline at approximately 2 weeks post-SCI. This is a time after astrocyte 
activation and scar deposition has begun, and thus is a rigorous test of whether Sox9 ablation can 
reduce CSPG levels in the glial scar after its formation has commenced.  Since this subacute time 
period after SCI is a window of time at which SCI patients might reasonably be expected to 
undergo therapeutic interventions, this experimental protocol enabled us to evaluate whether 
potential SOX9 inhibitors could yield beneficial effects when applied within a clinically 
achievable time frame. 
To evaluate the effect of Sox9 ablation after SCI on SOX9 target gene expression, we 
measured the mRNA levels of Sox9, gfap, neurocan and aggrecan in a 5 mm section of spinal 
cord centered on the lesion at 6 weeks post-SCI.  As expected Sox9 mRNA levels were 
approximately 75% lower in the lesions of delayed knockdown mice compared to controls.  The 
reduction in Sox9 mRNA levels was accompanied by a similar reduction in SOX9 protein in 
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these lesions.  The reduction in SOX9 levels were also accompanied by reduction in the mRNA 
and protein levels of GFAP, neurocan and brevican.  Thus despite the delayed time course of 
Sox9 ablation, by 6 weeks post-SCI the delayed knockdown lesions had significantly lower 
CSPG and GFAP levels compared to controls suggesting that these lesions had less astrocyte 
activation and less scar deposition.  
To evaluate the effect of Sox9 ablation after SCI on locomotor recovery we performed 
open field locomotor testing weekly and quantified hind limb function using the BMS  [29].  In 
addition, as a more general indication of mobility, we also measured the total distance traveled 
by each mouse in a 2 h period using rodent activity boxes at 1, 6 and 14 weeks after SCI.  The 
open field testing demonstrated that whereas the locomotor recovery in spinal cord-injured 
Sox9flox/flox and Sox9flox/flox;Cre mice were indistinguishable for the first two weeks of recovery 
(i.e. before tamoxifen administration)  Sox9flox/flox;Cre mice began to show improved hind limb 
function thereafter. The rodent activity box data supported these findings and indicated that at 14 
weeks post-SCI the delayed Sox9 knockdown mice traverse about twice the distance of control 
mice and are not different from uninjured Sox9 ablated or wild type mice. The degree of 
improvement in locomotor function as assessed by the BMS scores may seem modest and stands 
in contrast to the more obvious improvement in mobility as measured using the rodent activity 
boxes.  This indicates that whereas the spinal cord-injured Sox9 knockdown mice are much more 
mobile than the spinal cord-injured controls their method for ambulation is abnormal and does 
not fully translate into greater BMS scores.  
We have previously suggested that improved locomotor recovery in conditional Sox9 
knockdown mice could potentially be explained by one or more of the following: a muted 
inflammatory response, altered neural stem cell behavior or increased structural neuroplasticity 
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[22] .  We suggested that the muted inflammatory response could be due to reduced astrocyte 
activation in the Sox9 knockdown mice as evidenced by their reduced GFAP expression.  
However as the most damaging inflammatory response in SCI is found to occur within the first 
hours and days of SCI [38] it would seem unlikely that a muted inflammatory response 
commencing at about 2 weeks after SCI could likely account for the improved recovery observed 
in the delayed Sox9 knockdowns described in the present study.  The possibility that improved 
locomotor recovery observed in Sox9 knockdown mice is due to altered neural stem cell behavior 
rests on studies demonstrating that SOX9 directs stem cell fate down a glial lineage  [39, 40] .  
Thus, Sox9 ablation could result in the generation of fewer astrocytes and more neurons after SCI 
and lead to better outcomes.  We are currently testing this hypothesis using a tamoxifen-
inducible neural stem cell-specific line of Sox9 knockdown mice.  
The most likely explanation for improved locomotor recovery in Sox9 conditional 
knockdown mice is that the reductions in SOX9 activity resulted in lower CSPG levels in the 
glial scar and in PNNs which permitted increased structural neuroplasticity. The importance of 
developing methods to reduce CSPG expression both at and far from the lesion site has been 
suggested by others based on increased CSPG expression at these sites after SCI [41] .We have 
shown that Sox9 ablation by tamoxifen administration starting at 1 week after SCI results in 
reduced Sox9 mRNA levels as early as 13 days after SCI and reduced levels of Sox9, GFAP, 
neurocan and aggrecan mRNA and protein levels at the lesion by 6 weeks after SCI.  
Immunohistochemistry demonstrated reduced levels of GFAP and CSPGs at the lesion site in 
delayed Sox9 knockdowns at 14 weeks post-SCI.  Reductions in PNN matrix in delayed Sox9 
knockdown mice was demonstrated in the ventral horn of the lumbar enlargement by staining 
with WFA, a lectin that  binds N-acetylgalactosamine side chains in proteoglycans including 
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CSPGs [18, 30].  We suggest that the reductions in CSPG levels in the Sox9 conditional 
knockdown mice removes the limits on neuroplasticity that these matrix molecules normally 
impose and accounts for the improved outcomes in the Sox9 conditional knockdown mice.  We 
further suggest that the reduction in PNN CSPGs, more than the reduction in glial scar CSPGs, 
underlies the improved outcomes as long-range axonal growth from above to below the lesion is 
less likely to result in functional, productive circuitry than short range reactive sprouting of 
spared fibers. Evidence for increased neuroplasticity in delayed Sox9 knockdown mice comes 
from the demonstration of increased 5-HT immunoreactivity at the lumbar enlargement in the 
ventral horns of these animals.    
We have previously shown that Sox9 ablation before SCI results in reduced CSPG levels 
in the spinal cord and improvements in motor function post-SCI [22]. The present study extends 
our previous work by demonstrating that Sox9 ablation in the subacute period after SCI also 
reduces CSPG levels in the injured spinal cord and yields improvements in locomotor function.  
These findings are supported by previous work demonstrating that chondroitinase treatment 2 
weeks after SCI improves recovery in spinal cord-injured mice  [42].  Thus, as a general 
approach, increasing neuroplasticity may be a therapeutic option well after SCI. These results 
suggest that Sox9 inhibition is a clinically viable and practical therapeutic strategy for the 
treatment of SCI.  
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3.7 Supplementary Table 1. Two Way ANOVA Summary Table 
 
Experiment Source DF SS MS F P 
BMS Genotype 1 25.067 25.067 5.766 0.026 
  Time 15 46.542 3.103 22.150 <0.001 
  Interaction 15 8.204 0.547 3.904 <0.001 
Activity  Position 1 6808374.969 6808374.969 11.213 0.003 
Box  Genotype 2 7553409.742 3776704.871 8.544 0.002 
  Interaction 2 4619599.870 2309799.935 5.226 0.015 
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4.0 Abstract 
 
The absence of axonal regeneration after spinal cord injury (SCI) has been attributed to 
the up-regulation of axon-repelling molecules present in the glial scar that forms post-SCI. 
Amongst the most important of the inhibitory molecules in the scar are chondroitin sulfate 
proteoglycans (CSPGs) produced by reactive astrocytes  that respond to the injury. We have 
previously identified the transcription factor SOX9 as a key regulator of CSPG production both 
in vitro and in vivo. Sox9 conditional knockdown (KO) mice display decreased CSPG expression 
and improved hind limb function post-SCI. Herein we investigated sparing, long-range 
regeneration and reactive sprouting as possible explanations for the improved locomotor 
outcomes in Sox9 KO mice after SCI. Retrograde tract-tracing studies failed to reveal any 
evidence of increased sparing or of long-range regeneration in the Sox9 KO mice compared to 
controls.  However caudal to the lesion site we found evidence of increased neuroplasticity as 
indicated by increased levels of the presynaptic markers synaptophysin and vesicular glutamate 1 
transporter (VGLUT1) and by increased serotonin immunoreactivity. These findings were 
supported by anterograde tract-tracing experiments that demonstrated increased reactive 
sprouting caudal to the lesion after SCI.  The increased neuroplasticity after SCI in Sox9 KO 
mice highlights the clinical potential of SOX9 antagonists as a treatment strategy for SCI. 
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4.1 Introduction 
 
Spinal cord injury (SCI) is a catastrophic event that often results in the loss of mobility 
and sensation below the injury site, as well as impaired organ function and sensitivity to pain. 
The up-regulation of axon-repelling molecules in the glial scar that forms post-SCI leads to an 
absence of axonal regeneration. One of the key inhibitory factors preventing regeneration in this 
glial scar is the chondroitin sulfate proteoglycan (CSPG) family of extracellular matrix 
molecules [1-3]. CSPGs inhibit axonal regeneration by imposing both a physical and molecular 
barrier preventing axonal passage. CSPGs sterically inhibit access to substrate adhesion 
molecules [4], and receptor protein tyrosine phosphatase sigma (RPTPσ) present on axonal 
growth cones causes growth cone collapse on interaction with CSPGs [5-7]. CSPGs also play a 
critical role in the development of the central nervous system (CNS) as key components of 
perineuronal nets (PNNs). PNNs are highly condensed extracellular matrix structures which 
surround the cell bodies and dendrites of some classes of neurons [8]. The function of CSPGs in 
PNNs is to stabilize synapses during development by preventing axonal sprouting onto 
inappropriate targets after appropriate connections have been made, and thus modulate 
neuroplasticity [1, 9-12]. Following SCI, expression levels of CSPGs dramatically increase both 
in the glial scar at the site of injury and in distant PNNs [3, 13, 14].  
Specific CSPGs have been shown to inhibit neurite outgrowth including; NG2 [15], 
versican [16], neurocan [17], brevican [18] and phosphocan [19]. All of these CSPGs rely on the 
same enzymes, xylosyltransferase-I and -II (XT-I, XT-II) and chondroitin 4-sulfotransferase 
(C4ST), to add the axon-repelling chondroitin sulfate side chains to their core proteins [2, 20, 
21]. These chondroitin sulfate side chains play a crucial role in axon repulsion as their digestion 
by treatment with the enzyme chondroitinase [22], or interference with their synthesis by 
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inhibiting XT-I [23], increases axonal regeneration in rodent models of SCI. Thus, CSPGs are a 
potential target for therapeutics focused on improving recovery post SCI. 
We have previously identified SOX9 as a transcription factor that up-regulates the 
expression of CSPG synthesizing enzymes XT-I, XT-II and C4ST in reactive astrocytes [24], 
and hypothesized that SOX9 inhibition would lead to decreased CSPG expression, a lesion 
microenvironment more permissive to neuroregeneration, and improved neurological recovery 
after CNS injury. We have demonstrated that following SCI, Sox9 KO mice exhibit reduced 
expression of known SOX9 target genes including: XT-I, Collagen 2a, GFAP (glial fibrillary 
acidic protein, a marker of astrocyte activation) and three CSPG core proteins (aggrecan, 
brevican and neurocan) [24, 25]. This reduction in mRNA expression was accompanied by 
reductions in CSPG protein levels both in the glial scar and in peri-neuronal nets distant to the 
injury [25]. In addition to reduced CSPG levels, Sox9 KO mice also displayed improved 
hindlimb functional recovery as assessed by the Basso Motor Scale (BMS) and overall 
locomotor activity as assessed by activity boxes [25]. Finally, the Sox9 KO mice displayed 
increased serotonin immunostaining caudal to the injury site in the intermediolateral cell column 
as well as the ventral horn.  
In the present study we investigated sparing, long-range regeneration and reactive 
sprouting as possible explanations for the improved locomotor outcomes in Sox9 KO mice after 
SCI. We herein report that retrograde tract-tracing studies failed to reveal any evidence of 
increased sparing or of long-range regeneration in the corticospinal, rubrospinal, reticulospinal, 
vestibulospinal tracts or long descending propriospinal projections in the Sox9 KO 
mice.  However, Sox9 KO mice displayed increased synaptic plasticity caudal to the lesion as 
Sox9 KO mice displayed increased levels of the presynaptic markers synaptophysin and vesicular 
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glutamate 1 transporter (VGLUT1), as well as increased serotonin immunoreactivity. 
Anterograde tract tracing studies support the immunohistochemical evidence for increased 
reactive sprouting below the level of the lesion.  The data presented herein describes the 
mechanism by which conditional Sox9 KO mice display improved hind limb function and 
locomotor activity post SCI, and suggest the potential utility of an anti-SOX9 treatment for SCI.   
 
4.2 Materials and Methods 
 
Sox9 conditional knockdown (KO) mice 
Mice homozygous for floxed Sox9 (exons 2 and 3 of Sox9 surrounded by loxP sites) 
alleles [26] and heterozygous for Cre recombinase fused to the mutated ligand binding domain of 
the human estrogen receptor (ER) under the control of a chimeric cytomegalovirus immediate-
early enhancer/chicken β–actin promoter [27] (Sox9flox/flox;CAGGCreER refered to as 
Sox9flox/flox;Cre) were used as Sox9 KO animals. The mutated ER ligand binding domain of the 
fusion protein binds tamoxifen [28] allowing for Cre transport into the nucleus where it excises 
loxP-flanked Sox9 DNA [27]. Tamoxifen-treated Sox9flox/flox littermates (not carrying the Cre 
transgene) served as control animals (expressing normal levels of Sox9).  Tamoxifen (Sigma 
Aldrich, St. Louis, Missouri) was administered at 3 mg/20 g mouse by oral gavage to all 
Sox9flox/flox;Cre and Sox9flox/flox littermates starting 14 days prior to SCI, once per day, for 7 days.   
Animals were genotyped by polymerase chain reaction (PCR) analysis using the 
following primers:  
Sox9flox allele:  5’-ACACAGCATAGGCTACCTG-3’ and  
5’-TGGTAATGAGTCATACACAGTAC-3’. 
Sox9wildtype allele: 5’-GGGGCTTGTCTCCTTCAGAG-3’ and  
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5’- TGGTAATGAGTCATACACAGTAC-3’. 
Sox9knockdown allele: 5’-GTCAAGCGACCCATG-3’ and  
5’-TGGTAATGAGTCATACACAGTAC-3’. 
Cre+ allele: 5’-CAATTTACTGACCGTACAC-3’ and 5’-AGCTGGCCCAAATGTTGCTG-3’. 
 
Spinal cord injury 
All protocols for these experiments were approved by the University of Western Ontario 
Animal Care Committee in accordance with the policies established in the Guide to Care and 
Use of Experimental Animals prepared by the Canadian Council on Animal Care.  
Sox9flox/flox;Cre and Sox9flox/flox mice were anesthetized with 100 mg/kg ketamine: 5 mg/kg 
xylazine. The spinal cord was stabilized at vertebra T7 and T9 with forceps, and the 9th thoracic 
spinal cord segment (T9) was exposed by a T8 dorsal laminectomy. The T9 spinal segment was 
injured using the Infinite Horizon Impactor to deliver a 70 kdyne contusion injury with a 1 s 
dwell time (displacement range: 500-900 μM) (Precision Systems and Instrumentation, Fairfax, 
Virginia). Following SCI the mice were housed individually. Baytril (25 mg/kg, Bayer, Toronto, 
Ontario, Canada) and buprenorphine (0.01 mg/kg, Schering-Plough, Hertfordshire, UK) were 
injected subcutaneously twice daily for 3 days post-SCI. Bladders were emptied manually twice 
daily for the duration of the experiment. The experimental timeline is shown in Figure 1. 
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Figure 1. Experimental Timeline. Sox9flox/flox;Cre and Sox9flox/flox control mice received daily 
administrations of tamoxifen for one week. Following a week for cre mediated recombination 
and tamoxifen clearance the mice were subjected to a SCI at T9 using the infinite Horizons 
Impactor.  1 week post-SCI a subset of mice underwent a second T10 spinal cord transection 
along with the insertion of fluorogold soaked gel foam. These mice were sacrificed at week 3 to 
assess axonal sparing post-SCI. 8 weeks post-SCI a subset of mice underwent a second T10 
spinal cord transection along with the insertion of fluorogold soaked gel foam. These 8 week 
flourogold mice were sacrificed at week 10 to assess long range regeneration post-SCI. 8 weeks 
post-SCI a subset of mice underwent BDA injections into the primary motor cortex. These 8 
week BDA mice were sacrificed at week 10 to assess reactive sprouting caudal to the lesion. The 
BDA mice were also used for WFA, synaptophysin, VGLUT1, VGAT, and serotonin 
immunohistochemical analyses. 
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Figure 1. Experimental Timeline. 
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Spinal cord sectioning 
Groups of mice were sacrified over the 10 week post-SCI timeline by deep anesthesia 
with 50 mg/kg ketamine: 5 mg/kg xylazine, and cardiac perfusion with 20 ml of saline at pH 7.4 
followed by 20 ml 4% paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH 7.4). Spinal 
cords were dissected and post-fixed for 2 h in 4% PFA followed by cryoprotection in 20% 
sucrose in 0.1 M phosphate buffer at pH 7.4 at 4 ˚C overnight. Spinal cords were embedded in 
Tissue-Tek O.C.T. Compound (Sakura Finetek U.S.A. Inc, Torrance, California), frozen over dry 
ice, and stored at -80 ˚C overnight. Frozen cords were then sectioned at 16 µm using a cryostat, 
and serially thaw-mounted on SuperfrostTM glass slides (Fisher Scientific Company, Ottawa, 
Canada).  
 
Immunohistochemistry  
Immunohistochemistry was conducted at the end of the study, 10 weeks post SCI, using 
the primary antibodies listed in Table 1. Slides were rinsed in PBS and treated with 5% normal 
goat serum and 0.1% triton-X-100 in phosphate buffered saline (PBS) at room temperature for 1 
h and then incubated with the primary antibodies in a humidified chamber at 4 ˚C overnight. 
Sections to be stained for PNNs were washed in PBS 3 x 10 min, and incubated with biotinylated 
Wisteria Floribunda Agglutinin (WFA at 1:1000, Sigma Aldrich) for 1 h at room temperature. 
Biotinylated WFA was detected by streptavidin conjugated Alexa-Fluor 594 (1:500 Invitrogen, 
Carlsbad, California) for 45 min at room temperature. Sections were stained for serotonin with 
an antibody against 5-hydroxytryptamine (5-HT) (1:500 ImmunoStar, Hudson, Wisconsin). Anti-
5-HT was detected by Alexa-Fluor 488-conjugated goat anti-rabbit IgG (1:500, Invitrogen) for 1 
h at room temperature. Sections were stained for synaptophysin (1:150 Sigma Aldrich). Anti-
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synaptophysin was detected by Alexa-Fluor 488-conjugated goat anti-mouse IgG (1:500, 
Invitrogen) for 1 h at room temperature. Sections were stained for VGLUT1 (1:200 Synaptic 
Systems, Goettingen, Germany). Anti-VGLUT1 was detected by Alexa-Fluor 488-conjugated 
goat anti-rabbit IgG (1:500, Invitrogen) for 1 h at room temperature. Sections were stained for 
VGAT (1:200 Synaptic Systems). Anti-VGAT was detected by Alexa-Fluor 488-conjugated goat 
anti-mouse IgG (1:500, Invitrogen) for 1 h at room temperature. All fluorescently labeled slides 
were washed in PBS and coverslips applied with ProLong Gold Anti-Fade mounting medium 
(Invitrogen).   
 
Table 1. List of primary antibodies and stains used for spinal cord staining 
Antibody  Dilution Isotype Source 
WFA   1:1000    Sigma Aldrich, St. Louis, Missouri  
Synaptophysin 1:150  Mouse IgG Sigma Aldrich, St. Louis, Missouri 
VGLUT1  1:200  Rabbit IgG Synaptic Systems, Goettingen, Germany 
VGAT   1:200  Mouse IgG Synaptic Systems, Goettingen, Germany 
NeuN   1:300  Mouse IgG Millipore, Billerica, Massachusetts 
5HT   1:500  Rabbit IgG ImmunoStar, Hudson, Wisconsin 
 
Retrograde labeling study 
Either 1 week or 8 weeks post-SCI mice were anaesthetized and underwent a second 
dorsal laminectomy one segment caudal to the original dorsal contusion, a T9 dorsal 
laminectomy exposing the 10th thoracic spinal cord segment (T10). The T10 spinal cord was 
fully transected by scalpel and a gel foam pledget soaked in 4% hydroxystilbamidine (a 
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fluorescent molecule responsible for retrograde transport in the common retrograde tracer 
Fluoro-Gold [29]) (4% w/v in saline; Invitrogen) was inserted into the T10 site. The incisions 
were sutured and the mice returned to animal housing.  Two weeks later the mice underwent 
cardiac perfusion with 4% paraformaldehyde after which their spinal cords were cryosectioned in 
cross section (16 μm thick sections) at the cervical enlargement, and their brains were 
cryosectioned in coronal section (30 μm thick sections). Sections from the cervical enlargement 
as well as several areas of the brain (primary motor cortex, red nucleus, reticular formation, and 
vestibular formation), were directly visualized for retrograde tracer labeling.   
 
Anterograde labeling study 
Eight weeks post-injury mice were re-anesthetized and their heads stabilized in a 
stereotaxic frame. A burr hole (1.5 mm in diameter) was made in the skull overlying the left 
sensorimotor cortex. BDA (biotinylated dextran amine, 10,000 d, Molecular Probes, Invitrogen) 
was injected by Hamilton syringe with a 33G needle (0.4 μl of 10% BDA suspended in PBS) at a 
depth of 0.5 mm from the cortical surface in the hindlimb area of the motor cortex at 4 sites 
centered on +1.5mm lateral, -1mm posterior to bregma (+1mm lateral, -0.5mm posterior, +2mm 
lateral, -0.5mm posterior, +1mm lateral, -1.5mm posterior; +2mm lateral, -1.5mm posterior) [30] 
to label corticospinal neurons. The syringe remained in position for 1 min after BDA injection. 
Two weeks after BDA injections, mice underwent cardiac perfusion with 4% paraformaldehyde 
and their spinal cords were cut in cross section (16 μm thick sections) at C4, and in the lumbar 
enlargement (L1). Sections for BDA fiber staining in the cervical enlargement were incubated 
for 45 min with avidin-peroxidase conjugate (Elite Kit, Vector laboratories, Burlingame, 
California) at room temperature, and the signal visualized by peroxidase diaminobenzine (DAB, 
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Invitrogen). All DAB staining was conducted with a 2-min DAB reagent incubation time and 
processed at the same time. The number of BDA-labeled fibers at C4 were counted in both 
uninjured and SCI mice, and used to assess sprouting rostal to injury as well as BDA labeling 
efficiency. Sections for the quantification of BDA puncta surrounding motor neurons in the 
ventral horn cervical enlargement or lumbar enlargement by high magnification confocal 
imaging were stained for 45 min with streptavidin conjugated Alexa-Fluor 594 (1:500 
Invitrogen, Carlsbad, California) at room temperature, and co-stained with anti-VGLUT1 and 
anti-NeuN.  BDA and VGLUT1 labeled puncta surrounding motor neurons in the ventral horn of 
the cervical and lumbar enlargements were compared between Sox9 KO and control mice to 
assess reactive sprouting both rostral and caudal to the injury site. 
 
Quantification of retrograde tracer, anterograde tracer, WFA, Serotonin, Synaptophysin, 
VGLUT1, and VGAT immunostaining 
Retrograde tracer labeled neurons were counted individually in the primary motor cortex, 
red nucleus, reticular formation, and vestibular formation using 30 μm thick cross-sections 
spaced 300 μm apart spanning the relevant structures (~1.8mm bregma - ~0.3mm bregma, ~3mm  
bregma - ~3.9mm bregma, ~-5.1mm bregma - ~-7.2mm bregma and ~-6mm bregma - ~-6.9mm 
bregma for the primary motor cortex, red nucleus, reticular formation, and vestibular formation 
respectively). Long range pro-priospinal neuron retrograde tracer labeling was evaluated in the 
cervical enlargement (C4) using ten 16 μm thick spinal cord cross-sections spaced 160 μm apart 
from each area. 
The number of BDA labeled fibers were counted across ten 16 μm thick spinal cord 
cross-sections each spaced 160 μm apart from the cervical enlargement (C4). BDA labeling was 
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assessed throughout the grey matter, and fibers measuring at least 5 μm in length were counted 
as real BDA labeled fiber staining. BDA labeling was robust at C4 in both uninjured and injured 
mice, with no statistical difference between Sox9 KO and control mouse labeling. BDA puncta 
surrounding motor neurons was evaluated in both the cervical enlargement and the lumbar 
enlargement by imaging five high magnification z-stacks (10 slices 0.2 μm apart) per mouse 
taken at NeuN stained motor neurons defined by their position in Rexed laminae layer 8 or 9, as 
well as their size and appearance, at 63x with a 3x zoom by a Zeiss LSM-510-Meta confocal 
microscope. Positive staining was identified as individual puncta measuring at least 1.5 μm in 
diameter as quantified by the spots algorithm in the Imaris x64 7.0 software package (Bitplane 
USA, South Windsor, CT).  
The area of WFA and 5-HT immunoreactivity was examined just caudal to the lesion site 
(T10) as well as in the lumbar enlargement (L1) using ten 16 μm thick spinal cord cross-sections 
spaced 160 μm apart from each area. A single pre-set area of interest was used to define all 
ventral horn regions in all cords across sections from both Sox9 KO and control animals. Positive 
WFA and 5-HT staining was quantified using ImagePro Plus Software (Media Cybernetics Inc, 
Bethesda, Maryland) using a threshold which identified positive signal (staining above 
background levels).  
Synaptophysin, VGLUT1, and VGAT were examined at the lumbar enlargement (L1) 
using ten 16 μm thick cross-sections 160 μm apart captured by Zeiss LSM-510 confocal 
microscope. A single pre-set area of interest was used to define all ventral horn regions in all 
cords across sections from both Sox9 KO and control animals. Positive staining was quantified 
using ImagePro Plus Software (Media Cybernetics Inc, Bethesda, Maryland) using a threshold 
which identified positive signal (staining above background levels). Five high magnification 
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ventral horn motor neuron z-stack images (10 slices 0.2 μm apart) per mouse were taken at 63x 
with a 3x zoom by a Zeiss LSM-510-Meta confocal microscope. Positive staining was identified 
as individual puncta measuring at least 1.5 μm in diameter as quantified by the spots algorithm in 
the Imaris x64 7.0 software package (Bitplane USA, South Windsor, CT).  All microscopy was 
completed using a Olympus BX-50 epifluorescence microscope except when a Zeiss LSM-510-
Meta confocal was used as indicated. 
   
Statistical analysis 
WFA, Synaptophysin, VGLUT1, VGAT, and 5-HT areas of immunoreactivity, as well as 
retrograde tracer neuronal labeling, were compared between Sox9 KO and controls using a one 
way ANOVA with a Neuman Keuls post hoc test. Synaptophysin, VGLUT1, VGAT, and BDA 
positive individual puncta counts were compared between Sox9 KO and controls using Student’s 
T-test. Analyses were conducted with GraphPad Prism software (GraphPad Software Inc, La 
Jolla, California). Statistical significance was accepted at p<0.05. Mean values are expressed ± 
SE. 
 
4.3 Results 
 
Sox9 KO mice demonstrate decreased PNN matrix post-SCI 
CSPGs are a major component of the PNN that stabilizes synapses during development  
and limits plasticity in the adult central nervous system [1]. As Sox9 KO mice demonstrate 
reduced CSPG levels throughout the injury site [25], we evaluated whether they may also have 
reductions in their PNNs directly caudal to the injury, as well as at the distant lumbar 
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enlargement where descending axons synapse on the motor neurons that innervate the hind limb 
musculature. Cross-sections from T10 and the lumbar enlargement of both uninjured and SCI 
Sox9 KO and control mice were stained with biotinylated Wisteria floribunda agglutinin (WFA).  
WFA binds N-acetylgalactosamine side chains in proteoglycans including CSPGs [8, 31]. WFA 
staining revealed that spinal cord-injured Sox9 KO mice had significantly lower levels of PNN 
matrix in their ventral horns at T10 (a 56% reduction) and in the distant lumbar enlargement (a 
58% reduction) compared to the PNN matrix in control mice 10 weeks post SCI (p<0.05 by one-
way ANOVA, Figure 2). WFA staining of PNN matrix was not different between uninjured 
control, uninjured Sox9 KO mice or spinal cord-injured Sox9 KO mice.  
 
Sox9 KO mice display no evidence of altered axonal sparing or of long range axonal 
regeneration post-SCI 
Retrograde labeling was carried out to examine axonal sparing and long range 
regeneration in the Sox9 KO mice. At 1 week or 8 weeks after T9 SCI control and Sox9 KO mice 
underwent retrograde labeling by placing a hydroxystilbamidine-soaked pledget caudal to the 
lesion (at T10). Since axons can not regenerate a full segment (~3 mm) caudal to the lesion 
within a week of injury, the neurons labeled at 1 week after injury must have axons that were 
spared from injury [32, 33].  We examined retrograde labeling in the cervical enlargement for 
long range propriospinal neurons, as well as in the motor cortex for corticospinal tract neurons, 
the red nucleus for rubrospinal tract neurons, the reticular formation for reticular spinal tract 
neurons, and the vestibular formation for vestibulospinal tract neurons. At 1 week post SCI both 
Sox9 KO and control mice displayed similar significant reductions in retrograde tracer-labeled 
corticospinal, and reticulospinal neurons when compared to uninjured controls (Figure 3). To  
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Figure 2. WFA staining is reduced both just caudal to the injury site, as well as in the lumbar 
enlargement in Sox9 KO mice 10 weeks post-SCI. A) Perineuronal net staining in uninjured control 
mice at T10. B) Perineuronal net staining in uninjured Sox9 KO mice at T10. C) Perineuronal net staining 
in control mice just caudal to the injury site (T10). D) Perineuronal net staining in Sox9 KO mice just 
caudal to the injury site (T10). E) Sox9 KO mice display reduced WFA staining just caudal to the injury 
site (p<0.05, one way ANOVA). F) Perineuronal net staining at the ventral horn of the lumbar 
enlargement (L1) in uninjured control mice. G) Perineuronal net staining in the ventral horn of the lumbar 
enlargement (L1) in uninjured Sox9 KO mice. H) Perineuronal net staining in the ventral horn of the 
lumbar enlargement (L1) in control mice post-SCI. I) Perineuronal net staining in Sox9 KO mice in the 
ventral horn of the lumbar enlargement (L1) post-SCI. J) Sox9 KO mice display reduced WFA staining in 
the ventral horn of the lumbar enlargement post-SCI (p<0.05, one way ANOVA). This suggests the 
potential for increased plasticity in Sox9 KO mice. Scale bars = 100μm. 
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Figure 2. WFA staining is reduced both just caudal to the injury site, as well as in 
the lumbar enlargement in Sox9 KO mice 10 weeks post-SCI. 
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evaluate whether long-range regeneration of corticospinal, and reticulospinal axons through the 
lesion site might occur in the Sox9 KO mice we investigated retrograde labeling after allowing 
sufficient time for axonal regrowth (8 weeks after SCI).  This analysis failed to demonstrate any 
increase in retrogradely labeled neurons (Figure 3). Similar results were obtained both 1 week 
and 8 weeks after SCI when evaluating retrogradely-labeled rubrospinal, vestibulospinal or 
propriospinal interneurons (Supplementary Figure 1). 
 
Sox9 KO mice display increased levels of presynaptic protein markers caudal to the lesion 
site post-SCI 
 We predicted that increased neuroplasticity in spinal cord injured Sox9 KO mice would 
be most evident around lumbar motor neurons as they demonstrate reduced levels of PNN 
CSPGs and are deafferented by the spinal lesion. Thus we evaluated the area of 
immunoreactivity of presynaptic markers in the ventral horn of the lumbar enlargement in 
control and Sox9 KO mice.  Synaptophysin has been used as a marker of synaptic density [34]. 
At 48 h after SCI both Sox9 KO and control mice demonstrated a similar large reduction in 
synaptophysin area of immunoreactivity caudal to the lesion when compared to uninjured mice 
(Figure 4). At 10 weeks post-injury the Sox9 KO mice demonstrated a significant 31% increase 
in the area of synaptophysin immunoreactivity compared to injured controls.  
To characterize this neuroplasticity further, we evaluated the area of immunoreactivity of the 
presynaptic markers VGLUT1 and VGAT. At 48 h after SCI, spinal cord sections from both 
Sox9 KO and control mice had approximately the same amount of VGLUT1+ and VGAT+ area 
of immunoreactivity, but by 10 weeks post-SCI sections from Sox9 KO mice demonstrated a 
significant 39% increase in VGLUT1 immunoreactivity compared to controls (Figure 5). No  
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Figure 3. Sox9 KO mice do not display increased axonal sparing or long range axonal 
regeneration post-SCI. Uninjured mice display more fluorogold labeled corticospinal and 
reticulospinal tract neurons, than injured mice. Control and Sox9 KO mice do not display 
differing fluorogold labeling at 1 week after SCI indicating that Sox9 KO does not improve 
sparing post-SCI in these tracts. Control and Sox9 KO mice do not display differing fluorogold 
labeling at 8 weeks post-SCI indicating that Sox9 KO does not result in increased long range (at 
least 1 spinal segment) axonal regeneration after SCI in these tracts (p=<0.05, one way ANOVA. 
* indicates significantly different from the injured groups.  a, b, c indicates significantly different 
from each other). Scale bars = 100μm. Supplementary Figure 1 contains fluorogold labeling data 
depicting that Sox9 KO mice also do not display increased sparing or long range axonal 
regeneration in cervical spinal cord propriospinal interneurons, the rubrospinal tract or the 
vestibular spinal tract post-SCI.  
 
 
 
 
 
146 
 
 
 
 
 
 
 
 
 
Figure 3. Sox9 KO mice do not display increased axonal sparing or long range axonal 
regeneration post-SCI. 
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Figure 4. Sox9 KO mice display increased synaptophysin immunoreactivity in the ventral 
horn of the lumbar enlargement 10 weeks post-SCI. A) Synaptophysin immunoreactivity in 
uninjured control mice. B) Synaptophysin immunoreactivity in uninjured Sox9 KO mice. C) 
Synaptophysin immunoreactivity in control mice 48 hrs post-SCI. D) Synaptophysin 
immunoreactivity in Sox9 KO mice 48 hrs post-SCI. E) Synaptophysin immunoreactivity in 
control mice 10 weeks post-SCI. F) Synaptophysin immunoreactivity in Sox9 KO mice 10 weeks 
post-SCI. G) Both control and Sox9 KO mice display increased synaptophysin immunoreactivity 
at 10 weeks post-SCI in comparison to 48 hr post-SCI, and Sox9 KO mice display significantly 
increased synaptophysin immunoreactivity 10 weeks post-SCI compared to control mice (p<0.05 
by one way ANOVA with Neuman Keuls post-hoc test, a,b,c,* each significantly different from 
each other). Dotted line separates GM (grey matter) from WM (white matter). Scale bars indicate 
100μm. 
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Figure 5. Sox9 KO mice display increased VGLUT1 immunoreactivity in the ventral horn 
of the lumbar enlargement 10 weeks post-SCI. A) VGLUT1 immunoreactivity in uninjured 
control mice. B) VGLUT1 immunoreactivity in uninjured Sox9 KO mice. C) VGLUT1 
immunoreactivity in control mice 48 hrs post-SCI. D) VGLUT1 immunoreactivity in Sox9 KO 
mice 48 hrs post-SCI. E) VGLUT1 immunoreactivity in control mice 10 weeks post-SCI. F) 
VGLUT1 immunoreactivity in Sox9 KO mice 10 weeks post-SCI. G) Both control and Sox9 KO 
mice display increased VGLUT1 immunoreactivity at 10 weeks post-SCI in comparison to 48 hr 
post-SCI, and Sox9 KO mice display significantly increased VGLUT1 immunoreactivity 10 
weeks post-SCI compared to control mice (p<0.05 by one way ANOVA with Neuman Keuls 
post-hoc test, a,b,c,* each significantly different from each other). Dotted line separates GM 
(grey matter) from WM (white matter). Scale bars indicate 100μm. 
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Figure 6. Control and Sox9 KO mice display similar VGAT immunoreactivity in the 
ventral horn of the lumbar enlargement 10 weeks post-SCI. A) VGAT immunoreactivity in 
uninjured control mice. B) VGAT immunoreactivity in uninjured Sox9 KO mice. C) VGAT 
immunoreactivity in control mice 48 hrs post-SCI. D) VGAT immunoreactivity in Sox9 KO mice 
48 hrs post-SCI. E) VGAT immunoreactivity in control mice 10 weeks post-SCI. F) VGAT 
immunoreactivity in Sox9 KO mice 10 weeks post-SCI. G) Both control and Sox9 KO mice 
display increased VGAT immunoreactivity at 10 weeks post-SCI in comparison to 48 hr post-
SCI (p<0.05 by one way ANOVA with Neuman Keuls post-hoc test, a,b,c each significantly 
different from each other). Dotted line separates GM (grey matter) from WM (white matter). 
Scale bars indicate 100μm. 
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differences were found in VGAT immunostaining between controls and Sox9 KO mice 10 weeks 
post SCI (Figure 6). 
To investigate whether the increased areas of synaptophysin and VGLUT1 
immunoreactivities might indicate increased number of presynaptic release sites, the number of  
synaptophysin and VGLUT1 immunoreactive puncta were counted 10 weeks after injury in the 
ventral horns of sections from the lumbar enlargements of Sox9 KO and control spinal cords 
using high-power magnification.  Increased individual synaptophysin+ (a 52% increase, Figure 
7) and VGLUT1+ (a 2.34 fold increase, Figure 8) puncta were noted in Sox9 KO mice in 
comparison to controls, whereas individual VGAT+ (Figure 9) puncta were found to be similar 
in both Sox9 KO and control mice 10 weeks post SCI.  
 
Sox9 KO mice display increased reactive sprouting caudal to the lesion site post-SCI 
The increased presynaptic marker immunoreactivity and puncta density observed in the 
lumbar enlargement of Sox9 KO mice could theoretically be explained by an increased level of 
protein expression or by an increased level of reactive sprouting.  To investigate reactive 
sprouting in the spinal cord anterograde labeling experiments were performed.  BDA was 
injected into the motor cortex of control and Sox9 KO mice at 8 weeks after SCI and then after 
allowing 2 weeks for anterograde transport the mice were sacrificed and BDA labeling at 
cervical and lumbar spinal levels was evaluated.  Counting individual BDA labeled puncta 
around motor neurons in the lumbar enlargement demonstrated a greater than two-fold increase 
in BDA labeling in Sox9 KO mice compared to controls (a 2.28 fold increase, Figure 10). In 
support of the prediction that the increased sprouting of corticospinal axons might underlie the 
improved locomotor recovery, in comparison to controls the Sox9 KO mice displayed a greater  
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Figure 7. Sox9 KO mice display increased pre-synaptic terminal synaptophysin positive 
boutons in layer IX of ventral horn at the lumbar enlargement 10 weeks post-SCI. A) 
Confocal micrograph of synaptophysin+ pre-synaptic boutons in control mice 10 weeks post-
SCI. B) Confocal micrograph of synaptophysin+ pre-synaptic boutons with Imaris identified 
individual puncta overlayed in control mice 10 weeks post-SCI. C) Imaris identified individual 
synaptophysin+ puncta alone in control mice 10 weeks post-SCI. D) Confocal micrograph of 
synaptophysin+ pre-synaptic boutons in Sox9 KO mice 10 weeks post-SCI. E) Confocal 
micrograph of synaptophysin+ pre-synaptic boutons with Imaris identified individual puncta 
overlayed in Sox9 KO mice 10 weeks post-SCI. F) Imaris identified individual synaptophysin+ 
puncta alone in Sox9 KO mice 10 weeks post-SCI.  G) Sox9 KO mice display significantly 
increased synaptophysin+ pre-synaptic boutons 10 weeks post-SCI compared to control mice 
(p<0.05 by Student’s T-test). Visualized with a 63x magnification objective, scale bar = 25 μm. 
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Figure 7. Sox9 KO mice display increased pre-synaptic terminal synaptophysin 
positive boutons in layer IX of ventral horn at the lumbar enlargement 10 weeks post-SCI. 
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Figure 8. Sox9 KO mice display increased pre-synaptic terminal VGLUT1 positive boutons 
in layer IX of ventral horn at the lumbar enlargement 10 weeks post-SCI. A) Confocal 
micrograph of VGLUT1+ pre-synaptic boutons in control mice 10 weeks post-SCI. B) Confocal 
micrograph of VGLUT1+ pre-synaptic boutons with Imaris identified individual puncta 
overlayed in control mice 10 weeks post-SCI. C) Imaris identified individual VGLUT1+ puncta 
alone in control mice 10 weeks post-SCI. D) Confocal micrograph of VGLUT1+ pre-synaptic 
boutons in Sox9 KO mice 10 weeks post-SCI. E) Confocal micrograph of VGLUT1+ pre-
synaptic boutons with Imaris identified individual puncta overlayed in Sox9 KO mice 10 weeks 
post-SCI. F) Imaris identified individual VGLUT1+ puncta alone in Sox9 KO mice 10 weeks 
post-SCI.  G) Sox9 KO mice display significantly increased VGLUT1+ pre-synaptic boutons 10 
weeks post-SCI compared to control mice (p<0.05 by Student’s T-test). Visualized with a 63x 
magnification objective, scale bar = 25 μm. 
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Figure 8. Sox9 KO mice display increased pre-synaptic terminal VGLUT1 positive 
boutons in layer IX of ventral horn at the lumbar enlargement 10 weeks post-SCI. 
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Figure 9. Control and Sox9 KO mice display similar pre-synaptic terminal VGAT positive 
boutons in layer IX of ventral horn at the lumbar enlargement 10 weeks post-SCI. A) 
Confocal micrograph of VGAT+ pre-synaptic boutons in control mice 10 weeks post-SCI. B) 
Confocal micrograph of VGAT+ pre-synaptic boutons with Imaris identified individual VGAT+ 
puncta overlayed in control mice 10 weeks post-SCI. C) Imaris identified individual VGAT+ 
puncta alone in control mice 10 weeks post-SCI. D) Confocal micrograph of VGAT+ pre-
synaptic boutons in Sox9 KO mice 10 weeks post-SCI. E) Confocal micrograph of VGAT+ pre-
synaptic boutons with Imaris identified individual VGAT+ puncta overlayed in Sox9 KO mice 
10 weeks post-SCI. F) Imaris identified individual VGAT+ puncta alone in Sox9 KO mice 10 
weeks post-SCI.  G) Sox9 KO mice display significantly increased VGAT+ pre-synaptic boutons 
10 weeks post-SCI compared to control mice (p<0.05 by Student’s T-test). Visualized with a 63x 
magnification objective, scale bar = 25 μm. 
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Figure 9. Control and Sox9 KO mice display similar pre-synaptic terminal VGAT 
positive boutons in layer IX of ventral horn at the lumbar enlargement 10 weeks post-SCI. 
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Figure 10. High magnification images display increased BDA and VGLUT1 positive puncta 
around ventral horn motor neurons in the lumbar enlargement in Sox9 KO mice. Motor 
neurons in the ventral horn of the lumbar enlargement stained for BDA+ puncta, VGLUT1+ 
puncta, and BDA-VGLUT1 co-localized puncta viewed by confocal z-stack. BDA confocal z-
stack (A) and Imaris identified individual BDA+ puncta (B) in control mice. BDA confocal z-
stack (C) and Imaris identified individual BDA+ puncta (D) in Sox9 KO mice. E) Motor neurons 
in the ventral horn of the lumbar enlargement displayed increased BDA+ puncta in Sox9 KO 
mice (p=<0.05, Student’s t-test). VGLUT1 confocal z-stack (F) and Imaris identified individual 
VGLUT1+ puncta (G) in control mice. VGLUT1 confocal z-stack (H) and Imaris identified 
individual VGLUT1+ puncta (I) in Sox9 KO mice. J) Motor neurons in the ventral horn of the 
lumbar enlargement displayed increased VGLUT1+ puncta in Sox9 KO mice (p=<0.05, 
Student’s t-test). NeuN (blue) BDA-VGLUT1 confocal z-stack (K) and Imaris identified 
individual BDA-VGLUT1+ co-localized puncta (L) in control mice. NeuN (blue) BDA-
VGLUT1 confocal z-stack (M) and Imaris identified individual BDA-VGLUT1+ co-localized 
puncta (N) in Sox9 KO mice. O) Motor neurons in the ventral horn of the lumbar enlargement 
displayed increased numbers of BDA-VGLUT1 co-localized puncta in Sox9 KO mice (p=<0.05, 
Student’s t-test). Scale bars indicate 10μm. 
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Figure 10. High magnification images display increased BDA and VGLUT1 positive 
puncta around ventral horn motor neurons in the lumbar enlargement in Sox9 KO mice. 
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than three-fold increase in the number of BDA-labeled puncta that were co-localized with 
VGLUT1 (a 3.03 fold increase, Figure 10). 
BDA labeling in the cervical enlargement of uninjured Sox9 KO and control mice was 
investigated to evaluate whether Sox9 ablation on its own (without an accompanying injury) 
might lead to increased reactive sprouting. BDA labeling of axons in uninjured mice was found 
to be the same in both Sox9 KO and control mice (Supplemental Figure 2). To evaluate BDA 
labeling distant to a denervated site we investigated BDA labeling around ventral horn motor 
neurons in the cervical enlargement following SCI. In comparison to control mice, Sox9 KO 
mice did not display altered BDA+ puncta, VGLUT1+ puncta, or BDA-VGLUT1 co-localized 
puncta, around ventral horn motor neurons in the cervical enlargement following SCI 
(Supplementary Figure 3). 
 
Sox9 KO mice display increased 5-HT immunoreactivity caudal to the lesion site after SCI 
Serotonergic projections from the Raphe Nuclei synapse in the ventral horn and are 
believed to directly modulate motor activity [35]. Injuries which lead to a reduction in these 
serotonergic inputs to the ventral horn result in decreased motor function [36]. To evaluate 
whether the improvements in hind limb function seen in Sox9 KO mice could be the result of 
increased ventral horn serotonergic input, we investigated serotonin immunoreactivity in spinal 
cord cross-sections sections taken from T10 and the lumbar enlargement of both uninjured and 
SCI Sox9 KO and control mice. Following injury both Sox9 KO and control mice demonstrate 
decreased serotonin immunoreactivity compared to uninjured controls, however, Sox9 KO mice 
demonstrate a statistically significant increase in serotonin immunoreactivity in the ventral horn 
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at spinal levels T10 (a 2.19 fold increase) and L1 (a 2.39 fold increase), compared to control 
mice 10 weeks post SCI (p<0.05 by one-way ANOVA, Figure 11).  
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Figure 11. Sox9 KO mice display increased serotonin immunoreactivity both just caudal to 
the injury site and in the ventral horn of the lumbar enlargement 10 weeks post-SCI. A) 
Serotonin immunoreactivity in uninjured control mice at T10. B) Serotonin immunoreactivity in 
uninjured Sox9 KO mice at T10. C) Serotonin immunoreactivity in control mice just caudal to 
the injury site (T10). D) Serotonin immunoreactivity in Sox9 KO mice just caudal to the injury 
site (T10). E) Just caudal to the injury site, Sox9 KO mice display increased serotonin 
immunoreactivity in comparison to control mice post-SCI (p<0.05, one way ANOVA). F) 
Serotonin immunoreactivity at the ventral horn of the lumbar enlargement (L1) in uninjured 
control mice. G) Serotonin immunoreactivity in the ventral horn of the lumbar enlargement (L1) 
in uninjured Sox9 KO mice. H) Serotonin immunoreactivity in the ventral horn of the lumbar 
enlargement (L1) in control mice post-SCI. I) Serotonin immunoreactivity in Sox9 KO mice in 
the ventral horn of the lumbar enlargement (L1) post-SCI. J) Sox9 KO mice display increased 
serotonin immunoreactivity in the ventral horn of the lumbar enlargement post-SCI (p<0.05, one 
way ANOVA, a,b,c are significantly different from each other). Scale bars = 100μm. 
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Figure 11. Sox9 KO mice display increased serotonin immunoreactivity both just caudal to 
the injury site and in the ventral horn of the lumbar enlargement 10 weeks post-SCI. 
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4.4 Discussion 
 
Recovery following SCI is significantly impeded by the CSPG-rich inhibitory 
extracellular matrix that serves to prevent neuroplasticity both at the lesion site as well as distant 
to the lesion [37-39]. Degradation of CSPG side chains by administration of the bacterial enzyme  
chondroitinase results in enhanced regeneration following SCI in rodents [4, 13, 22, 40], as well 
as improved skilled locomotor function in adult cats following T10 hemisection [41]. We 
previously proposed that SOX9 inhibition could serve as an alternate strategy for reducing CSPG 
levels in the injured spinal cord by reducing the expression of CSPG biosynthetic enzymes and 
core proteins [24, 25].  This proposition was supported by our previous study demonstrating that 
conditional Sox9 ablation reduces CSPG levels in the injured spinal cord and improves hind limb 
function after SCI [25]. However that study did not address the mechanism through which Sox9 
ablation resulted in improved locomotor recovery. 
Sox9 ablation could lead to better locomotor outcomes after SCI for a variety of reasons. 
First, we have previously demonstrated that Sox9 KO is associated with a concomitant reduction 
in GFAP expression [25]. Astrocytes activated at the time of SCI display upregulated GFAP as 
well as increased cytokine production and stimulate the inflammatory response [42, 43]. As Sox9 
KO mice display reduced GFAP, they may have a reduced inflammatory response post-SCI 
compared to controls. This could result in increased sparing of descending axons at the time of 
injury, and perhaps the preservation of injured nervous tissue. Alternatively, reduced CSPG 
levels at the glial scar [25] could create an environment more permissive to long-range axonal 
regeneration through the lesion site.  Finally reduced CSPG levels in PNNs [25] could provide an 
environment that promotes reactive sprouting. Herein we evaluated each of these potential 
mechanisms of neuroplasticity in the Sox9 KO mice.  
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We assessed neuronal sparing by labeling axons with retrograde tracer one segment 
caudal to the original injury site one week after SCI.   It has been estimated that roughly 5 days 
are required for the proximal stump of a severed axon to prepare for growth, and axonal growth 
rates are suggested to be 0.25 mm/day through an injury site [32, 33]. Thus, 1 week of recovery 
is not enough time for regeneration through the lesion to the site of retrograde tracer labeling (a 
distance of ~3mm).  Thus at 1 week post-SCI only axons spared from injury should be available 
for retrograde labeling. The absence of significant difference in the number of neurons with 
descending projections labeled in this way between Sox9 KO and control mice suggests that 
increased sparing of axons through the lesion site in Sox9 KO mice is not the explanation for 
their improved locomotor recovery after SCI.  
To assess the possibility of long-range regeneration in spinal cord-injured mice we 
carried out retrograde labeling at 8 weeks post-SCI, a time point at which one would predict that 
sufficient time has elapsed from the injury to allow for regeneration through the lesion [32, 33]. 
This labeling study failed to reveal any evidence for long range regeneration in the corticospinal, 
reticulospinal, rubrospinal, vestibulospinal or long range propriospinal tracts within the Sox9 KO 
mice. This may not be all that surprising as a considerable number of anti-regenerative molecules 
likely still remain at the lesion site. Semaphorins, ephrins, netrins, slit, Nogo, myelin-associated 
glycoprotein, repulsive guidance molecule, and oligodendrocyte myelin glycoprotein are all 
expressed after injury in the glial scar and induce axonal growth cone collapse [3, 44-50]. Thus 
the failure to demonstrate long-range regeneration in the Sox9 KO mice after SCI may be due to 
the expression of various inhibitors to axon growth that are not affected by Sox9 ablation. With 
that said, perhaps the reason that long range regeneration does not contribute to natural recovery 
post-SCI is the difficulty a regenerating axon would have in travelling the distance to its intended 
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target site and in making a functional synapse on its correct target while ignoring all the  
incorrect potential targets.  
In contrast to the difficulty posed by long range axonal regeneration, there are forms of 
neuroplasticity that normally occur post-CNS trauma for which appropriate targeting may be less 
problematic. Spontaneous re-wiring of limb somatotopic maps occurs in the somatosensory and 
motor cortices as well as within the brainstem post-neurotrauma [51-53]. Rat corticospinal tract 
axons cut in the thoracic dorsal funiculus sprout rostrally into the cervical spinal cord gray matter 
resulting in novel forelimb whisker and trunk activation evoked by hindlimb motor cortex 
stimulation [54]. After unilateral pyramidotomy, axons originating on the uninjured side of the 
corticospinal tract sprout and grow into the denervated side of the cord [55, 56]. Following a 
lesion of the dorsal corticospinal tract, a small proportion of ventral corticospinal fibers sprout 
into the denervated dorsal spinal cord [57]. Hindlimb corticospinal tract axons were found to 
sprout into the cervical gray matter and connect with long propriospinal neurons which bridged 
the lesion site and innervated lumbar spinal cord motorneurons, and electrophysiological 
stimulation of the hindlimb motor cortex revealed these circuits to be functional [58]. All of 
these are examples of naturally occurring axonal plasticity post SCI.  The reduction in CSPG 
expression seen in Sox9 KO mice may improve these endogenous reactive sprouting 
mechanisms, allowing newly formed collateral sprouts from spared axons traversing the lesion to 
make functional connections on motor neuron targets in the same field as the original targets of 
the injured axons.   
If the spinal cord injured Sox9 KO mice displayed increased neuroplasticity we reasoned 
that it would be most evident around deafferented lumbar motor neurons demonstrating reduced 
PNN CSPGs. Thus, we investigated synaptic plasticity by examining acute and chronic changes 
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in pre-synaptic markers in the ventral horn of the lumbar enlargement in control and Sox9 KO 
mice after SCI. After SCI, synaptic inputs in the ventral horn are decreased acutely and then, 
over time some synaptic inputs return [59]. This return of synaptic inputs is attributed to 
neuroplasticity within the spinal cord. At 48 h post SCI, Sox9 KO mice and controls had 
approximately the same number of pre-synaptic synaptophysin vesicle markers remaining, 
supporting our finding that Sox9 KO does not result in sparing of axons. However, at 10 weeks 
post-SCI Sox9 ablated mice displayed increased synaptophysin immunoreactivity as well as 
increased synaptophysin+ individual puncta.  
The synaptic losses observed at 48 hours after injury are likely due to substantial 
reductions in glutamatergic and GABAergic inputs, like those occurring in autonomic circuits 
[60]. As the majority of inputs onto spinal motor neurons are either glutamatergic or GABAergic 
[61, 62], densities of VGLUT1+ and VGAT+ presynaptic vesicles have been used to reveal 
changes in synaptic input due to remodeling after injury [61] as they reflect the number of 
synapses on cell bodies [34, 63, 64]. We thus investigated VGLUT1 and VGAT pre-synaptic 
markers in the Sox9 KO mice. At 48 h post SCI, Sox9 KO mice and controls had approximately 
the same number of VGLUT1+ and VGAT+ pre-synaptic vesicle markers remaining but by 10 
weeks post-SCI Sox9 ablated mice displayed increased VGLUT1 immunoreactivity as well as 
VGLUT1+ individual puncta compared to controls, and similar levels of VGAT 
immunoreactivity and individual puncta compared to controls. Thus following SCI the VGLUT1 
pre-synaptic marker increases more quickly in the Sox9 KO mice than in controls.  
The increased presynaptic markers displayed in Sox9 KO lumbar enlargements could 
indicate an increased number of neuronal synapses, an increased number of neurotransmitter 
release sites, or an increased number of presynaptic vesicles per release site. Each of these 
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possibilities are examples of neuroplasticity, and each would indicate increased synaptic strength 
in the lumbar enlargements of Sox9 KO mice 10 weeks post-SCI. As Sox9 KO mice did not 
display evidence of long-range axonal regeneration, this increase in presynaptic markers is likely 
due to the sprouting of spared fibers below the spinal lesion.  
To investigate reactive sprouting in Sox9 KO mice we carried out an anterograde labeling 
study. Anterograde labeling demonstrated an increased number of BDA+ puncta around ventral 
horn motor neurons below the lesion in Sox9 KO mice in comparison to controls.  Since we did 
not observe an increase in neuronal sparing in the Sox9 KO mice the increased BDA labelling 
indicates that fibers spared from injury undergo reactive sprouting to a greater extent in Sox9 KO 
mice than in controls.  Our data also demonstrated that more anterogradely labeled pre-synaptic 
terminals co-localize with the VGLUT1 pre-synaptic marker in Sox9 KO mice than in control 
mice. This suggests that many of the  reactive sprouts found in Sox9 KO mice terminate in 
VGLUT1+ pre-synaptic boutons near motor neurons, and are likely to be at least partly 
responsible for the improved functional recovery seen in these mice.  
Others have shown that the limited recovery after SCI is likely due to remodeling of 
existing circuits rather than to the re-growth of descending supraspinal inputs [58, 65].  Thus we 
were not surprised to see an increase in reactive sprouting as opposed to long-range regeneration 
of damaged descending spinal tracts. As we did not find increased BDA+ puncta or VGLUT1+ 
puncta around ventral horn motor neurons in the cervical enlargement, we suggest that the 
increased reactive sprouting in Sox9 KO mice occurs due to two signals: deafferentation of target 
neurons and reduced levels of CSPGs in the PNNs of those target neurons. 
Most spinal cord injuries in humans are in fact incomplete injuries where a proportion of 
axonal projections running through the lesion site remain intact post injury [66]. Thus, a 
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therapeutic strategy that promotes sprouting of these surviving spared axons may greatly 
improve functional outcome post SCI. It has been suggested that increased collateral sprouting in 
cervical level injuries might increase spared lower cervical level fiber innervation and improve 
control of the triceps, thus affording improved control over a wheelchair [67], and that increased 
innervation by spared serotonergic fibers might yield improved bladder control [68] or reduced 
pain [69].  
We have previously shown that Sox9 ablation both before SCI and in the subacute period 
after SCI results in reduced CSPG levels in the spinal cord and improvements in motor function 
post-SCI. The present study extends our previous work by demonstrating that Sox9 ablation leads 
to increased reactive sprouting caudal to the lesion post-SCI. Taken together, increasing 
neuroplasticity by way of SOX9 inhibition is a promising therapeutic strategy for the treatment 
of SCI.  
 
 
 
 
 
 
 
 
 
 
 
172 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Sox9 KO mice also do not display increased sparing or long range 
axonal regeneration in propriospinal interneurons, the rubrospinal tract or the vestibular 
spinal tract post-SCI. Uninjured mice display more fluorogold labeled propriospinal 
interneurons, rubrospinal tract neurons or vestibular spinal tract neurons, than in injured mice. 
Control and Sox9 KO mice do not display differing fluorogold labeling at 1 week post-SCI 
indicating that Sox9 KO does not improve sparing post-SCI in these tracts. Control and Sox9 KO 
mice do not display differing fluorogold labeling at 8 weeks post-SCI indicating that Sox9 KO 
does not result in increased long range (at least 1 spinal segment) axonal regeneration post-SCI 
in these tracts. (p=<0.05, one way ANOVA. * indicates significantly different from the injured 
groups.  a, b, c indicates significantly different from each other). Scale bars = 100μm. 
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Supplementary Figure 1. Sox9 KO mice also do not display increased sparing or 
long range axonal regeneration in propriospinal interneurons, the rubrospinal tract or the 
vestibular spinal tract post-SCI. 
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Supplementary Figure 2. Control and Sox9 KO mice display similar numbers of BDA 
labeled fibers in the cervical enlargement in both uninjured mice as well as 10 weeks post-
SCI.  A) BDA labeling in the cervical enlargement of uninjured control mice. B) BDA labeling in 
the cervical enlargement of uninjured Sox9 KO mice. C) The cervical enlargements in uninjured 
Sox9 KO and control mice display equal BDA labeling (p=>0.05, Student’s t-test). D) BDA 
labeling in the cervical enlargement of control mice post-SCI. E) BDA labeling in the cervical 
enlargement of Sox9 KO post-SCI. F) In the cervical enlargement (rostral to the injury site) Sox9 
KO and control mice display equal BDA labeling (p=>0.05, Student’s t-test). Scale bars = 100μm. 
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Supplementary Figure 2. Control and Sox9 KO mice display similar numbers of BDA labeled fibers in the 
cervical enlargement in both uninjured mice as well as 10 weeks post-SCI. 
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Supplementary Figure 3. High magnification images display similar numbers of BDA and 
VGLUT1 positive puncta around ventral horn motor neurons in the cervical enlargement in 
Sox9 KO mice. Motor neurons in the ventral horn of the cervical enlargement stained for BDA+ 
puncta, VGLUT1+ puncta, and BDA-VGLUT1 co-localized puncta viewed by confocal z-stack. 
BDA confocal z-stack (A) and Imaris identified individual BDA+ puncta (B) in control mice. 
BDA confocal z-stack (C) and Imaris identified individual BDA+ puncta (D) in Sox9 KO mice. 
E) Motor neurons in the ventral horn of the lumbar enlargement displayed similar numbers of 
BDA+ puncta in control and Sox9 KO mice (p=<0.05, Student’s t-test). VGLUT1 confocal z-
stack (F) and Imaris identified individual VGLUT1+ puncta (G) in control mice. VGLUT1 
confocal z-stack (H) and Imaris identified individual VGLUT1+ puncta (I) in Sox9 KO mice. J) 
Motor neurons in the ventral horn of the lumbar enlargement displayed similar numbers of 
VGLUT1+ puncta in control and Sox9 KO mice (p=<0.05, Student’s t-test). NeuN (blue) BDA-
VGLUT1 confocal z-stack (K) and Imaris identified individual BDA-VGLUT1+ co-localized 
puncta (L) in control mice. NeuN (blue) BDA-VGLUT1 confocal z-stack (M) and Imaris 
identified individual BDA-VGLUT1+ co-localized puncta (N) in Sox9 KO mice. O) Motor 
neurons in the ventral horn of the lumbar enlargement displayed similar numbers of BDA-
VGLUT1 co-localized puncta in control and Sox9 KO mice (p=<0.05, Student’s t-test). Scale bars 
indicate 10μm. 
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Supplementary Figure 3. High magnification images display similar numbers of 
BDA and VGLUT1 positive puncta around ventral horn motor neurons in the cervical 
enlargement in Sox9 KO mice. 
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Chapter 5: Discussion 
 
5.0 Sox9 knockdown, a potential pro-regenerative treatment for SCI  
 
The ultimate goal of post-SCI nervous system repair strategies is to reestablish the 
required neuronal connections for recovery of neurological function. Such connections may 
occur by way of retracted axons undergoing long-distance regeneration through the lesion site 
followed by proper synapse formation on downstream motor neurons. For this type of 
regeneration to occur, damaged axons would need not only to survive near the post-injury lesion 
epicenter, but would also need to extend through the inhibitory lesion site to the caudal spinal 
cord and make functional synapses on correct targets while choosing from millions of potentially 
incorrect targets. Although there have been no confirmed reports of such regeneration in humans, 
there is reason to believe pro-regenerative treatments for chronic SCI can be developed.  
The initiation of walking is handled by the brain that sends a message down spinal cord 
axons to initiate walking [1]. This message needs to be received by a center in the lumbar spinal 
cord referred to as the central pattern generator (CPG) that initiates and coordinates the muscles 
required for proper walking motion [2]. The CPG region contains neural circuits that produce 
self-sustaining patterns of muscle activation independently of sensory input [3]. CPG activity has 
been observed in newborn children including anencephalic newborns suggesting that CPGs are 
likely to exist in adult humans as well [4, 5]. It is possible to exogenously stimulate the lumbar 
enlargement in the lower spinal cord and activate a walking motion [2, 6]. In humans with 
significantly impaired ability to move their legs, epidural spinal cord stimulation of lumbar 
segment 2 results in improved locomotion as well as recruitment of more muscle fibers and 
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improved gait post incomplete SCI [7-9]. A significant challenge then is to ensure the brain can 
send the required initiation of walking signal through the spinal cord to this central pattern 
generator machinery. While considering this, it is important to note that rats and cats can walk 
normally with less than 10% of their spinal cord intact at a lesion site [10], and spinal surgeons 
have suggested that this may be true for humans as well [11]. If only 10% of the axons in the 
spinal cord are necessary and sufficient to initiate locomotor activity, it is not unreasonable to 
think pro-regenerative treatments for chronic SCI could be developed. In this thesis I 
investigated one such potential pro-regenerative treatment, the effect of Sox9 knockdown on hind 
limb function and neuroplasticity post-SCI in the mouse.    
 
5.1 Obstacles to regeneration, activation of SOX9 post-SCI 
 
Many animals found low on the evolutionary tree such as teleost fish, the salamander, 
and newt display profound axonal regeneration throughout life whereas more evolved animals 
such as mammals do not [12]. In fact, the CNS of mammals develops early in ontogeny, and 
once the critical period of plasticity closes in early adulthood mammals only display regeneration 
of their PNS [12, 13]. Thus, it may be more feasible to reprogram the local environment of an 
adult mammal to be more reminiscent of early life so as to activate pro-regenerative genetic 
programs native to the CNS as opposed to trying to activate regenerative programs native to the 
PNS or those found in more primitive animals.  Unfortunately there are significant cellular and 
molecular differences between the adult-injured spinal cord and the embryonic spinal cord [14], 
not the least of which being that the development of the spinal cord takes place in an 
environment devoid of inflammation, and that the inflammatory response is dramatically up-
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regulated post-SCI resulting in a complete change in the local microenvironment. One of the key 
outcomes of increased inflammation is a cytokine and chemokine storm that contains many 
molecules capable of activating the transcription factor SOX9. Pro-inflammatory cytokines 
including transforming growth factors β1 and 3, interleukin-6, and platelet-derived growth factor 
all work to activate SOX9 [15, 16]. Thus the inflammatory environment post-SCI provides 
ample opportunity for SOX9 activation, increased glial scarring, and amplified expression of 
anti-regenerative CSPGs. We hypothesized that inhibition of SOX9 would combat these 
environmental changes.   
 
5.2 Sox9 knockdown results in improved hind limb motor function post-SCI 
 
 Our contusion model of SCI results in paralysis of the hind limbs immediately post-
injury. Injured mice recover a minimal degree of hind limb function over time. In our initial 
proof of principle study we knocked down SOX9 expression in a group of mice prior to SCI. 
These Sox9 knockdown mice displayed remarkably quick recovery of hind limb function post 
contusion, scoring statistically higher than control mice expressing normal levels of SOX9 on the 
Basso Mouse Scale by 1 week post-SCI. This statistically significant improvement continued 
throughout the 14 weeks of our initial proof of principle study. The obvious caveat to this study 
was that the experiment occurred in mice which had already had Sox9 knocked out prior to SCI. 
This type of experimental design works well to demonstrate the potential of a SOX9 inhibition 
based therapy, but does not speak toward the clinical feasibility of such a treatment. To address 
this we conducted a follow up study where our contusion injury occurred 1 week prior to 
tamoxifen administration. As it requires roughly 6 days of tamoxifen administration for 
186 
 
 
 
appreciable Sox9 knockdown to occur this second study investigated the effect of Sox9 
knockdown almost two weeks post-SCI. In this model Sox9 knockdown mice performed 
statistically better than control mice on the Basso Mouse Scale from 6 weeks post-SCI. This 
study demonstrates not only a clinical relevance and potential of an anti-SOX9 treatment for 
SCI, but suggests that the mechanism leading to recovery seems to be effective even after glial 
scar formation in Sox9 knockdown mice. We next investigated the anatomic mechanism behind 
this functional improvement.  
 
5.3 Sox9 knockdown reduces anti-regenerative CSPG expression post-SCI  
 
Following SCI damaged axons retreat a short distance before they attempt to grow back 
towards the injury site.  Contact with CSPGs rich inhibitory extracellular matrix throughout the 
lesion site leads to growth cone collapse and axonal dystrophy, however these dystrophic axons 
are surprisingly dynamic and continually attempt to cross the lesion site [17]. Some invade the 
lesion area but do not exit on the distal side, but the great majority stop at the border of injury 
and appear to wait there even years post-SCI [18, 19]. If provided an avenue for growth through 
the inhibitory extracellular matrix, spinal axons do possess the ability to not only grow in the 
spinal cord but to form functional synapses on novel targets. David & Aguayo used peripheral 
nerves to bridge a spinal lesion and found spinal axons would grow into and through these nerves 
[20, 21]. These axons were found to innervate muscle at the distal end of the inserted peripheral 
nerve [22], and form functional glutamatergic synapses on their new targets [23, 24].  These 
studies emphasized how the inhibitory matrix in the local tissue microenvironment plays a key 
role in regulating axonal growth post-SCI [25]. It is also pertinent to note that lampreys, teleost 
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fish, and the urodele amphibians that can regenerate an injured spinal cord throughout their 
lifespan do not develop a CSPG rich glial scar [26]. Sox9 knockdown mice consistently display a 
reduction in CSPG expression both at the mRNA and protein level at the lesion epicenter and in 
the lesion penumbra. Our prediction was that the reduction in inhibitory matrix in Sox9 
knockdown mice would provide a needed avenue for growth through the glial scar and allow 
dystrophic axons to finally traverse the lesion. Sox9 knockdown mice also display reduced PNN 
matrix throughout the lesion site, and at the distant lumbar enlargement. Enzymatic digestion of 
PNNs by chondroitinase results in reactivation of plasticity [27, 28], and enhances spared fiber 
reactive sprouting and synapse plasticity [29], in injured adult animals. We therefore investigated 
whether the Sox9 knockdown mice displayed increased neuroplasticity that could account for 
their improved hind limb motor function following SCI.  
 
5.4 Investigating neuroplasticity post-SCI; axonal regeneration, reactive sprouting, and 
synapse plasticity 
 
There are three main types neuroplasticity leading to recovery post injury; axonal 
regeneration, axonal sprouting, and synaptic plasticity. Axonal regeneration refers to the growth 
of an injured axon over long distances across, and extending beyond, the lesion site [30, 31]. 
Successful regeneration would thus require a damaged axonal fiber to grow several millimeters 
or more along its original trajectory toward its original synaptic partner [30]. Axonal sprouting 
applies to growth from either a damaged or intact axonal fiber over shorter distances [30, 31]. 
There is no precise definition as to the required length at which axonal growth transitions from 
sprouting to regeneration [30]. Reactive sprouting occurs in response to the injury when an 
uninjured fiber sprouts and makes new connections in an attempt to re-connect damaged tracts 
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[31]. Synaptic plasticity is the re-organization of existing synapses, or the creation of new 
synapses which would result in correct activation of the original targets which lost connectivity 
as a result of SCI [32].  
Due to reduced glial scar CSPGs and lumbar enlargement PNNs, Sox9 knockdown CNS 
axons damaged at the time of SCI should have a more hospitable growth environment through 
the lesion, and the lumbar enlargement environment should be more permissive to reactive 
sprouts finding motor neuron targets. We thus predicted that increased long range regeneration 
would occur through the glial scar, and that increased reactive sprouting and increased synaptic 
plasticity would occur in the ventral horn of the lumbar enlargement.   
 
5.5 Sox9 knockdown does not promote axonal sparing post-SCI 
 
Prior to assessing axonal plasticity we must ensure that we rule out the possibility of 
axonal sparing in the Sox9 knockdown mice so as to not confuse increased axonal sparing with 
increased axonal growth. We saw no evidence of descending axonal sparing in Sox9 knockdown 
mice. We observed similar amounts of neurofilament traversing the lesion site in Sox9 
knockdown and control mice post-SCI. Our 1 week post-SCI fluorogold labeling study 
confirmed the absence of increased sparing in the Sox9 knockdown mice by demonstrating equal 
numbers of retrogradely labeled neurons post-SCI in Sox9 knockdown and control mice. Thus, 
Sox9 knockdown mice do not display increased axonal sparing post-SCI.   As the Sox9 
knockdown mice did not display evidence of axonal sparing, but did display reduced anti-
regenerative extracellular matrix, we turned our attention to an investigation of axonal plasticity. 
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5.6 Sox9 knockdown does not promote long range axonal regeneration post-SCI 
 
Although we hypothesized that successful reduction in CSPG expression throughout the 
lesion environment would result in improved long range axonal regeneration, we saw no 
evidence of this.  The lesion epicenter in injured Sox9 knockdown mice 14 weeks post-SCI did 
not display increased neurofilament immunoreactivity arguing against significant regeneration 
across the lesion site. Secondly, our retrograde labeling study demonstrated a significant loss of 
labeled axonal tracts 1 week post-SCI, and that none of the injured tracts studied displayed long 
range axonal regeneration 8 weeks post-SCI.  
The Sox9 knockdown mice do however display improved locomotor function in 
comparison to controls post-SCI. Long range regeneration may not be occurring in our Sox9 
knockdown mice, but there are other potential mechanisms for regeneration known to occur 
endogenously post-SCI that are based on smaller neuronal changes that could potentially be 
improved by Sox9 knockdown. Thus, we investigated short range reactive sprouting of spared 
axons as well as axonal synapse plasticity. 
 
5.7 Sox9 knockdown results in increased short range reactive sprouting and synapse 
plasticity post-SCI  
 
An endogenously occurring compensatory and functional response to denervation post-
SCI, termed reactive sprouting, has been studied for over 50 years. In 1958 McCouch et al. 
demonstrated that sensory afferents undergo sprouting in the spinal cord after SCI in both cats 
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and monkeys [33]. CSPGs restrict this reactive sprouting as chondroitinase injection into the 
brainstem post-cervical SCI resulted in digestion of PNNs and anatomical evidence of sprouting 
by spinal cord afferents in the cuneate nucleus [34]. Further studies on combined BDNF and 
chondroitinase treatment induced significant sprouting of undamaged retinal afferents into the 
denervated superior colliculus after a partial retinal lesion in the adult rat [29], and anti-synapsin 
antibody staining demonstrated increased synapse plasticity at the ends of the newly sprouted 
axons [29]. Beneficial alterations to the strength of existing neural connections may also occur 
post-SCI. An increased density of postsynaptic neurotransmitter receptors, increased excitatory 
neurotransmitter release, decreased inhibitory neurotransmitter release, or the removal of 
inhibition from excitatory input would all be beneficial to recovery from SCI [35, 36]. It is these 
types of short range plasticity we believe Sox9 knockdown facilitates, and are in fact much easier 
to imagine occurring in a human than the aforementioned long range regeneration. 
Recovery in the Sox9 knockdown mice occurred quickly, within 1 week in the proof of 
principle model. It would thus seem unlikely that long range regeneration would be the 
mechanism behind such quick recovery, and therefore it was not surprising that we did not see 
evidence of long range regeneration in the Sox9 knockdown mice. Short-range sprouting of 
spared axons onto deafferented targets due to the profound reduction in PNN burden in the Sox9 
knockdown mice would be expected to occur rapidly. This type of repair may also be less prone 
to mis-wiring of circuits as the most likely axons to form new synapses on a target will be those 
that are already innervating adjacent neurons in the same target field. We hypothesized that PNN 
reduction in the distant lumbar enlargement would allow for increased reactive sprouting and 
synapse plasticity in the ventral horn of the lumbar enlargement.  
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 Our neurofilament immunostaining suggests the same amount of axonal matter crosses 
the lesion site in both controls and Sox9 knockdown mice, however significantly more 
neurofilament was noted just rostral and just caudal to the injury penumbra.  This suggests local 
sprouting of spared axons and potentially bridging connections created to circumvent the lesion 
site. Our BDA labeling data confirm these hypotheses as significantly increased BDA labeling 
was noted in the distant lumbar enlargement. As more BDA positive puncta were found in the 
lumbar enlargement, and PNNs in the lumbar enlargement were found to be down regulated in 
Sox9 knockdown mice we were not surprised to see increased synaptic plasticity in these 
animals’ lumbar enlargements. We noted increased synaptophysin expression in the ventral horn 
of Sox9 knockdown mice lumbar enlargements. Synaptophysin was increased not only in total 
immunostaining, but also in the number of individual synaptophysin+ puncta, suggesting either 
increased synaptic release sites, increased vesicles per release site, or increased number of 
individual synapses. Each of these possibilities would indicate increased synaptic plasticity in 
these animals. Our data thus suggest that spared descending supraspinal and/or propriospinal 
axons sprout beneath the lesion and form synapses on ventral horn layer VIII and IX targets, 
probably motor neurons. We also investigated excitatory and inhibitory input in the ventral horn 
by assessing vesicular glutamate transporter VGLUT1 (excitatory neurotransmitter of the 
corticospinal tract) and vesicular GABA transporter VGAT (inhibitory neurotransmitter of the 
corticospinal tract) neurotransmitter expression [37]. We found increased VGLUT1 excitatory 
input and unchanged VGAT inhibitory input in Sox9 knockdown mice in comparison to controls 
post-SCI.  
The majority of human SCI are incomplete [19], and it has been suggested that these 
incomplete SCI may be more permissive to regeneration as cortical and subcortical structures, as 
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well as distant spinal cord circuitry, remain largely intact, while the damaged local spinal cord 
circuitry still remains partially connected by unlesioned axonal fibers [32]. Reactive sprouting as 
described herein would fit this model as a potential mechanism to stimulate beneficial 
neuroplasticity in the human post-SCI. 
It is important to note that untargeted sprouting might lead to abnormally formed reflexes 
and detrimental sprouting of uninjured sensory afferents. However, the BDA labeling experiment 
described herein found no evidence for sprouting in the cervical enlargement away from the 
injury site. Sox9 knockdown mice did not display altered numbers of BDA fibers identified in the 
cervical enlargement. We also investigated BDA labeling as well as VGLUT1 expression around 
ventral horn motor neurons in the cervical enlargement, but did not find increased BDA positive 
puncta or VGLUT1 staining. Thus, we suggest that the neuroplasticiy displayed by Sox9 
knockdown mice described herein requires not only a decrease in anti-regenerative CSPG and 
PNN expression, but also the loss of synaptic input and creation of free synaptic space. Given 
our T9 SCI model, it would be expected that motor neurons of the lumbar enlargement would 
display significant denervation whereas those in the cervical cord would likely be undamaged. 
This lack of denervation in the cervical enlargement may not have allowed the reactive sprouting 
or synaptic plasticity demonstrated in the lumbar enlargement. Thus, it is possible that the great 
majority of functional connections that are made due to increased plasticity after reduction of 
CSPG expression occur near the injury site.  They likely serve as positive forms of 
neuroplasticity allowing restored functionality rather than detrimental improperly formed 
connections. Adding credence to the belief is data from chondroitinase treated animals 
suggesting that, despite the increased growth, sprouting and connectivity displayed following 
chondroitinase treatment there has been no reported evidence of increased sensitivity to pain in 
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these animals [38-40]. However, previous studies have demonstrated that, following a 
hemisection at T13 and a complete transection at T5, sensory afferents sprouted in the dorsal 
horn and are believed to have contributed to the development of mechanical allodynia and 
autonomic dysreflexia [41, 42]. Although we see no evidence of such changes through day to 
day handling and visual observation of Sox9 knockdown mice, a thorough investigation of pain 
and sensory function is an important study that needs to be conducted. The presence of 
mechanical allodynia (a pain syndrome in which innocuous stimuli are perceived as painful) 
could be assessed by stimulating the backs of injured mice with a Semmes Weinstein 
monofilament at, and rostral, to the level of SCI. The number of avoidance responses (attempts 
to escape, vocalization, jumping, flinching and/or attempting to bite the filament) due to the 
stimulation over a number of trials would be recorded and compared between control and Sox9 
knockdown mice. Autonomic function could be assessed by measuring autonomic dysreflexia 
(episodic hypertension triggered by sensory stimulation below the level of the spinal lesion) in 
the mice. Autonomic dysreflexia is thought to be due to the loss of descending inhibitory inputs 
and the generation of abnormal reflexes in the injured spinal cord [43]. Autonomic dysreflexia 
can be assessed by measuring increases in blood pressure in response to colon distension [44], 
the extent of which correlates with the degree of SCI [45]. Blood pressure increases due to the 
stimulation over a number of trials could be recorded and compared between control and Sox9 
knockdown mice. 
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5.8 Combination therapies may be required to produce maximal beneficial effect post-SCI 
 
The reduction in the inhibitory CSPG barrier which results from SOX9 inhibition creates 
an environment permissive to neuroplasticity, but optimal axonal regeneration may require 
exogenous administration of other growth factors, and perhaps inhibition of other anti-growth 
factors.  Molecularly, the signaling pathways which regulate neurite and axonal growth are 
complex. Addition of neurotrophins [46], and inhibition of myelin-associated inhibitory 
molecules such as Nogo, myelin associated glycoprotein or myelin oligodendrocyte 
glycoprotein, may prove beneficial in promotion of reactive sprouting. For a review see Hagg et 
al. [47]. Recent studies suggest that combining pharmacological and activity based therapies may 
yield the best results post-SCI. Chondroitinase administration in concert with activity training 
resulted in improved rat forelimb function and locomotion recovery post-SCI [48]. Rats were 
assigned to one of two rehabilitation paradigms, the first receiving only skilled reaching training, 
and the second receiving only locomotion training. Chondroitinase treatment resulted in 
increased sprouting of corticospinal axons in both rehabilitation groups. Rats receiving the 
combination of chondroitinase and reaching training displayed increased reaching ability. Rats 
that received chondroitinase and locomotor training displayed improved locomotor abilities. 
Importantly, a major caveat appeared in this study. The rats that underwent the locomotor 
training scored worse on reaching tests than rats that received no specific activity training. The 
authors conclude that, although reducing CSPG burden opens a window of plasticity during 
which rehabilitation can promote recovery, only specifically trained skills appeared to improve, 
and other functions may in fact be negatively affected. Thus, combination therapies that 
emphasize a particular type of activity may eventually prove beneficial, but significant work 
needs to be undertaken to characterize the full effect of activity training on neuroplasticity and 
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recovery post-SCI. Regardless, we recognize that in the future combined therapies that target 
more than one axon-repelling molecule or make use of physical training may yield the best 
results post-SCI. 
 
5.9 Complete Sox9 knockdown is unlikely to be optimal for recovery post-SCI; beneficial 
role of astrocytes post-SCI 
 
One of the benefits of a SOX9 targeted approach is the coinciding reduction in astrocyte 
activation (GFAP expression). It is however important to note that it is likely unwise to 
completely eliminate astrocyte activation and glial scarring post-SCI. Thus close regulation of 
SOX9 activity will be required in any future anti-SOX9 therapy devised for treatment of SCI.  
Astrocytes do not only express molecules known to block axonal regeneration, but have 
also been shown to secrete extracellular matrix molecules conducive to axonal growth such as 
laminin, N-cadherin [49], neural cell adhesion molecule [50], and fibronectin [51]. Laminin and 
fibronectin have been shown to be good substrates for neurite extension in various in vitro 
models [52]. In neuron-astrocyte co-cultures, the ability of astrocytes to support neurite 
outgrowth depends upon astrocyte expression of laminin [53]. Neonatal rats regenerate 
transected connections and recover locomotor function after SCI [54], perhaps because glial 
tissue from lesioned neonates is rich in laminin and fibronectin and adequately supports neurite 
extension [55]. In general, astocyte cell lines that support neurite outgrowth produce an ECM 
rich in laminin and fibronectin while astrocyte lines producing ECM rich in CSPGs are 
nonpermissive to neurite extension [56]. In vivo, the regeneration of microtransplanted sensory 
neurons through inhibitory CNS myelin has been shown to be dependent on astrocyte-associated 
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fibronectin [51, 57, 58] and intrathecal administration of laminin promoted regeneration in a rat 
model of SCI [59]. Astrocytes provide trophic support including required metabolites, nutrients, 
and growth factors, brain-derived neurotrophic factor and neurotrophin 3, to the injury site which 
may help preserve spared neurons  [60, 61]. Astrocytes play a key role in molecular scavenging 
and are thus important in regulating excessive levels of glutamate, potassium, and other ions 
post-SCI. In fact, astrocytes can directly protect neurons from nitric oxide toxicity through a 
glutathione-dependent mechanism [62]. The glial scar itself may be crucial for the survival of 
spared axons as it helps create a scaffold for the vasculature. Astrocytes and extracellular matrix 
components recruit endothelial cells and fibroblasts to the lesion site and induce the formation of 
new capillaries [63]. Recent studies suggest that complete removal of astrocytes results in 
significantly larger lesions, local tissue disruption, demyelination, and local neuron and 
oligodendrocyte death [64-67]. Thus, it is not optimal to completely inhibit astrocyte activation 
post-SCI.  
 
5.10 Complete Sox9 knockdown is unlikely to be optimal for recovery post-SCI; beneficial 
role of CSPGs post-SCI 
 
It is also important to consider the possibility that CSPGs may be physiologically 
necessary to minimize inflammation and provide a scaffold for remodeling post-SCI [68, 69]. 
Thus, completely ablating CSPG presence at the site of injury may in fact exacerbate SCI rather 
than promote recovery. Michal Schwartz’s group has shown that inhibition of CSPG expression 
immediately following SCI results in increased leukocyte infiltration, a dramatic change in 
microglia/macrophage organization at the lesion, decreased growth promoting insulin-like 
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growth factor 1 production, and increased pro-inflammatory tumor necrosis factor alpha 
production, by microglia/macrophages. This contributed to impaired functional motor recovery, 
and increased tissue loss. Inhibiting CSPG expression 2 days post-injury resulted in significantly 
improved outcome [70]. Their conclusion was that, in the acute stages of SCI, CSPGs appear to 
be beneficial for repair and subsequent recovery of function, but that chronic CSPG production 
does in fact inhibit axonal regeneration [70]. Thus, maximal recovery and improvements in 
quality of life for those with a nervous system injury may require careful modulation of CSPG 
levels over time.  
 
5.11 Why do we our Sox9 knockdown mice only display ~65% Sox9 reduction? 
 
Given that astrocytes and CSPGs undoubtedly make some beneficial contribution to 
wound healing and recovery post-SCI, it is likely wise to allow a moderate degree of astrocyte 
activation and CSPG production post-SCI. Thus, our conditional knockdown strategy may have 
significant advantages over a complete knockout model. As we only see ~65% Sox9 knockdown 
following tamoxifen administration a significant amount of SOX9 remains to carry out its 
normal function. With this said, it is interesting to contemplate why we have not seen more 
complete Sox9 knockdown post tamoxifen administration. In the animals used for these 
experiments Sox9 knockdown occurs due to Cre recombinase acting on loxP sites flanking exons 
2 and 3 of the Sox9 gene. Researchers in the Brown laboratory have investigated Cre 
recombinase activity in ROSA-YFP mice in which tamoxifen administration activates YFP 
expression by removing a STOP codon in front of the YFP gene. As both the Sox9 
recombination, and the ROSA-YFP recombination, events are based on Cre activity, they should 
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occur equally under the same tamoxifen administration schedule. However, in practice these 
recombination events do not occur with equal frequencies. While we see ~65% Sox9 
knockdown, we see ~90% YFP expression as assessed by immunohistochemistry and flow 
cytometry. In a neural stem cell-specific Sox9 knockdown mouse model that also contains the 
ROSA-YFP allele ~20% of the YFP positive cells found in the ependymal layer (those that were 
affected by tamoxifen and had a recombination event) still expressed SOX9 (unpublished 
observation in the Brown Laboratory). This indicates that when a cell receives tamoxifen the Cre 
enzyme is more efficient at excising the STOP codon in front of the ROSA-YFP than the Sox9 
loxP flanked locus. In the mouse the ROSA locus resides on chromosome 6, and the Sox9 locus 
resides on chromosome 11 (Genbank). We hypothesize that the Cre recombinase has easier 
access to the loxP sites flanking the STOP codon preceding the ROSA locus than to the loxP 
sites flanking Sox9. Such a situation would account for the reduced Cre recombination efficiency 
seen in Sox9 knockdown mice in comparison to the ROSA-YFP mice. 
 
5.12 Alternative competing strategies, chondroitinase ABC 
   
Chondroitinase is a very promising strategy currently being investigated for treatment of 
human SCI. There are however significant caveats with chondroitinase treatment which must be 
addressed. First, there are inherent dangers associated with treating humans with bacterial 
enzymes due to the potential for eliciting a damaging immune response. Chondroitinase also 
loses its enzymatic activity at body temperature [71] and must be repeatedly administered by 
intrathecal injection or infusion, an administration strategy that is not only invasive but also 
prone to inducing infection. Chondroitinase also does not diffuse far within the cord and thus 
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only acts on CSPGs at the local injection site. Finally, chondroitinase attempts to cleave 
carbohydrate stubs off of the large CSPG core proteins, but small inhibitory stubs remain as do 
the large core proteins themselves, thus axonal regeneration and functional recovery is limited 
[72, 73].  
 
5.13 Alternative competing strategies, decorin 
 
Another strategy being investigated is the use of decorin, a small proteoglycan with high 
affinity for binding transforming growth factor β. This interaction prevents transforming growth 
factor β from interacting with its receptors and thereby inhibits its signaling. As transforming 
growth factor β is a key inducer of CSPG biosynthesis, decorin has been used to inhibit glial 
scarring at the site of injury. Significant reduction of inhibitory proteoglycans neurocan, NG2, 
phosphacan and brevican was seen following pump infusion of recombinant decorin into acute 
stab injuries in the adult rat spinal cord [74]. Decorin also allowed transplanted adult sensory 
axons to grow across the acute stab injuries [74]. Decorin treatment resulted in an increase in 
plasminogen and plasmin protein expression, molecules which cleave CSPGs and activate 
neurotrophins and thereby seem a likely candidate for promoting axonal plasticity post-SCI. 
However, until now no reports have suggested that decorin confers a functional benefit post-SCI.  
 
5.14 Alternative competing strategies, inhibition of N-acetylgalactosaminyltransferase-1 
 
A third strategy aims to reduce CSPG expression while increasing heparan sulphate 
proteoglycan (HSPG) expression. HSPGs are structurally similar to CSPGs, but have been 
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shown to promote axonal growth. The assembly of HSPGs and CSPGs rely on the same initial 
enzymatic activity by XT-I and XT-II, thus by inhibiting XT-I and XT-II activity by way of Sox9 
knockdown we may be inhibiting not only CSPG synthesis but HSPG synthesis as well. An 
interesting competing strategy to the one presented herein made use of inhibitors to the 
downstream enzyme N-acetylgalactosaminyltransferase-1 which will specifically block CSPG 
synthesis but allow HSPG synthesis. Following SCI, N-acetylgalactosaminyltransferase-1 
knockdown mice display significantly increased functional recovery [75]. As Sox9 knockdown 
mice appear to display a reduced scarring phenotype in general, it is possible that Sox9 
knockdown mice may display reductions in N-acetylgalactosaminyltransferase-1 post-SCI. As 
Sox9 knockdown does not completely eliminate XT-I and XT-II expression it is still possible that 
HSPGs are being synthesized. Therefore, it would be interesting to investigate N-
acetylgalactosaminyltransferase-1 and HSPG expression in Sox9 knockdown mice.  
 
5.15 Alternative competing strategies, inhibition of Nogo-A 
 
Nogo-A is a neurite growth inhibitory molecule expressed by differentiated 
oligodendrocytes and found in high concentrations in CNS myelin [76].   The interaction 
between myelin based Nogo-A and the Nogo-66 receptor on the axon surface restricts neuronal 
growth through negative modulation of growth cone actin dynamics [77]. Following SCI in the 
rat, inhibiting Nogo-A with an antibody resulted in improved CNS axon regeneration [78], and 
inhibiting the Nogo-66 receptor with a competitive antagonist resulted in significant 
corticospinal tract regeneration, and improved functional recovery [79]. Targeting Nogo-A has 
proven beneficial in primates as well as the recovery of manual dexterity and sprouting of 
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corticospinal tract axons were improved post-SCI in monkeys treated with anti-Nogo-A antibody 
[80, 81]. 
Early phase clinical trials targeting Nogo-A are currently in progress for the treatment of 
SCI. The pharmaceutical company Novartis AG created a humanized anti-Nogo-A antibody 
which has been used for a Phase I clinical trial. The antibody was delivered intrathecally via a 
pump for time periods ranging from 24 h to 4 weeks. The drug was tolerated well with no 
reported side effects. A Phase II study is currently underway and aims to test the efficacy of the 
anti-Nogo-A antibody treatment in paraplegic and quadraplegic SCI patients [82].    The authors 
admit that dosing will be particularly challenging as completely inhibiting Nogo-A activity is in 
fact detrimental as seen in Nogo-A KO mice which do not display increased neuronal growth or 
recovery due to a compensatory up-regulation of other inhibitory factors such as ephrinA3, 
ephrinA4, Sema 4D and 3F and plexin B2 [83].  
 
5.16 Alternative competing strategies, inhibition of Rho 
 
 Another potential treatment for SCI focuses on the inhibition of the small GTPase Rho. 
Following SCI there is an up-regulation of Rho activity due to the release of growth inhibitory 
proteins and inflammatory cytokines whose receptors signal to Rho [84]. Activated Rho inhibits 
axonal growth by acting on the actin cytoskeleton and thus collapsing the neuronal growth cone 
[85, 86]. Rho normally cycles between the cytosolic compartment and the cell membrane where 
it interacts with its receptors. Clostridium botulinum exoenzyme C3 (C3) leads to sequestration 
of Rho in the cytosolic compartment, preventing its interaction with receptors on the cell 
202 
 
 
 
membrane [87]. Local application of C3 to the injury site in a mouse hemi-section model of SCI 
resulted in long-distance regeneration of cortico-spinal neurons, and improved functional 
recovery as assessed by locomotor scores and limb coordination [88, 89].  
Cethrin is a cell-permeable derivative of Clostridium botulinum exoenzyme C3 (C3) 
which has been investigated in a Phase I/IIa clinical trial. In a group of thoracic or cervical SCI 
patients Cethrin was delivered as a gel topically to the spinal cord at the time of decompression 
surgery by placement on the dura mater of the spinal cord at the end of the surgical procedure, a 
delivery mechanism shown to be effective in rodents [84]. Motor recovery scores displayed a 
trend suggestive of neurological recovery [90]. However, the authors compared their motor 
outcomes to historical controls, thus a larger scale trial comparing Cethrin to placebo treatment 
will need to be conducted so as to properly assess efficacy. The authors also suggest increasing 
the Cethrin dosage for a follow up study. Of course, increased dosage would need to be closely 
monitored for safety.  
 
5.17 Alternative explanations for functional recovery post Sox9 knockdown 
 
All of the above strategies hold promise as potential future treatments for SCI. However, 
all of the above strategies also focus on combating anti-regenerative molecules up-regulated 
following SCI.  There are several alternative explanations for the recovery seen in Sox9 
knockdown mice that do not focus on combating anti-regenerative CSPG molecules. These 
alternative mechanisms have not as of yet been thoroughly studied, but may contribute to 
improved functional recovery post-SCI in Sox9 knockdown mice. Such versatility and the 
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potential to promote regeneration and recovery through multiple avenues may be the biggest 
advantage of an anti-SOX9 based therapy for SCI.  
A reduction in CSPG expression leading to an environment more permissive to axonal 
regeneration is not the only potential route by which functional recovery could be occurring in 
Sox9 knockdown mice. Inflammation is one of the key causes of secondary SCI, and is at least 
partially the result of leukocyte recruitment by activated astrocytes, thus as a result of decreased 
astrocyte activation Sox9 knockdown might lead to reduced inflammation at the site of injury. 
SOX9 may also play a role in neural precursor cell differentiation down a glial lineage, thus Sox9 
knockdown might lead to reduced gliogenesis and increased neurogenesis. It is probable that the 
functional recovery seen in Sox9 knockdown mice is due to a combination of these potentially 
contributing mechanisms. 
 
5.18 Alternative explanations for functional recovery post Sox9 knockdown; the effect of 
Sox9 knockdown on inflammation 
   
The inflammatory response is one of the major contributors to secondary injury after SCI. 
Following SCI, endothelial cells up-regulate vascular cell adhesion molecules and reactive 
astrocytes express cytokine pro-inflammatory and chemoattractant molecules which attract 
inflammatory leukocytes to extravasation from the blood to the injured tissue. Leukocytes 
recruited to the site of injury may play a phagocytic role cleansing the area of bacterial infection; 
however, such activity can be detrimental to the spinal cord. The release of oxygen free radicals 
and reactive nitrogen species during phagocytosis can lead to neuronal damage through 
demyelination and scarring of spinal tissue [91, 92]. In addition, the release of pro-inflammatory 
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cytokines from activated phagocytes promotes further inflammation. Ongoing damage to 
neurons and the area surrounding the primary lesion contributes to increased lesion size and 
further neurological dysfunction [92, 93]. Inhibiting the inflammatory response by macrophage 
depletion following SCI decreases cavitation size and improves axonal regeneration [93, 94]. 
Sox9 knockdown mice display reduced GFAP expression. However, we have noted 
similar levels of glutamine synthetase positive cells in Sox9 knockdown and control mice 
(unpublished observation). In the brain, glutamine synthetase is expressed predominantly in 
astrocytes.  Thus Sox9 knockdown mice display the same numbers of astrocytes as measured by 
glutamine synthetase, but a reduced astrocyte activation state as indicated by reduced GFAP 
expression. Reduced astrocyte activation may translate into reduced pro-inflammatory 
chemokine and cytokine production by astrocytes, and thus Sox9 knockdown mice may display a 
muted inflammatory response to SCI.  
A pilot study was conducted finding that in comparison to control mice Sox9 knockdown 
mice demonstrate reduced macrophage numbers at the lesion site 14 weeks post-SCI 
(unpublished observation).  This opens an interesting avenue for the future investigation of the 
effect of Sox9 knockdown on the inflammatory response. As we have only investigated 
macrophage present at the lesion site at the end point of our study (14 weeks post-SCI), a 
complete time course of leukocyte infiltration must be conducted, as well as evaluation of 
reactive oxygen and nitrogen species, and determination of a complete pro-inflammatory 
cytokine profile at the lesion site post-SCI. If indeed anti-inflammatory, timing an anti-SOX9 
based intervention would be critical as the inflammatory response operates in several phases, 
with an initial more destructive phase composed predominantly of neutrophil influx over the first 
24 h post-SCI [95], followed by a pro-inflammatory phenotype macrophage influx between days 
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2 and 7 [95], and finally a more drawn out macrophage response over the second week of injury, 
thought to be beneficial for wound healing.  
 
5.19 Alternative explanations for functional recovery post Sox9 knockdown; the effect of 
Sox9 knockdown on neural stem cells 
 
Neural stem cells constantly self-renew and eventually differentiate into neurons, 
astrocytes, or oligodendrocytes [96]. Considerable research has been conducted investigating the 
transplantation of exogenous neural stem cells as a potential method to replace cells lost at the 
time of injury or to produce new neurons capable of building connections across the injury site 
and contributing to improved function [97]. One of the main findings of these works was that the 
majority of cells surviving the transplant differentiate into astrocytes and do not result in 
improved functional recovery [98, 99]. Perhaps the injury environment only supports glial neural 
stem cell differentiation. This is not surprising as neural stem cells differentiate into neurons 
when transplanted into hippocampal brain areas, but differentiate into astrocytes when 
transplanted into uninjured spinal cords [100]. It has been shown that by priming or genetically 
modifying neural stem cells it is possible to promote their neural differentiation once 
transplanted into the CNS [97, 101-104]. However, such strategies are not optimal clinical 
treatments as injecting highly proliferative cells may lead to tumor formation [105], and still rely 
on transplant allograft with a high likelihood of immunological rejection [106]. It may be safer 
and more efficient to alter the differentiation of the endogenous neural stem cells to produce 
more neurons and oligodendrocytes, and fewer astrocytes.  
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The developing CNS in Sox9 knockdown mice displays altered neuronal/astroglial 
numbers. Twelve and one half days post conception Sox9 deficient embryos displayed a 30% 
increase in motor neurons, and at 14.5 days post conception Sox9 knockdown embryos displayed 
25% as many oligodendrocyte progenitors as wild-type embryos and almost a complete lack of 
astrocytes in their spinal cords [107]. Together these findings suggest that during development 
SOX9 promotes neural stem cell differentiation down the astroglial lineage while inhibiting 
differentiation into new neurons. SOX9 is also required to maintain fully functioning neural stem 
cells as modulation of SOX9 expression results in altered neurosphere formation [108]. In both 
mouse and chick embryos neural stem cells appear just after up-regulation of SOX9 expression. 
Increasing SOX9 expression at an earlier time point before the normal appearance of neural stem 
cells resulted in early neurosphere formation and when Sox9 was knocked out fewer 
neurospheres were found [108]. miRNA treatment has since confirmed the finding that inhibiting 
Sox9 expression reduces neural stem cell function and proliferation as well as the formation of 
astroglia, while promoting neuronal differentiation [109]. 
In the Sox9 knockdown mice described herein tamoxifen administration results in Sox9 
ablation in all cell types. Thus the improved locomotor recovery seen could be the result of 
reduced SOX9 expression in a variety of cell types, with astrocytes and neural stem cells known 
to be the two major cell types in the spinal cord that express SOX9 [110]. The improved 
functional recovery seen in these mice may not be due to just reduced CSPG expression leading 
to increased neuroplasticity of existing neurons, but perhaps due to changes in neural stem cell 
behavior as well. Sox9 ablation in neural stem cells should generate new neurons and neuroblasts 
at the lesion site after spinal cord injury and may thus contribute to recovery. 
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  Investigators in Dr. Brown’s laboratory have knocked down Sox9 specifically in neural 
stem cells and assessed hind limb functional recovery after a contusion SCI. Although the 
average BMS score for neural stem cell Sox9 knockdown mice was 1.30, and only 0.65 for the 
control mice expressing wild type levels of SOX9, these scores were not significantly different. 
However, this does not mean that Sox9 knockdown neural stem cells are not contributing any 
benefit leading to the functional recovery seen in the Sox9 knockdown mice. Also, a mouse line 
expressing Cre recombinase only in astrocytes exists and could be bred to our Sox9flox/flox;Cre 
mice. It would be interesting to know if the improvements in motor function described herein 
using a mouse line in which Sox9 is knocked down throughout the CNS could be recapitulated 
by a combination of improvements seen in the neural stem cell Sox9 knockdowns and astrocyte 
specific Sox9 knockdowns.  
 
5.20 Conclusion 
 
Sox9 knockdown reduces the expression of anti-regenerative extracellular matrix genes, 
results in increased reactive sprouting and synaptic plasticity, and improves motor function in a 
mouse model of SCI. The data presented in this thesis demonstrate the potential anti-SOX9 
strategies have for treatment of spinal cord injury, and the mechanism leading to anatomic CNS 
plasticity described herein suggests that anti-SOX9 strategies may in fact be beneficial for the 
treatment of other types of CNS neurotrauma.  
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